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Pancreatic cancer is relatively uncommon. Despite its relative scarcity, it is 
the fourth-ranked cancer killer in the Western world with less than a 5% 5-year 
survival rate. The high mortality rate is due to the asymptomatic nature of the disease 
and the advanced stage at which it is usually diagnosed. S100P is a calcium-binding 
protein that has been shown to be highly expressed in the early stages of pancreatic 
cancer and has been proposed as a potential therapeutic target via the blocking of its 
interaction with its receptor RAGE, the receptor for advanced glycation end-
products.  
In this thesis, computational techniques were employed on the NMR 
ensemble of S100P (PDB Accession code 1OZO) to identify potential inhibitors of 
the S100P-RAGE interaction in the hope of identifying a series of novel leads that 
could be developed into clinical candidates for the treatment of pancreatic cancer. In 
silico studies identified putative binding sites at the S100P dimeric interface capable 
of accommodating cromolyn, an anti-allergy drug shown to bind to the protein both 
in vitro and in vivo. Virtual screening of >1 million lead-like compounds using 3D 
pharmacophore models derived from the predicted binding interactions between 
S100P and cromolyn, identified 9,408 “hits”. These were hierarchically clustered 
according to similarities between chemical structures into 299 clusters and 77 
singletons.  
Biological screening of 17 of the “hits” identified from virtual screening 
stuidies, 4 of which were synthesised in-house, against pancreatic cancer cell lines 
identified five compounds that demonstrated an equal or greater capacity to reduce 
BxPC-3 S100P-expressing pancreatic cells’ metastatic potential in vitro relative to 
cromolyn. Compound 24 in particular, showed significant (p<0.05) inhibition of 
invasion of these cells at a concentration of 100 μM that was comparable to 
cromolyn at the same concentration. This compound, structurally distinct from 
cromolyn, was successfully synthesised, purified and characterised in-house 
alongside 39 of its analogues. Biological screening of compound 24 and four of its 
analogues for anti-proliferative activity against BxPC-3 and Panc-1 pancreatic 
ii 
 
cancer cell lines showed all five compounds significantly (p<0.0001) inhibiting 
proliferation in both cell lines at a concentration of 1 μM relative to the non-treated 
control. Hence, structurally distinct compounds that show promising inhibitory 
activity on the metastasis and proliferation of pancreatic cancer cells have been 
identified using a structure-based drug design methodology. These compounds, with 
further optimisation, could provide good starting points as therapeutic lead 
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CHAPTER 1: General Introduction 
 





Cancer is a collective term used to describe a group of diseases characterised 
by uncontrolled cell growth and division, with the potential to migrate to and invade 
distant tissues [1]. The World Health Organisation’s (WHO) International Agency 
for Research on Cancer (IARC) estimated about 14 million new cancer cases and 8.2 
million cancer-related deaths worldwide in 2012 [2]. In Europe, 3.45 million new 
cancer cases (excluding non-melanoma skin cancer) were estimated in 2012 with 
1.75 million deaths occurring from the disease in the same year [3]. In the US the 
estimate for new cancer cases in 2014 was 1,665,540 with 585,720 deaths in the 
same period [4]. Data relating to cancer survival and mortality rates tend be 2-3 
years behind the current year due to the time involved in data collection, analysis, 
compilation and dissemination [4]. 
The cost involved in cancer care – the term cancer used henceforth refers 
collectively to all diseases as described in [1] – and treatment is a huge financial 
burden for healthcare systems globally [5-8]. In the US, cancer care is projected to 
cost $173 billion in 2020, an increase of 39% from the estimated cost of $124.54 
billion in 2010 [9] and according to the UK’s Department of Health, cancer care 
costs the National Health Service (NHS) £5 billion annually [10]. Loss in 
productivity due to premature cancer-related deaths, or from family members taking 
time off work to care for sick relatives, also has an indirect but significant economic 
impact [11-13].  
Many cancers have an unknown aetiology. However mutations in genes that 
play key roles in tumour suppression such as p53 [14-17], BRCA1 and BRCA2 [18-




20], and/or over-expression of proto-oncogenes – normal genes that have the 
potential to differentiate into cancer-promoting genes i.e. oncogenes – have been 
linked with the disease [21-24]. These mutations can be hereditary or result from 
exposure to external factors such as smoking in lung cancer [25-28].  
The search for a cure for almost all types of cancer has been ongoing for 
more than five decades with billions spent on research [29, 30]. Yet, despite the 
advances in scientific and medical knowledge, technology, and a deep and better 
understanding of the human body, a cure is yet to be found. Whilst there has been 
progress in chemotherapy since the use of nitrogen mustard compounds as 
chemotherapeutic agents in the 1940s [31], reducing toxicity of many anti-cancer 
drugs still remains a huge challenge [32-34]. Since cancer drugs are designed to 
target rapidly dividing cancer cells, healthy cells with similar characteristics are 
often susceptible to these drugs. Temporary alopecia (hair loss) is a common side 
effect of chemotherapy because many anti-cancer drugs impair the mitotic process of 
actively dividing hair follicles [35].   
Despite the lack of a cure, early screening [36, 37], better screening methods 
such as computed tomography (CT, [38]), mammography [39], positron emission 
tomography (PET) scanning [40], medical resonance imaging (MRI, [41]), 
chemotherapy, radiotherapy, and changes in lifestyle behaviours have resulted in an 
improvement in incidence rates for some cancers. For example, a decline in smoking 
among men has seen a fall in lung cancer incidence for this group in Europe since 
the sixties [42, 43]. Lung cancer accounts for the top cause of cancer deaths in the 
developed world, followed by colon, breast, prostate and pancreatic cancers [4, 44-




46]. However, prognoses for lung, breast, prostate and colon cancers have improved 
considerably over time when compared to prognoses for pancreatic cancer [4, 47, 
48]. Pancreatic cancer, as will be discussed later, remains one of the most lethal 
cancers [49-51].   
In this thesis, work will be presented relating to studies on one of the 
proposed clinical markers for pancreatic cancer, S100P, as a therapeutic target. This 
protein has been reported to be useful in the early detection of the disease but little 
has been done to target it as a point of therapy. Using computational, synthetic and 
biological methods, this thesis will show a medicinal chemistry approach to 
identifying a lead compound against S100P using a rational structure-based drug 
discovery. It is hoped that the results of this project will contribute significantly 
towards the search for a cure for pancreatic cancer and explore S100P as a 
therapeutic target.  
 
  




1.1 The pancreas 
The pancreas (Figure 1.1A) is a digestive organ and an endocrine gland 
situated in the peritoneal cavity [52]. It is covered by the first part of the small 
intestine and surrounded in front by the stomach, liver, left kidney, spleen and aorta 
(Figure 1.1B). Its location in the body makes it a rather inaccessible organ [53, 54]. 
The pancreas is divided into four parts: the head, neck, body and tail. Histologically, 
almost 80% of the pancreas is made up of exocrine acinar cells and their associated 
ducts, while the Islet of Langerhans, characterised by their distinctive clusters within 
the exocrine cells, make up the rest of the this dual-functioning organ [55].  
As a digestive organ, the pancreas produces enzymes and fluids through its 
acinar cells and ducts [52]. These are then secreted into the duodenum via the ducts 
where they mix with the chyme from the stomach to help with digestion. The 
endocrine function of the pancreas is carried out by cells in the Islets of Langerhans. 
These synthesise and secrete the hormones insulin, glucagon, and somatostatin, 
which are involved in glucose metabolism [55]. 
  





Figure 1.1: The pancreas. A) The pancreas is divided into four main parts: the head, neck, 
body and tail. B) Location of the pancreas in the duodenal cavity relative to organs nearby. 









Both the endocrine and the exocrine components of the pancreas can be 
affected by disease or tumours [52, 55]. Either component can be affected by disease 
independent of the other. For example, diseases that affect exocrine cells of the 
pancreas may not generally affect the endocrine cells producing hormones. The main 
diseases that can afflict the pancreas are pancreatitis (acute or chronic), pancreatic 
endocrine tumours (PETs) and pancreatic ductal adenocarcinomas (PDACs) [54, 56].  
1.1.1.1 Pancreatitis 
The term pancreatitis means inflammation of the pancreas [52, 54]. This can 
occur when digestive enzymes produced by the acinar cells are released in the 
pancreas instead of their intended destination (duodenum) and they, in turn, digest 
the pancreas [52]. In a 1983 meeting under the auspices of the Pancreatic Society of 
Great Britain and Ireland, a group of international doctors specialising in pancreatitis 
offered the following definition to aid in the classification of pancreatitis:- 
 ‘‘a continuing inflammatory disease of the pancreas, characterised by 
irreversible morphological change, and typically causing pain and/or permanent 
loss of function’’ [57].  
In acute pancreatitis, the pancreas becomes inflamed over a short period of 
time resulting in severe abdominal pain and distention, nausea and vomiting [58]. 
Gallstones and alcohol consumption have been reported to be the main cause of 
acute pancreatitis although in some cases the cause seems to be idiopathic [59]. 
While this condition affects many people and has been reported to be on the rise, 




many of those affected only require brief hospital admission and few suffer fatality 
[60].  
Chronic pancreatitis has a more dismal prognosis with a higher mortality rate 
compared to acute pancreatitis [61]. Although alcohol consumption has been 
reported to be the major contributing factor to chronic pancreatitis (in Western 
countries), some cases have been attributed to genetic mutations, whilst, others have 
an idiopathic aetiology [62]. Diminished pancreatic function has been reported to be 
a major sign of chronic pancreatitis [63] although other diagnostic tools such as 
endoscopic ultrasonography and invasive techniques are needed to confirm the 
presence of the disease. Acute pancreatitis acquired from severe alcohol abuse has 
also been linked to the subsequent development of chronic pancreatitis [64]. Like 
acute pancreatitis, pain is a major feature of chronic pancreatitis and takes centre 
stage in the management of the disease in addition to other measures such as use of 
painkillers e.g. opiates [65] and abstinence from alcohol (if the latter is factor) [62]. 
1.1.1.2 Pancreatic cancer 
More than 95% of pancreatic cancers are of exocrine origin [52, 56]. 
However, despite the exocrine pancreas being mainly composed of acinar cells, these 
are believed to make up less than 1% of the total pancreatic cancers with the vast 
majority arising from the pancreatic ducts (also known as adenocarcinomas) [66]. 
Pancreatic ductal adenocarcinoma (PDAC) is the most common form, accounting for 
more than 85% of all pancreatic cancer cases [67]. Other types of cancers affecting 
the exocrine pancreas include acinar cell carcinoma, adenosquamous carcinoma, 
giant cell tumour, intraductal papillary-mucinous neoplasm (IPMN), mucinous 




cystadenocarcinoma, pancreatoblastoma, serous cystadenocarcinoma and solid and 
pseudopapillary tumours [68].  
Advances in molecular biology techniques have led to a better understanding 
of the cellular changes that occur leading to the development of pancreatic cancer 
[69]. It is believed that invasive pancreatic ductal adenocarcinoma (PDAC) – any 
reference to pancreatic cancer henceforth refers to PDAC – begins from non-
invasive precursor lesions such as mucinous cystic neoplasms (MCNs), intraductal 
papillary neoplasms (IPMNs) and pancreatic intraepithelial neoplasia (PanIN) [70, 
71]. The first two lesions, MCNs and IPMNs, are non-inflammatory cystic lesions 
and can be distinguished from each other by the presence of an ovarian-type stroma 
in the former which is absent in the latter [72]. PanIN, which is subdivided into four 
groups: PanIN-1A, PanIN-1B, PainIN-2, and PanIN-3, is <5 mm in diameter and is 
the most common neoplastic lesions present in invasive adenocarcinoma [73, 74]. 
IPMNs in comparison to PanIN, are larger, >5 mm in diameter, and less common in 
invasive cancer [74, 75]. The distinct cellular and molecular changes that occur in 
PanINs (Figure 1.2) have been suggested as a model to follow the progression of 
pancreatic cancer from precursor lesions to infiltrating neoplasm [69].  
 





Figure 1.2: Progression model for pancreatic cancer. The different stages of cellular changes that take place during the development of PanIN into 
infiltrating cancer. (Image reproduced from Chang et al. [76] with permission from John Wiley and Sons, 2015). 




Unlike exocrine pancreatic adenocarcinomas, cancers of the endocrine 
pancreas are less common, occurring more frequently in the young and have a much 
better prognosis [66]. Pancreatic endocrine tumours arise from cells of the Islet of 
Langerhans and are usually associated with a lack of, or excessive, secretion of 
hormone from cancer cells [77]. Although the molecular origins of pancreatic 
endocrine tumours are poorly understood, it is believed that genes that are mainly 
associated with exocrine pancreatic cancer are not involved in pancreatic endocrine 
tumours [78]. 
1.1.1.2.1 Pancreatic ductal adenocarcinoma (PDAC) incidence and mortality rates 
Pancreatic ductal adenocarcinoma (PDAC) is the fourth most common cause 
of cancer deaths in the United States and Europe behind lung, colon and breast 
cancers [3, 4, 66, 79, 80]. Unlike lung, colon, breast and prostate cancers which have 
high incidence rates, PDAC has a modest incidence rate and does not feature in the 
top five common cancers [3, 4]. However, the mortality rate from this cancer is as 
high as its incidence rate, highlighting its lethality [4]. In the USA, 46,420 new cases 
were estimated in 2014, with 39,590 deaths in the same year [4]. This was an 
increase from the number estimated in 2012 when more than 43,000 new cases of 
pancreatic cancer were predicted with an estimated 37,000 deaths in the same year 
[81]. In Europe, the estimated incidence for 2012 was 103,770, with 104,460 deaths 
(Table 1.1, [3]). According to the Office for National Statistics (ONS) for the UK, 
approximately 7,300 people were newly diagnosed with pancreatic cancer in 
England in 2011, with around 7,000 dying from the disease in the same period [82].  
 




  Incidence   Mortality 
  Both sexes   Male   Female   Both sexes   Male   Female 
  Cases ASR (E)   Cases ASR (E)   Cases ASR (E)   Deaths ASR (E)   Deaths ASR (E)   Deaths ASR (E) 
Oral cavity and pharynx 99.6 11  73.9 18.2  25.8 4.9  43.7 4.7  34.2 8.4  9.4 1.6 
Oesophagus 45.9 4.7  35.1 8.4  10.8 1.8  39.5 3.9  30.3 7.1  902 1.4 
Stomach 139.6 13.7  84.2 19.5  55.4 9.3  107.3 10.3  63.6 14.6  43.7 7 
Colon and rectum 446.8 43.5  241.6 55.7  205.2 34.7  214.7 19.5  113.2 25.2  101.5 15.4 
Liver 63.4 6.2  42.8 10  20.6 3.3  62.1 5.9  39.9 9.1  22.2 3.4 
Gallbladder 29.7 2.7  11.9 2.7  17.9 2.8  20.9 1.9  7.9 1.8  13 2 
Pancreas 103.8 10.1  51.9 12.1  51.8 8.3  104.5 9.9  52.6 12.2  51.9 8.1 
Larynx 39.9 4.4  36 8.8  3.9 0.8  19.8 2.1  18.1 4.3  1.7 0.3 
Lung 409.9 41.9  290.7 68.3  119.2 21.6  353.5 35.2  254.4 59.1  99 17.2 
Melanoma of skin 100.3 11.1  47.2 11.4  53.1 11  22.2 2.3  12.1 2.8  10.1 1.8 
Breast       463.8 94.2        131.2 23.1 
Cervix uteri       58.3 13.4        24.4 4.9 
Corpus uteri       98.9 19.3        23.7 3.9 
Ovary       65.5 13.1        42.7 7.6 
Prostate    416.7 96        92.2 19.3    
Testis    21.5 5.8        1.6 0.4    
Kidney 115.2 12.1  71.7 17.2  43.4 8.1  49 4.7  31.3 7.2  17.7 2.8 
Bladder 151.2 14.4  118.3 26.9  32.9 5.3  52.4 4.5  39.5 8.5  12.9 1.8 
Brain, nervous system 57.1 6.6  30.7 7.8  26.4 5.6  45 4.9  24.6 6  20.4 4 
Thyroid 52.9 6.3  12.3 3.1  40.7 9.3  6.3 0.6  2.1 0.5  4.3 0.7 
Hodgkin lymphoma 17.6 2.3  9.3 2.5  8.3 2.1  4.6 0.5  2.6 0.6  2 0.4 
Non-Hodgkin lymphoma 93.4 9.8  49.5 11.9  43.9 8  37.9 3.5  20.3 4.6  17.5 2.7 
Multiple myeloma 38.9 3.8  20.5 4.7  18.4 3.1  24.3 2.2  12.2 2.7  12.1 1.8 
Leukaemia 82.3 8.8  46.4 11.3  35.9 6.9  53.8 5.1  29.5 6.7  24.3 3.9 
All sites but non-melanoma skin cancers 3439.6 355.7  1829.1 429.9  1610.5 306.3  1754.6 168  975.9 222.6  778.6 128.8 
Table 1.1: Estimated numbers of new cancer cases and deaths from cancer (thousands), age-standardised rates (ASRs) (per 100,000) by sex and cancer site in 
Europe in 2012.  (Table reprinted from Ferlay et al. [3] with permission from Elsevier Ltd, 2015). 




Of the top five common causes of cancer death, pancreatic cancer has the 
worst head-to-head prognosis, with a less than 3% 5-year survival rate ([4], Figure 
1.3). This is mainly due to the asymptomatic nature of the disease and the late stage 
at the time of diagnosis [83]. Risk factors for developing the disease include age, 
smoking, alcohol consumption, chronic pancreatitis [84, 85] and genetic 
predisposition/defects [68].  
1.1.1.2.2 Diagnosis and staging 
Some of the tools used to currently diagnose PDAC in the UK include 
ultrasound scanning, computerised tomography (CT) scanning, magnetic resonance 
imaging (MRI) scanning, endoluminal ultrasonography (EUS), laparoscopy, 
endoscopic retrograde cholangiopancreatography (ERCP), and biopsy [86]. 
Endoscopic ultrasonography-guided fine-needle aspirational biopsy (FNAB) is also 
used to aid in diagnosis and staging of PDAC [87-89]. These methods are used in 
combination to help increase the accuracy of the diagnosis. However, due to the 
asymptomatic nature of the disease and a lack of adequate indicative biomarkers, 
these techniques are not normally sensitive enough to detect the disease in its early 
stages [86]. Diagnosis often only occurs once the cancer has metastasised to nearby 
structures such as the bile duct, mesenteric and coeliac nerves, and duodenum [90]. 
Cancer of the head of the pancreas may sometimes lead to the obstruction of the bile 
duct leading to painless jaundice as one of the symptoms [91]. The similarities 
between PDAC and chronic pancreatitis [92] can make diagnosing pancreatic cancer 
a challenging task, with the latter being a high risk for the development of the cancer 
[85, 93, 94]. This can sometimes lead to initial misdiagnosis of the cancer as chronic 
pancreatitis and cause a delay to timely intervention and treatment.  




Once the cancer is detected, it is “staged” based on the size or the tumour (T), 
the involvement of lymph nodes (N), and metastasis (M) of the cancer to nearby 
tissues or organs ([95], Figure 1.4, Table 1.2). In addition to the TNM classification, 
there is also a stage grouping that can include a combination of the TNM stages at 
different levels (Table 1.3). The accurate staging of the cancer is crucial in order to 
offer the best possible outcome for treatment, hence the ability and sensitivity of the 
diagnostic tool(s) used to detect the disease for accurate staging is vital. 
  





Figure 1.3: Five-year survival rates for selected cancers by race and stage at diagnosis, US, 
2003-2009. Pancreatic cancer (enclosed) has the worst survival rate of all cancers shown. 
(Image reproduced from Siegel et al. [4] with permission from John Wiley and Sons, 2015).   





Figure 1.4: TNM staging of pancreatic cancer. The staging is used to describe the size of the 
primary tumour (T), presence of lymph nodes with cancer (N), and metastasis of the cancer 









Table 1.2: Breakdown of the TNM (Tumour, lymph Nodes, Metastasis) staging of 
pancreatic cancer. (Table adapted from Evans et al. [95]). 
 
Table 1.3: Stage grouping of pancreatic cancer in combination with the TNM staging. 









Stage 0 Tis N0 M0 
Stage IA T1 N0 M0 
Stage IB T2 N0 M0 
Stage IIA T3 N0 M0 
Stage IIB T1                      N1             M0                  
  T2 N1             M0 
  T3 N1             M0 
Stage III T4 Any N M0 
Stage IV Any T Any N M1 
  
  Primary tumour (T) Lymph nodes (N) Distant metastasis (M) 
Tis Carcinoma in situ (includes 
PanINs) 
    
X Primary tumour cannot be 
assessed 
Regional lymph nodes 
cannot be assessed 
Distant metastasis cannot 
be assessed  
0 No evidence of primary 
tumour 
No regional lymph node 
metastasis  
No distant metastasis 
1 Tumour limited in pancreas, 
2 cm or less in diameter 
Regional lymph node 
metastasis 
Distant metastasis 
2 Tumour limited to pancreas, 
more than 2 cm in diameter 
    
3 Tumour extends beyond the 
pancreas but without 
involvement of celiac axis or 
superior mesenteric artery 
    
4 Tumour involves the celiac 
artery (unresctable primary 
tumour) 
    





The type of treatment offered to combat PDAC usually depends on the stage 
at which the cancer is detected. Once the cancer has been conclusively confirmed, 
initial treatment is then based on whether the cancer is localised within the pancreas 
(0, IA and IB), locally invasive (IIA, IIB and III) or has metastasised to distant 
organs (IV) [91]. Surgery is offered as the first line of treatment to patients where the 
cancer has not metastasised [91, 96]. However because pancreatic cancer is usually 
quite advanced at the time of diagnosis only 5-25% of patients presenting with 
tumours are amenable to resection [79]. The three main types of operations offered 
to patients are the pylorus preserving pancreaticoduodenectomy (PPPD) where the 
head of the pancreas, duodenum, part of the bile duct and gall bladder are removed 
[97, 98]; the Whipple procedure – which is similar to PPPD but also involves 
removal of the lower part of the stomach [99]; and total pancreatectomy – a 
procedure where the whole pancreas is removed in addition to the duodenum, part of 
the stomach, part of the bile duct, gall bladder, the spleen, and surrounding lymph 
nodes [100]. Radiation therapy (radiotherapy) is often offered concomitantly with 
surgery for better efficacy [101].  
For patients in whom the cancer is at an advanced stage, surgery is often too 
late and not the route of therapy offered [102]. For these people, their only hope lies 
with chemotherapy and radiotherapy. In the UK, current chemotherapeutic 
interventions for pancreatic cancer include treatment with gemcitabine [96, 102, 
103], an anticancer agent which is sometimes used alongside 5-fluorouracil (5-FU, 
[104], Figure 1.5). Nab-paclitaxel, the protein-bound form of paclitaxel (Figure 1.5) 
given in combination with gemcitabine [105], is the only drug on the Cancer Drugs 




Fund (CDF) list in the UK for untreated metastatic pancreatic cancer [106]. This 
fund was established as an additional resource of funding to provide access to cancer 
drugs otherwise not routinely available on the National Health Service (NHS, [106]). 
However, this drug is being withdrawn from the CDF list because it is deemed to be 
economically unviable due to the perceived diminished benefits it offers to patients 
in comparison to its high cost [106], underlining the urgent need for drugs with 
better efficacy. Other treatments currently under clinical trial phases include the use 
of gemcitabine in combination with cytotoxic compounds other than 5-FU [107-
109].  
Chemotherapeutic intervention with these medicines only delays the return of 
the cancer and offers patients a modest extension of lifespan [110], with gemcitabine 
and 5-FU reportedly conferring only an 18% and 2% increased survival rate 
respectively at 12 months in patients with advanced pancreatic cancer [104]. The 
survival rate for nab-paclitaxel in combination with gemcitabine was found to be 
35% after 12 months compared to 22% for the gemcitabine-only treatment group in 
Phase III clinical trials [111]. PDAC has a high recurrence rate that contributes to the 
high mortality rate. Survival rates after resection are low [112], and less than 5% of 
people diagnosed with the cancer survive beyond five years [67, 113].  
  





Figure 1.5: Chemotherapeutic agents used to treat pancreatic cancer. 
 
  




1.1.1.2.4 Current research  
Recently a lot of research has been carried out to develop a molecular [114-
116] and genetic profile of pancreatic adenocarcinoma [117, 118]. Implicated genes 
include KRAS, TP53, INK4A, as well as abnormal or genetic mutations of the 
epidermal growth factor (EGF) and transforming growth factor (TGF)-β signalling 
pathways [69, 70, 119]. Carbohydrate antigen 19-9 (CA19-9) is a tumour marker 
present in pancreatic and biliary tract cancers [120] and has been used as a marker 
for pancreatic cancer in the advanced stages of the disease [121]. Its use as a clinical 
marker is however not encouraged, as it can give unreliable results given that it is 
also highly expressed in pancreatitis, cirrhosis [120] and other diseases involving 
bile ducts [120, 122]. It is for these reasons that, in 2006, the American Society of 
Clinical Oncology (ASCO) advised against its use for this purpose [123]. Their 
recommendation is to use the marker to monitor levels in people receiving 
chemotherapy.  
Consequently, the need arises to find a marker(s) that can identify pancreatic 
cancer in its early stage to enable adequate intervention for better prognosis. A lot of 
research into PDAC is geared towards such an outcome and recently, three proteins, 
LYVE1, REG1A and TFF1, present in urine were reported to be able to differentiate 
between patients with, and without pancreatic cancer with better accuracy compared 
to CA19-9 [124]. The findings of this study offers an inexpensive, non-invasive 
method for early diagnosis of the disease, which is very promising. However, it 
remains to be seen how successful the results translate clinically. S100P is another 
small protein that has been shown to be highly expressed in early development of 




pancreatic cancer, and has the potential to be used as a clinical marker for the disease 
[114, 121, 125, 126].  
1.2 S100 proteins 
S100 proteins are so named due to their 100% solubility in ammonium 
sulphate and were first identified in bovine brain cells approximately 50 years ago 
[127]. Since then 24 human isoforms have been identified [128-130].   
S100 proteins are EF-hand type Ca2+-binding proteins involved in signal 
transduction, regulation of protein phosphorylation, enzyme activities, transcription 
factors, Ca2+ homeostasis, cell cycle progression and cell motility [128, 131]. They 
form the largest subgroup of the EF-hand Ca2+-binding superfamily of proteins but 
unlike other Ca2+ binding proteins such as calmodulin, troponin C, myosin light 
chains and parvalbumin, S100 proteins only act as modulators and are not involved 
in altering key cellular functions [132].   
The term EF was first coined by Kretsinger and Nokolds [133] when they 
were describing the carp muscle calcium-binding protein parvalbumin. EF was used 
to describe two of the six α-helices of the main chain of the parvalbumin protein: 
helices E and F and their relationship to the bound calcium ion (Figure 1.6). In EF-
hand Ca2+-binding proteins, the EF region can be visualised as a clenched right hand 
with the forefinger and thumb extended at an approximate right angle to each other 
(Figure 1.6B). The extended thumb represents the direction of the COOH-terminus 
of helix F while the pointed forefinger is directed towards the NH2-terminus of helix 
E. The clenched fingers represent the EF loop where the calcium ion is bound [133]. 




The EF-hand has a helix-loop-helix conformation and each hand is able to bind two 
calcium ions per protein [128].  
Besides the canonical EF-hand on the C-terminus (with 12 amino acids) 
which is common to all EF-hand proteins, S100 proteins also exhibit another 
“pseudo” EF-hand present on the N-terminus (with 14 amino acids, Figure 1.6C) 
[134]. In S100 proteins, the N-terminal domain is made up of helices I and II (HI and 
HII) joined by loop 1 (L1) while the C-terminal domain is formed by helices III and 
IV linked by loop 3 (HIII-L3-HIV) (Figure 1.6A). This means that each S100 protein 
with the exception of S100A10 [135] can bind two Ca2+ ions. However, since S100 
proteins mainly exist as homodimers or in some cases heterodimers with other 
family members [136], each dimer is able to bind four calcium ions. Calcium 
binding in the different loops is not identical (Figure 1.6C); the C-terminus has a 
higher affinity for binding calcium ions than the N-terminus [137-140]. However, 
interaction with target proteins is not always calcium dependent and studies have 
shown that some S100 proteins are able to bind to their target with or without bound 
calcium ions [141, 142]. Binding of calcium ions is believed to induce a 
conformational change in the protein which results in exposure of a hydrophobic 
binding domain that helps with target recognition and binding [140]. In addition to 
binding calcium ions, some S100 proteins also bind other metal ions such as Mg2+, 
Zn2+ or Cu2+ [143, 144] and sometimes binding of these metals increase the affinity 
for calcium binding [138]. 
Most S100 proteins are believed to exert their function by interacting with 
RAGE, the receptor for advanced glycation end-products [145, 146]. RAGE is an 




immunoglobulin protein present in large quantities during inflammation and damage 
to epithelial cells [147]. Interaction of RAGE with its ligands which include S100 
proteins has been implicated in Alzheimer’s disease [148], diabetes [149], 
inflammation, colon [150], pancreatic [151], lung [152] and breast cancers [153]. 
Many S100 proteins have been isolated and their 3D holo structure [154-159] 
and/or apo form resolved experimentally [158, 160-164]. In addition, the three-
dimensional structures of some family members bound to their target proteins have 
also been elucidated [165-168]. S100 proteins are found only in vertebrates and 
function both intracellularly and extracellularly [169]. Expression of S100 proteins is 
tissue specific [170] and they can be present in both normal and diseased cells [171]. 
It is their elevated presence in diseased cells that has been the focal point of intense 
research in recent years [118, 172-177].  
  





Figure 1.6: Calcium-binding S100 protein. A) Cartoon model showing the helix-loop-helix 
domains with bound Ca2+ (image taken from http://goo.gl/aepDse. Last accessed 11th 
October, 2015). B) Illustration of Ca2+ at the EF-hand using the thumb and index fingers 
(image taken from Zhou et al. [178] with permission from Elsevier Limited, 2015). C) 
Calcium-binding affinity of S100P (highlighted in blue and red), a member of the S100 








1.2.1 S100P and pancreatic cancer 
S100P (Figure 1.7) is a 95 amino acids member of the S100 protein family 
first identified and isolated from human placenta in 1992 [179, 180]. Like other 
members of the S100 family of proteins, S100P consists of two EF-hands linked 
together by a flexible linker [159]. Studies have shown that the protein exists as a 
homodimer, with the monomers held together at the dimeric interface by non-
covalent interactions [141]. The two EF-hands (EF-hand 1 and 2) lie in positions 12–
47 and 49–84 respectively. The loop (position 62–73) linking the canonical EF-hand 
2 on the C-terminus has a much higher affinity for binding calcium ions than loop 1 
(position 19–32) linking the “pseudo” EF-hand 1 on the N-terminus [139, 141].  
S100P has been reported to be present in both normal and malignant tissues 
[171] and it is its expression in the latter which is the subject of much research as it 
is overexpressed in many cancers [121, 172, 181, 182]. Its role in normal tissues is 
not clear, but a study by Sato and Hitomi [183] showed that it is present during the 
differentiation of human oesophageal epithelial cells implying that it may play a role 
in this process. In tumour cells, over-expression is believed to lead to tumour 
malignancy and proliferation [170, 177], increased resistance to therapy [181], 
decreased survival rates in cancer patients [184], immortalisation of breast cancer 
cells [174] and decreased sensitivity to treatment with chemotherapeutic agents [185, 
186]. These actions are believed to be mediated through the protein’s interaction 
with its receptor RAGE, the receptor for advanced glycation end-products [150, 151, 
187, 188]. 
  


















Figure 1.7: S100P protein homodimer. A) Ball and stick and ribbon depiction of the protein. 
B) Ribbon model of the protein showing the dimeric interface (enclosed in red). C) 









There has been considerable evidence implicating S100P over-expression in 
pancreatic cancer [118, 151] and it has been proposed as a novel marker in 
identifying this cancer [121, 125, 126, 190-193]. A study of the salivary 
transcriptome for early markers of pancreatic cancer identified S100P as one of the 
over-expressed proteins in patients with pancreatic cancer [194]. This is promising as 
it will provide an easy and non-invasive procedure for early detection of the cancer 
in the clinic. The protein has also been shown to be highly sensitive and specific in 
discriminating between chronic pancreatitis and pancreatic cancer [121, 194].   
1.3 S100P as a therapeutic target and project aims 
Although much has been reported on S100P and its expression in many 
tumours, there is little research published targeting the protein as a possible route of 
therapy for pancreatic cancer at the start of this project in 2011. In 2006 a study by 
Arumugam et al. [195] showed that S100P interacts with cromolyn (Figure 1.8), an 
anti-allergy drug that is used in the treatment of asthma [196], and that this 
interaction inhibits cell proliferation and tumour growth by blocking the formation of 
the S100P-RAGE adduct in pancreatic cancer cells. They showed that cromolyn’s 
inhibitory effect was more significant in combination with gemcitabine than on its 
own [195]. An analogue of cromolyn, C5OH (Figure 1.8) has been reported to be 
more potent than cromolyn in inhibiting S100P-RAGE interaction both in vitro and 
in vivo [197]. However, cromolyn is a very water-soluble compound and is poorly 
absorbed by the gastrointestinal (GI) tract with less than 1% oral bioavailability 
[198, 199]. This renders it highly unsuitable as a drug candidate for cancer therapy. 
Consequently, there is a gap in the market to exploit this area in order to combat 
pancreatic cancer.  




This project seeks to identify potential novel chemotherapeutic agents that 
will act as inhibitors of S100P-RAGE adduct formation. This will be achieved using 
computational and synthetic chemistry techniques to rationally design novel 
inhibitors based on an understanding of cromolyn-S100P interaction. Identified 
compounds will be subsequently screened for activity against pancreatic cancer cell 
lines. This project will use a medicinal chemistry approach incorporating computer-
aided drug design (CADD) techniques (Chapter 2), synthetic chemistry (Chapters 3 
and 4), and biological screening (Chapters 3 and 4) techniques – these form the early 
stages of a drug discovery process (Figure 1.9) – to identify the potential lead 
candidates.  
  






Figure 1.8: Cromolyn and its analogue C5OH. 
 
  





Figure 1.9: Drug discovery stages. Academia is mainly involved in (but not limited to) basic research involving target identification and validation, 







































1.4 Overview of drug-target/receptor interaction  
A drug can be viewed of as a compound that interacts with a biological 
system to elicit a physiological response [201]. Drugs are thus a diverse group of 
compounds and can vary broadly from caffeine in a cup of coffee to keep the mind 
alert, morphine to numb pain and snake venom that has the potential to kill [201]. In 
order for a drug to exert its effect, toxic or otherwise, it has to interact with a target 
or receptor. A biological target is an entity within a living system whose activity is 
modified by a drug or external stimulus [202]. This interaction between drug and 
target occurs via complementarity between the two and is held together by weak 
forces such as hydrogen bonding and hydrophobic interactions [201].  
Medically, drugs are developed to fill a therapeutic void e.g. where there is 
no known cure for a disease, or to improve the efficacy of existing drugs [203]. In 
order to do so, a target is first identified and validated. A drug target could be a 
protein, receptor, an enzyme, ion channel, nuclear hormone receptor, membrane 
transport protein or nucleic acid [202]. One or more of these targets can be 
implicated in disease states, thus it is not unusual to have different drugs designed 
for different targets in the same disease. For instance, in cancer therapy, alkylating 
agents such as cisplatin target DNA [204] while topoisomerase inhibitors like 
Topotecan (Hycamtin, GSK) are designed to target the topoisomerase enzymes that 
separate DNA strands [205].  
Target validation – defining the target’s role or involvement in disease [206], 
is part of the first stages in a drug discovery process after the target’s discovery 
(Figure 1.9). Many approaches, in vitro, in vivo, and in silico, are employed to 




validate a target’s role in disease. In sense reversal, an in vitro technique, the target 
gene’s expression is reduced and the corresponding physiological response and 
effect on disease is studied [207]. Examples of such an approach include antisense 
technology, gene knockouts, use of ribozymes and RNA interference (RNAi) [208-
211]. In contrast, proteomic validation techniques which include the use of 
antibodies [212], aptamers [213], peptides [214], and microarrays, can be used to 
modify a target protein’s activity without affecting its expression [206, 215].  
In vivo target validation techniques include the use of animal models e.g. 
mice and zebrafish to study the effect of gene silencing in disease states [216-218] 
whereas with in silico methods, computers are used to predict potential drug targets, 
e.g. from the human genome [219], or to predict interactions between a potential 
drug molecule and a model of a target macromolecule via computer simulation 
[206]. This simulation is carried out with or without prior knowledge of the structure 
of the biological target [220]. Examples of in silico drug validation techniques 
include in silico gene expression analysis [221], and homology modelling which 
involves building a 3D model of a target protein using information from known, 
homologous proteins as templates [222, 223].   
Once a target is validated, it then becomes druggable. A druggable target is 
one that has the potential to interact with drug-like chemical compounds to produce a 
pharmacological effect [224]. S100P has been validated and identified as a druggable 
target [125, 150, 175, 177, 181, 185, 195, 225-228]. It has thus passed the first stages 
required of a drug discovery project i.e. target identification and validation. This 
project is mainly involved in the next stage of drug discovery i.e. “hit” finding, and 




will achieve this by using in silico software to first identify putative pockets on the 
protein, then predict the interaction of cromolyn with these pockets via molecular 
simulations and docking. The predicted interactions will be used to design 
pharmacophore constraints as filters to identify “hits” from virtual libraries. All these 
steps are part of what is known as computer-aided drug design (CADD), and will be 
achieved using the Molecular Operating Environment (MOE) drug discovery 
software suite [189]. 
1.5 Computer-Aided Drug Design (CADD) 
The use of computing power to solve chemical problems – computational 
chemistry, or to study biological systems – computational biology, or to organise and 
analyse biological and genomic data – bioinformatics, demonstrates the important 
role that computers play in modern-day drug discovery and development.  
Computer-aided drug design (CADD) involves the use of computer power to 
expedite the time and resources spent at the discovery stage by identifying 
compounds with favourable properties and potential to be successful drug candidates 
[229]. To facilitate this, specialised software and algorithms have been developed 
with the ability to carry out calculations to identify molecular targets, predict binding 
interactions between target(s) and small molecules, and estimate binding affinity 
[230]. Structural databases such as the Protein Data Bank (PDB) containing 3D 
experimental data of macromolecules [231], the ZINC database holding millions of 
compounds for virtual screening [232], and the Cambridge Crystallography Data 
centre which contains crystal structure data of small molecules [233], and private in-
house databases provide useful sources for starting points in most CADD projects. 




The Swiss Institute of Bioinformatics (SIB) Click2Drug website 
(www.click2drug.org) has detailed listings of software, databases and web servers 
used in CADD. 
The role of CADD following target identification and validation is dependent 
on two main factors: the availability of 3D experimental structure of the target, 
and/or known drugs that are active on the target. If there are no experimentally 
determined 3D structures of the target, a ligand-based or pharmacophore search of 
known compounds is adopted ([234], Figure 1.10). If the experimental 3D structure 
of the target macromolecule is available, a structure-based drug design (SBDD) 
approach is often taken to identify lead compounds [234].  
In ligand-based drug design studies, structure/activity data from compounds 
that bind to a target with a known affinity is used to build 3D quantitative structure 
activity relationship (QSAR) pharmacophore models to search databases for 
structurally related compounds on the premise that compounds with similar 
structures/pharmacophores will share similar properties [235-238]. A pharmacophore 
is an abstract 3D representation of the geometric, steric and electronic properties of a 
compound that are necessary for target recognition and binding [239].  
Receptor- or structure-based drug design (SBDD), which includes docking 
and de novo design, is employed where the 3D structure of a therapeutic target is 
known or available. It involves docking of a ligand(s) into the binding site of the 
target and predicting the quality of fit between ligand and target which is then scored 
and ranked according to the best fit [240-242]. A SBDD approach is used in this 
thesis as there is 3D experimental data available on S100P in the PDB database.  





Figure 1.10: Simplified pathways of computer-aided drug design. (Image adapted from 
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1.5.1 Docking  
Docking is used in SBDD for two main purposes: to predict the best pose of a 
ligand at the binding site of a target macromolecule and to estimate the tightness of 
fit between ligand and target [243, 244]. Docking plays a key role in SBDD where 
the information from the macromolecule–ligand complex could form the basis of 
whether a ligand is progressed through to the lead-optimisation stage or discarded. 
The strength of any docking algorithm lies in its ability to predict the binding affinity 
between the macromolecule and ligand complex [245]. This ability, known 
computationally as the scoring function, is a set of computed mathematical 
constraints designed to predict the experimental free energy of binding (∆G) between 
the ligand and macromolecule after docking [246]. Whereas docking will try and 
mimic as closely as possible the native conformation of the protein–ligand complex 
in the experimental structure, it is the scoring function that decides the quality of this 
fit [247].  
For many docking algorithms, there is a high success rate in reproducing the 
conformational pose of the X-ray crystal structure but predicting the binding affinity 
is not usually as successful [248, 249]. Most scoring functions are designed based on 
experimental data and the accuracy of their results reflect that of the observed 
experimental data [250]. Any errors contained in the experimental data could 
therefore influence the results of the scoring function. Despite this limitation, 
docking algorithms, in most cases, are still capable of discriminating between 
potential actives and non-binding compounds [251]. 




Several docking algorithms are available, either free of charge or 
commercially via drug discovery software suites. The most commonly used docking 
programs, according to the number of citations in published articles between 1990-
2013 [230], are AutoDock [252], GOLD [253], and Glide [254]. Others include 
FlexX [255], Surflex-Dock [256], Fitted, AutoDock Vina [257], and MOE [258].  
1.5.2 Structure-based Drug Design (SBDD) on S100P 
In this thesis, SBDD techniques were employed on the publically available 
3D experimental structures of S100P to identify lead candidates with potential to 
bind to the protein (Chapter 2). This was achieved using pocket-detection 
algorithms, free and commercial, to identify putative binding pockets on the protein. 
The Molecular Operating Environment (MOE) drug discovery software suite [189] 
was used for docking, pharmacophore design and virtual screening studies once 
putative sites have been identified. ChemAxon’s JChem software package 
(www.chemaxon.com) was used to cluster identified “hits” from virtual screening 
studies.     
1.5.2.1 Algorithms used to identify putative binding pockets on S100P 
Knowledge of cavities on a target macromolecule is essential before 
embarking on structure-based drug design studies. These are the sites at which the 
designed small molecules will interact with the target. Most of the 3D experimental 
structures of macromolecules available in the PDB database are resolved in complex 
with ligands, showing the binding pocket(s). However, for those macromolecules 
that are not resolved in complex with ligands, as is the case in S100P, it becomes 
imperative to predict these sites prior to carrying out any SBDD studies.   




The four pocket-detection algorithms used in this work, Fpocket [259], Site 
Finder [260], Pocket-Finder and Q-SiteFinder [261], to identify putative binding 
pockets on S100P use either geometry- (Fpocket, Site Finder, Pocket-Finder) or 
energy-based (Q-SiteFinder) approaches. Geometry-based methods use the shape of 
the protein to predict potential binding sites [262] while energy-based methods 
employ small chemical probes to study energetically favourable interactions with the 
protein surface [263]. 
Fpocket’s search method uses alpha spheres and Voronoi tessellation to 
identify clefts and cavities on a protein surface [259]. An alpha sphere is one in 
contact with four other atoms on its boundary and contains no internal atom [259]. 
Voronoi tessellation involves the division of space into regions called Voronoi cells 
around a given set of centroid points [264]. In Fpocket, a cluster of alpha spheres is 
subjected to Voronoi tessellation, pruned to remove clusters with unfavourable 
characteristics such as polar groups, and then ranked according to their ability to 
bind to small molecules [259].  
MOE’s Site Finder uses the same alpha sphere method as Fpocket to detect 
potential binding pockets. Site Finder works by identifying regions of tight atomic 
packing and filtering out inaccessible regions and exposed hydrophilic spheres [260]. 
Spheres are then classified as hydrophobic or hydrophilic based on their hydrogen 
bonding character. Hydrophobic spheres with the most hydrophobic contacts with 
the receptor are ranked as the top predicted site [265].  
Q-SiteFinder, an energy-based pocket-detection algorithm, identifies 
potential binding pockets by calculating the van der Waals interaction between a 




methyl probe and the protein [266]. These probes are then clustered and ranked 
according to their probe energy [261]. Pocket-finder, a geometry-based algorithm 
developed by Laurie et al. [266] to compare against Q-SiteFinder, implements the 
POCKET algorithm [267] when searching for binding pockets. Potential sites are 
identified when a probe of radius 3 Å passes through a three-dimensional grid and 
undergoes a protein–site–protein (PSP) event, this occurs when there is an 
interaction between the probe sphere and an atom followed by an alternate period of 
no interaction then interaction [261]. Identified pockets are ranked by the number of 
probes in the sites instead of probe energy used in Q-SiteFinder. 
1.5.2.2 Virtual screening of lead-like databases 
Virtual screening plays a crucial role in the rational approach to drug design 
and discovery by speeding up part of the lead identification process, where, with 
appropriate computing power, millions of compounds within virtual libraries can be 
screened for novel bioactive hits within hours [268]. Virtual screening does not 
replace the long established high-throughput screening (HTS) used in lead 
identification in the pharmaceutical industry; it is seen as a complementary tool to 
help streamline the process of lead identification [269-271]. This means that 
thousands of compounds are filtered out via virtual screening with those that have 
been predicted to be active carried through to HTS thus eliminating/decreasing cost 
and waste.  
HTS is a highly automated process that uses robotics and sophisticated data 
analysis methods to screen a huge collection of molecules for biological actives in 
assays [272, 273]. The cost involved in putting together compound libraries and 




equipment for HTS, which analyses millions of individual compounds in a 
biochemical assay, can be prohibitive [274]. Its routine application is therefore 
limited to the pharmaceutical industry and very few in academia who can afford the 
financial resources and human expertise to run it.  
Virtual libraries for virtual screening could either be accessed from in-house 
databases [275, 276], commercial vendors, or from ZINC [232], a free database of 
commercially-available compounds for virtual screening. These databases contain 
compounds that are known as leads or lead-like compounds, a term that is used to 
differentiate them from drugs. Lead-like compounds have properties that make them 
amenable to optimisation before they could become drugs [277]. Some leads are 
marketed drugs whose structure have been modified to yield novel drugs whilst 
others, “pure leads”, have no prior therapeutic value [277]. Leads also fulfil 
Lipinski’s rule of five, which states that for a drug to be orally active it should have a 
molecular weight of less than 500, a lipophilicity (logP) value below 5, less than five 
hydrogen bond donors and less than 10 hydrogen bond acceptors [278]. Unlike 
drugs, leads tend to exhibit weak affinities in the high micromolar to millimolar 
range to their target [279]. 
The MOE software that was used in this study comes with lead-like 
databases that contain commercially available leads from specialist vendors. This 
database, and the ZINC lead-like database, were the virtual libraries screened for 
“hits” in this study.  




1.5.2.3 Compound clustering  
Given a group of heterogeneous compounds, clustering is an analysis 
technique that finds similarity between individual compounds in order to put them 
together in a cluster [280]. The premise is that compounds in a given cluster will 
have more in common with each other than with others in a different cluster.  
Clustering was applied in this study following virtual screening studies in 
order to identify a diverse collection of compounds that will be selected for 
validation studies. ChemAxon’s Library Maximum Common Substructure 
(LibMCS) application (Version 5.8.2, 2013, ChemAxon, www.chemaxon.com), 
which uses maximum common substructure subgraph [281, 282] to identify common 
fragments in compounds in a hierarchical manner, was employed. Compounds 
sharing a user-defined maximum common substructure are hierarchically grouped 
together until there are no more shared fragments (Figure 1.11). Singletons are 
outlier compounds that do not share common subgraphs with any of the clusters.  
The above SBDD techniques will form the basis for the next Chapter which 
presents a detailed methodology and results on computational studies on S100P. 
 





Figure 1.11: Substructure hierarchy system used by ChemAxon’s Library MCS for clustering compounds. Initial structures are shown at the bottom of the 
hierarchy, the next level contains maximum common substructure of initial structures, and above that on the first level is the fragment common to all 





















Despite published data on the S100P’s interaction with cromolyn [195], metal 
ions [141] and small peptides [138] at the outset of this project, there was limited 
published information regarding the mechanism by which these molecules might 
interact with the protein. The majority of the published work used biochemical methods 
such as column affinity chromatography [195, 283, 284], standard assays [172, 177, 
181, 227] and microarray techniques [285-287] to ascertain the existence of affinity, 
rather than to probe mechanisms that gave rise to it.  
As such, the following chapter details the computational tools used to identify 
and investigate potential binding sites on S100P and cromolyn, a ligand shown to bind 
to the protein [195]. The resulting binding interactions between the protein and ligand 
formed the basis for pharmacophore models used to screen lead-like databases, to 
identify novel “hit” molecules with potential to bind to S100P and inhibit the S100P 
RAGE interaction. 
  





Since the discovery of S100P in 1992 [179, 180], there is growing evidence of 
the crucial role it plays in many cancers. In breast cancer, S100P has been reported to 
immortalise human epithelial cells in vitro [174], make the cancer cells more 
proliferative [288], as well as confer poor survival rates to patients [289]. In prostate 
cancer, S100P over-expression is shown to positively correlate with tumour growth, 
metastasis and protection of host cells against camptothecin-induced apoptosis [181]. In 
lung cancer, increased expression of the protein was found to induce metastasis in non-
small cell lung cancer patients, leading to increased angiogenesis [290]. A decrease in 
survival rate in lung cancer patients was also observed to correlate with increased S100P 
expression [184]. In colorectal cancer, S100P is reported to induce cancer cell growth, 
proliferation and metastasis via its binding to RAGE – the receptor for advanced 
glycation end-products [150]. In pancreatic cancer, it has been shown to be highly 
present in the early stages of the disease [291], and promotes growth, metastasis and 
invasion of cancer cells via its interaction with RAGE [151, 177]. Of all these cancers, 
pancreatic cancer has the worst prognosis with no specific early markers to identify the 
disease in its early stage. It is this urgency to find specific markers for the disease that 
S100P has been proposed as a potential clinical marker for the cancer [121, 125] which 
makes it an ideal therapeutic target against the cancer [191, 192, 287].  
It is not known what causes the over-expression of S100P in pancreatic cancer 
[192] but hypomethylation of the gene has been found in many pancreatic cancer cell 
lines as well as in primary tumours [287]. Whilst the protein has been associated with 




many targets, including ezrin [283, 292] and S100P binding protein [118, 293], it is its 
interaction with RAGE that is believed to be instrumental in promoting cancer cell 
growth, migration and invasion [150, 151, 187, 225]. Since interaction with RAGE 
occurs via the dimeric protein [294], any attempts at designing potential inhibitors 
against this interaction must therefore be carried out on the protein dimer, particularly 
on the dimeric interface. Dimer interfaces in proteins have been targeted in drug 
discovery studies to prevent dimerization [295, 296] or interaction with target [297]. 
  





2.2.1 Identification, manipulation and analysis of experimental (3D) S100P 
structures 
A search of the RCSB Protein Data Bank (PDB) website ([231], www.rsb.org, 
accessed in October 2011) using the keyword “S100P” generated results that contained 
information on two structures of the protein deposited in the database: an X-ray crystal 
structure (PDB ID: 1J55, [159]) and an NMR ensemble (PDB ID: 1OZO; [298]).   
The X-ray crystal structure of S100P was extracted in its monomeric form 
(Figure 2.1A) and saved as a PDB file. The biologically functional homodimer was 
created using the UCSF Chimera package [299]. In the program, the protein was 
downloaded from the Protein Data Bank using its PDB Accession Code 1J55. Under 
Favourites, Model Panel, Biological Unit was selected for the program to display the 
biological oligomer using the REMARK 350 BIOMT matrices in the PDB file header. 
The generated dimer was saved as a PDB file.      
Conversely, the NMR ensemble was extracted from the PDB website as one 
huge PDB file containing 16 models (Figure 2.1B). Individual models were separated by 
copying the header and the 95 amino acid (aa) sequences of both chains A and B for 
each model onto a WordPad document that were then saved as a Rich Text File using 
the file extension .pdb.   





Figure 2.1: 3D experimental structures of S100P. A) X-ray crystal structure of S100P (PDB ID: 
1J55; [159]). Calcium ions are shown as green spheres and missing residues 45-51 are depicted 
by a broken line. B) NMR ensemble of S100P (PDB ID 1OZO; [298]). The sixteen conformers 
of the ensemble are overlaid in different colours. (Images generated in MOE).   
A
B




2.2.2 Identification of putative binding pockets at the dimeric interface of S100P 
Four different pocket-detecting algorithms – Fpocket (http://bioserv.rpbs.univ-
paris-diderot.fr/cgi-bin/fpocket [259]), Pocket-Finder 
(http://www.modelling.leeds.ac.uk/pocketfinder/ [261]), Q-SiteFinder 
(http://www.modelling.leeds.ac.uk/qsitefinder/ [261]), and Site Finder [260] – were 
employed to identify potential binding sites on the dimeric interface of the S100P 
protein. Where the algorithm was used online, individual S100P PDB files were 
uploaded to the respective servers and once potential pockets were identified, the 
resulting PDB files with cavity information were saved. 
With the exception of Site Finder, an application within the Molecular Operating 
Environment (MOE2010.09) drug discovery software suite, all pocket-detection 
algorithms were available to use online for free (all were accessed in October, 2011). 
When Site Finder was used, the protein was prepared using the Protonation 3D wizard, 
which assigned ionisation states to the macromolecule, added protons where necessary 
and checked for tautomers and rotamers [300]. Default settings for the calculation of 
binding pockets were retained as follows: probe radius of 1.4 Å for a hypothetical 
hydrophilic hydrogen bonding atom (such as N or O), probe radius of 1.8 Å for a 
hypothetical hydrophobic atom (such as C), rejection of a hydrophilic sphere that has no 
hydrophobic alpha sphere within 3 Å. Once prepared, potential pockets identified by 
Site Finder on the protein were rendered with dummy atoms for subsequent docking 
studies.      




2.2.3 Docking  
Docking studies were carried out using the Dock application within 
MOE2009.10 to investigate potential interactions between cromolyn and S100P. Prior to 
docking, the ligand was built using the Builder feature in MOE and energetically 
minimised using the default Merck Molecular Force Field 94 (MMFF94x) force field 
settings to optimise its 3D coordinates. Both ligand and protein were prepared for 
docking using the Protonate 3D tool. The binding site(s) to dock the ligand into were 
restricted to those identified at the dimeric interface of the protein by the pocket-
detecting algorithms previously described.  
With the exception of sites identified by Site Finder, the dimeric binding cavities 
were recreated during docking by selecting the amino acid residues identified as 
belonging to the site by the cavity detection algorithm and restricting docking to a cut-
off radius of 4.5 Å from these selected residues. The dimeric interfaces for Site Finder 
were rendered in MOE with dummy atoms using an identical distance restraint.  
Once both protein and ligand were prepared and the binding site defined, the 
ligand was docked into the binding site using the default Triangle Matcher docking 
placement method. The resulting poses were ranked with the London scoring function. 
Fifty poses were retained for energy minimisation in the pocket before they were 
rescored using the Generalized-Born Volume Integral/Weighted Surface area 
(GBVI/WSA) scoring function [301]. Output poses are ranked according to the 
GBVI/WSA binding free energy (S score).  




2.2.4 Pharmacophore design  
The Pharmacophore Query Editor in MOE2009.10 was used to build 
pharmacophore models with a set of constraints on the location and type of ligand 
annotations using the default Unified scheme. Using appropriate protein-ligand 
complexes from docking studies as templates, points of interactions between the ligand 
and S100P dimeric binding site were selected to create two three-point 3D 
pharmacophore queries. Both queries are the same except in the descriptors used to 
define them. In the first “stringent” query, the two hydrogen bond acceptors (HBAs) 
were defined as anionic, whilst in the second “relaxed” query, the same acceptors were 
defined as hydrogen bond acceptors. All query distances and angles remained the same.  
2.2.5 Virtual screening and clustering 
Two databases were screened using the pharmacophore queries described in 
section 2.2.4. The MOE Conformation Database within the MOE software package 
which contains 3D conformations for approximately 650,000 lead-like compounds, and 
lead-like compounds from the ZINC database [232] which had more than three million 
compounds at the time of access (November, 2011).  
Since the MOE database came ready-to-use, no further processing was applied to 
the compounds prior to virtually screening them. The database was screened using both 
pharmacophore queries. The same Dock settings were applied during the virtual 
screening. Additionally, the pharmacophores generated in section 2.2.4 were used as 
constraints to guide molecule selection.  




Lead-like compounds from the ZINC database were downloaded in their 
SMILES (Simplified Molecular-Input Line-Entry System) format [302] before 
converting them into 3D molecules using the conformational import tool in 
MOE2011.10. During the conformational import, molecules were “washed and filtered” 
to deprotonate/protonate acids/bases; filter out reactive groups; omit compounds with a 
molecular weight >600, sum of acceptor and donor atoms exceeding 12, rotatable bonds 
of more than 7, chiral centres greater than 4, more than 8 rings, and d-hybrids. The 
molecules satisfying the inclusion criteria were minimised to their lowest energy 
conformations using the default molecular mechanics settings within the conformational 
import tool. Minimised compounds were saved in the MOE molecular database (MBD). 
A similarity search using a Tanimoto Coefficient threshold of 0.7 was carried out 
between the MOE and ZINC databases to filter out the MOE compounds that had 
already been screened from the ZINC database. This was carried out using ChemAxon’s 
Instant JChem application (ChemAxon JChem Software Suite, Version 5.8.2). The final 
ZINC compound database, with a total of 765,278 molecules, was screened using the 
same Dock settings outlined in section 2.2.3.    
Compounds that match the pharmacophore restraints from the virtual screenings 
of both databases – “hits” – were clustered in ChemAxon’s Library Maximum Common 
Substructure (MCS) application (Version 5.8.2) [303]. Library MCS clustered the “hits” 
by matching all atom types, bond types, charge, and whole rings, using the default 
minimum MCS size of 9.  




2.2.6 Rescoring “hits” generated from virtually screening studies in “native” 
S100P 
The three mutated amino acid residues in the NMR ensemble of S100P: A6, S85, 
and T92 were mutated back to their original amino acids T6, C85, and A92 respectively 
using the Protein Builder tool in MOE. “Hits” identified from virtual screening were 
rescored in the “native” protein to compare any differences or otherwise between the S 
scores obtained from the virtual screenings.  
The Rescore protocol in the Dock panel of MOE2014.08 was used to rescore 
“hits” in the native protein. The binding sites were restricted to the sites used in the 
original virtual screening. “Hits” were rescored using the GBVI/WSA scoring function 
while the placement method was set to None.    
  




2.3 RESULTS AND DISCUSSION 
2.3.1 Identification, manipulation and analysis of experimental (3D) S100P 
structures  
Selecting the most appropriate experimental 3D structure on which to carry out 
structure-based drug design (SBDD) studies is a crucial step in any drug discovery 
project. In the case of S100P, there were two entries deposited in the PDB database 
using two different methods, a high resolution X-ray crystal structure, (PDB Accession 
Code 1J55) and an NMR ensemble containing sixteen conformers (PDB Accession 
Code 1OZO). Both methods can generate high quality structures although it has been 
claimed that X-Ray crystallography, being the older and more established method of the 
two, produces structures of better quality [304]. For proteins that crystallise readily, this 
method provides an excellent choice for structure determination.  
Alternatively, NMR solution spectroscopy is ideal for studying protein folding 
and dynamics [305, 306]. An advantage of this technique over X-ray crystallography is 
its ability to study proteins in solution, which gives an indication of protein dynamics. 
However, unlike X-ray crystallography, structure determination using NMR 
spectroscopy is limited to small proteins as large proteins can present overlapping peaks 
in the NMR spectra that are difficult to assign [307].  
  




2.3.1.1 S100P X-ray structure  
The X-ray crystal structure of S100P (PBD ID 1J55) was resolved at 2 Å with an 
R-value and free R-value (Rfree) of 0.214 and 0.267 respectively [159]. The R-values 
give an indication of the quality of the model. The smaller this value, the better the fit of 
the model to experimental data [306]. However, because calculation of the R-value 
could be biased following refinement of the model to better fit experimental data, the 
free R-value was introduced [308]. The free R-value is similar to the R-value in 
definition except it is calculated on a small subset of experimental observations that was 
not used in the refinement of the model [309]. In an ideal model, the difference between 
the two values is <0.05 [308]. For 1J55, the difference between R- and free R- values is 
0.053. This falls within the accepted range for a model to be considered an “accurate 
model” of the protein [310], thus making 1J55 an acceptable model to be used as a 
SBDD studies.  
The X-Ray crystal structure of S100P 1J55 has two calcium ions bound to the 
EF-hands with a classical pentagonal bipyramid geometry [159]. There are four helices 
present: helix 1 (E3-Y18), helix 2 (L30-E40), helix 3 (A53-61), and helix 4 (F71-A92) 
(Figure 2.2). Since no electron density was observed for loop residues 46-51, and C-
terminus residue 95, these are absent from the final model of the protein deposited in the 
PDB. The absence of these residues could impact on SBDD studies using this model, as 
any efforts to remodel the missing residues could introduce error into the system that 
could compound errors in subsequent drug design studies.  




S100P 1J55 was deposited in the PDB in its monomeric form. However, the 
authors provided information in the accompanying PDB Header for in silico generation 
of the biologically relevant dimeric form of the protein. The S100P dimer is formed by 
hydrophobic interactions related by a crystallographic 2-fold axis and hydrogen bonding 
between hydrophilic residues [159]. Three hydrophobic contacts are present at the 
dimeric interface all involving the 1/1’ and 4/4’ helices. The first contact is provided by 
residues L4, A7, M10, I11, and V14 in helices 1 and 1’, with hydrogen bonding from E3 
and D13 stabilising the contact; the second contact comes from residues F71, I75, A79 
and H86 in the 4/4’ helices, with hydrogen bonding between S72 and S83 reinforcing 
contact. This second hydrophobic contact also extends into the hydrophobic core of the 
protein which is formed by residues F74, F77, V78 and I81. The third and final contact 
involves interactions between L4, M10, I12, and F15 of helices 1/4’, with V78, T82 and 
H86 of helices 4/1’ (Figure 2.3). These residues involved in these hydrophobic contacts 
on the S100P dimeric interface will be crucial in putative binding pockets identified on 
the protein for subsequent SBDD studies.  
 





Figure 2.2: Monomeric X-ray crystal structure of S100P (1J55) showing helices 1-4 and the 
calcium ions (blue spheres). (Reprinted from Zhang et al. [159] with permission from Elsevier 
Limited, 2015). 
  





Figure 2.3: Hydrophobic contacts at the dimeric interface of two subunits of 1J55. A) The first 
contact between helices 1/1’. B) The second contact between helices 4/4’. C) Third contact 
between helices 1 and 4’. The residues forming the hydrophobic contacts are shown in ball and 
stick representation. Segments from each subunit of the protein are depicted in pink and green 








2.3.1.2 S100P NMR ensemble  
Unlike the crystal structure, structures of the NMR ensemble of S100P (PDB ID 
1OZO) were determined in the absence of Ca2+ by triple resonance NMR spectroscopy 
[298]. Triple resonance NMR spectroscopy uses three types of atomic nuclei – 1H, 15N 
and 13C – to assign resonances to atoms forming the backbone of proteins especially 
those proteins enriched with 13C and 15N [311]. Instead of defining a single set of atomic 
coordinates, NMR spectroscopy uses restraints that cover a range of allowed distances 
and angles, to thoroughly explore all regions of conformational space that a protein 
could adopt [306, 312]. Hence an ensemble of viable structures, as opposed to a single 
definitive model, are generated via this method. A huge advantage of using NMR 
spectroscopy to determine protein structure is its ability to provide information on the 
average structure of the protein as well as its dynamics in solution [313]. In addition, the 
NMR model revealed the intrinsically disordered regions in S100P i.e. residues 46-51 
[314] that were not resolved in the X-ray model of the protein.  
In comparison to X-ray crystallography, quality assessment of NMR structures is 
more complicated as there is no associated R or free-R value by which to gauge the 
accuracy of the generated models. Instead, from the initially generated conformers, a 
sub-group with the least residual error values, the ensemble, is selected to represent the 
NMR structure of the protein [305]. Calculation of the pairwise root mean square 
deviation (RMSD) of the C-α atoms or heavy backbone atoms of the ensemble members 
gives an indication of the precision, and quality, of the NMR data [305, 307]. Lower 
RMSD values signify a better overall fit to the experimental data [306]. A mean RMSD 




value of 1.0 Å for C-α atoms is comparable to a precision of approximately 2.0 Å for an 
X-ray crystal structure [307]. Precision is defined as the reproducibility of the 
experiment.   
Fifty conformers were initially calculated for 1OZO and from these, 16 members 
with the lowest energy and least restraint violations were selected to form the final 
ensemble [298]. The structure deemed most representative of the ensemble was 
conformer 15. Mean RMSD values for this member were 1.35 Å and 0.89 Å for 
backbone atoms of residues of 3-90 and 3-86 respectively, and 2.01 Å and 1.39 Å for 
heavy atoms of 3-90 and 3-86 respectively [298]. These values indicate that models in 
1OZO are suitable templates to use for SBDD studies.   
A second way of assessing the quality of NMR structures is to look at the 
geometric quality of the models. Since the quality of NMR structures is dependent on 
the force fields and refinement procedures used during optimisation of the models, it is 
critical that the resulting models contain minimal errors with respect to their geometry 
[306]. Ramachandran plots provide valuable information on the stereochemical quality 
of a protein by mapping the distribution of backbone dihedral angles ψ and φ onto the 
four regions of the plot: favoured, additionally allowed, generously allowed and 
disallowed [306, 315]. In MOE, three different colours are used to represent the 
distribution of torsion angles of different residues in the four quadrant of the 
Ramachandran plot (Figure 2.4). Small green squares represent residues with sterically 




hindered sidechain atoms that are clustered in the core region. Yellow squares represent 
residues in the allowed region and outliers are marked as red crosses.   
Ramachandran assessment of each of the conformers in the1OZO ensemble 
show a number of residues that lie outside of the allowed regions of the Phi-Psi plot 
(Appendix). For conformer 15, the most representative model in the ensemble, most of 
the amino acids fall within the favoured regions. There are however 13 outliers (Figure 
2.4, Table 2.1). Eight of the 13 residues that demonstrate unusual stereochemistry are 
located in the Ca2+-binding region [141]. However, it is not known if the absence of 
Ca2+ in the NMR-derived structure of S100P is responsible for the unusual conformation 
of these residues in the Ramachandran plot. These residues were found in the favoured 
regions in the Ramachandran plot of 1J55 (Figure 2.4B). 
 
  




Table 2.1: Ramachandran data for conformer 15 of 1OZO showing the outliers and their φ/ψ 
angles. Residues involve in Ca2+-binding are highlighted in blue. Residues absent in the X-ray 














Model Chain Residue Psi Phi 
15 A S21 -68.5 122.3 
A T25 127.2 96.5 
A Q26 86.2 -56.5 
A K49 -44.1 -159.4 
A D50 -72.3 19.2 
A A53 -71.3 41.4 
A H86 9.9 -54.0 
B T25 156.7 81.6 
B K49 101.1 146.3 
B K51 5.6 46.6 
B D62 -34.7 -31.1 
B D66 -41.4 -161.7 
B A67 -39.0 169.3 





Figure 2.4: Ramachandran plot for S100P showing residues in allowed (orange contours) and core (green contours) regions. A) Conformer 
15 of 1OZO. Outlier residues involved in Ca2+-binding are highlighted in blue. Outlier residues absent in the X-ray crystal structure 1J55 are 
shown in red. B) Ramachandran plot for 1J55. (Plots generated in MOE).  
A B




The S100P structures in the NMR ensemble were resolved as dimers in contrast 
to the crystal structure. There were three mutations in the ensemble members: residue 6 
(TA), residue 85 (CS) and residue 92 (AT). It is not known why these mutations 
are present but the initial templates the authors used in their calculation of the NMR 
ensemble have similar mutations in the same positions [141, 161].  
Despite these mutations, the geometric data and RSMD values for the NMR 
ensemble point to it being a good template for SBDD work. It is however important to 
note that the end-product of both X-ray diffraction studies and NMR spectroscopy is a 
model that is based on observed experimental data. This model could be a good or bad 
model depending on the accuracy of the experimental data on which it was determined 
from, as well as other factors during the modelling and refining of the data [313]. If 
there are uncertainties and/or errors present in the data or in the model, which is then 
used as a template for subsequent SBDD studies, this could lead to amplification of 
original errors resulting in inaccurate results. Given that independent X-Ray 
crystallographic- and NMR spectroscopy-derived models of S100P yielded similar 
models of the protein, gives confidence that both are accurate representations of the true 
nature of the protein, and that the models are good ones. However, since the protein was 
not fully represented in the crystal structure due to missing flexible regions, and since 
the model was monomeric, 1J55 was deemed undesirable as a template for SBDD 
studies. The NMR ensemble of S100P was therefore advanced for further in silico drug 
design studies. Nevertheless, information from the X-ray crystal structure was used as a 
guide in SBDD studies carried out using the NMR structures.  




2.3.2 Identification of putative dimeric bindings sites on S100P 
2.3.2.1 Potential binding sites on 1OZO 
With the exception of the calcium ion-binding regions observed when calcium 
ions were co-crystallised in the X-ray crystal structure of S100P (1J55), there is no direct 
experimental evidence for small-molecule binding sites on the S100P protein. 
Identifying putative binding pockets where small molecules can bind and hence disrupt 
the interaction between S100P and RAGE was therefore a critical step in the progression 
of the project. Understanding the nature of these potential binding cavities will play a 
central role in the rational design of a therapeutic agent targeting S100P.  
The use of a number of independent geometry- and energy-based cavity 
detection algorithms to identify potential binding pockets on S100P was done in order to 
increase confidence in the results generated and to ensure that the final binding site(s) 
selected were determined by consensus, thus eliminating the potential for bias present in 
any single algorithm. This is additionally important given that the pocket-detecting 
programs used were not developed using NMR structures. This is largely due to the 
lower numbers of NMR structures, when compared to X-Ray crystal structures, 
available in the PDB. As of May 18th 2015, of the 101,060 protein structures in the PDB 
archive, 90,662 (~90%) were determined by X-ray crystallography, 9,597 (9.5%) by 
NMR and the rest by other methods such as electron microscopy, and small angle X-ray 
scattering. This does not detract from the use of NMR structures in drug discovery as 
high quality NMR structures, where available, have been shown to be good templates 
for drug design studies [304, 316].  




Given that an NMR structure was used in this research, and to counteract 
criticism that the tools used to identify putative binding cavities were not suitable for 
such structures it was imperative that all conformers in the NMR ensemble were 
subjected to both energy- and geometry-based pocket-searching programs in order to 
demonstrate that similar pockets were identified by both methods, and that an objective 
consensus could be reached with respect to the most appropriate pocket at the S100P 
dimeric interface for further study.  
Four cavity-detection algorithms were investigated as part of this research: 
Pocket-Finder, Q-SiteFinder, Fpocket and Site Finder. These four tools use either 
energy-based (Q-SiteFinder) or geometry-based (Pocket-Finder, Fpocket and Site 
Finder) methods to determine potential binding sites on macromolecules. In a large-
scale validation study Fpocket and Site Finder were found to successfully predict the 
expected binding site for a group of diverse high quality X-ray crystal structure protein-
ligand complexes in their top five predicted pockets with a success rate of more than 
80% [262]. When Q-SiteFinder was used to predict binding sites in protein structures 
without a co-complexed ligand, the expected pocket was predicted in the top three sites 
for 86% of the proteins studied [261]. In contrast, Pocket-Finder, a geometry-based 
pocket-detecting algorithm developed to compare the performance of the energy-based 
algorithm, was found to be less successful than Q-SiteFinder in predicting putative 
binding sites, but performed better than LIGSITE [317], the pocket-detecting algorithm 
it was based on [261]. All four algorithms demonstrate a high success rate in predicting 




the correct site in their top 5 predictions, and as such were credible tools with which to 
identify putative binding sites on S100P.  
Both Q-SiteFinder and Pocket-Finder programmes returned the ten largest 
pockets detected for each S100P conformer in the NMR ensemble (Table 2.2 and 2.3). 
Although the same number of pockets were returned by both programmes, they were 
ranked differently and thus, pocket 1 for conformer 1 in Q-SiteFinder does not 
correspond to pocket 1 for the same conformer in Pocket-Finder. That said, some of the 
pockets identified by Pocket-Finder were subsets of those identified by Q-SiteFinder 
(discussed below).  
The volumes observed for putative binding pockets is not constant. Individual 
pocket volumes differed between the programmes used because each algorithm uses a 
different method to calculate pocket volumes. In addition, the volumes between similar 
pockets on different conformers of the ensemble will also differ. This is due to the 
variation in protein conformation that is representative of the dynamic nature of the 
protein in solution. Developers of Q-SiteFinder and Pocket-Finder used different 
parameters to calculate site volume [261]. In general, volumes estimated by Q-
SiteFinder on all conformers of 1OZO were 3-12 times bigger than those estimated by 
Pocket-Finder. Q-SiteFinder however was reported to have a higher accuracy and 
precision rate than Pocket-Finder in predicting binding sites, with predicted sites 
mapping accurately onto ligand coordinates [261].  




Table 2.2: Potential binding pockets and their estimated volumes identified by Q-SiteFinder for each of the S100P conformers in the 
1OZO ensemble. Pockets on the dimeric interface are highlighted in yellow. 
 






volume (Å³) 1 2 3 4 5 6 7 8 9 10 
1 18546 346 331 297 236 228 129 167 163 129 124 
2 18536 366 238 252 252 190 214 170 153 172 129 
3 18591 469 358 326 270 179 179 174 163 136 103 
4 18610 341 259 271 207 211 216 165 119 130 116 
5 18456 327 252 220 279 206 180 153 147 135 110 
6 18495 456 324 235 300 258 206 217 141 128 114 
7 18608 313 204 203 181 194 170 171 154 146 127 
8 18619 321 296 251 255 178 198 144 149 157 163 
9 18559 487 459 340 269 152 156 107 135 115 110 
10 18618 783 275 254 195 180 184 141 114 130 116 
11 18503 388 217 220 149 148 134 131 125 116 129 
12 18500 371 356 297 240 237 200 185 136 148 102 
13 18556 381 253 353 324 207 155 199 164 108 109 
14 18641 255 308 177 189 166 185 161 124 115 145 
15 18566 349 321 285 190 176 202 182 198 167 110 
16 18474 509 386 289 254 224 133 122 106 106 126 
  




Table 2.3: Potential binding pockets and their estimated volumes identified by Pocket-Finder for each of the S100P conformers in the 
1OZO ensemble. Pockets on the dimeric interface are highlighted in yellow.   
 
    Predicted site volumes (Å³) 
S100P NMR 
ensemble  conformer 
Protein 
volume (Å³) 1 2 3 4 5 6 7 8 9 10 
1 18546 67 51 44 28 22 21 24 20 20 16 
2 18536 101 67 56 52 54 44 38 29 30 25 
3 18591 58 54 51 36 27 24 23 20 15 14 
4 18610 77 66 47 51 44 40 35 37 28 20 
5 18456 88 59 54 49 47 37 31 25 23 24 
6 18495 148 79 70 55 44 38 35 20 17 15 
7 18608 86 63 70 41 38 35 19 19 17 17 
8 18619 75 44 42 38 24 20 22 18 17 16 
9 18559 71 62 58 39 35 31 28 25 23 17 
10 18618 65 62 34 32 21 20 20 14 17 13 
11 18503 90 72 61 51 46 41 39 40 35 26 
12 18500 65 58 58 55 49 45 36 34 32 29 
13 18556 105 82 56 52 54 48 33 33 26 24 
14 18641 86 76 67 40 26 19 18 16 14 15 
15 18566 70 68 47 47 48 50 39 30 28 25 
16 18474 65 65 59 55 50 34 34 23 17 14 
 




Similar to Pocket-Finder, both Fpocket and Site Finder employ geometric 
approaches to search for putative binding pockets. Geometric pocket-detecting programs 
use the geometry of the protein surface to compute potential binding sites [259, 265, 
318, 319].  
In contrast to Q-SiteFinder and Pocket-Finder, where 10 pockets were identified 
for each conformer of 1OZO, Fpocket identified between seven and 12 pockets in total 
(Table 2.4). Despite this disparity in the number of pockets identified in each conformer, 
some pockets identified by Fpocket were similar to those previously identified by both 
Q-SiteFinder and Pocket-Finder (as discussed below). 
The output for putative sites identified by Site-Finder was different to the three 
pocket-detecting algorithms discussed above. In addition to the residues involved in the 
identified sites, the program also returned the number of alpha spheres in the site which 
is indicated as Size in Table 2.5. The number of hydrophobic and sidechain contact 
atoms in the receptor are indicated under Hyd and Side respectively. In upgrades of 
MOE, sites were ranked according to their propensity for ligand binding (PLB) i.e. 
druggability (Table 2.5B, [320]). 




Table 2.4: Potential binding pockets identified by Fpocket for each of the S100P conformers in the 1OZO NMR ensemble. Pockets on the dimeric 











   Real volume approximation (Å³)  
S100P 
Protein 


























1 9 603 592 573 462 226 131 163 249 550       
2 8 272 256 179 405 541 427 135 101         
3 8 877 740 659 663 384 413 149 548         
4 10 727 665 751 672 209 483 140 712 613 433     
5 9 919 271 213 115 228 467 159 427 90       
6 7 875 876 160 161 547 151 633           
7 11 1196 504 317 556 497 286 179 323 131 310 571   
8 8 994 508 477 483 587 156 607 84         
9 8 489 575 288 401 168 410 92 431         
10 7 941 958 561 416 300 166 149           
11 8 884 247 613 305 218 267 146 78         
12 10 808 240 217 608 319 619 134 639 128 313     
13 10 309 199 490 378 550 258 473 165 96 112     
14 6 714 954 160 314 147 139             
15 7 958 447 302 198 653 341 880           
16 12 232 310 473 373 461 458 330 630 273 203 120 312 




Table 2.5: Pockets identified by two different versions of MOE’s Site Finder on conformer 15 of 1OZO.  A) MOE2010.09. B) 
MOE2011.10.Pockets on the dimeric interface are highlighted in yellow. 
 
*Number of contributing spheres 
ᵟNumber of hydrophobic points 




ᶿPropensity for ligand binding score 
 
 
Site Size* Hydᵟ Side† Residues 
1 101 22 82 1: (H86 K91 T92 K95) 2: (I12 F15 S16 S19 G20 S21 E22 Q26 D70 F71) 
2 77 19 64 1: (I12 F15 S16 S19 S21 Q26 F71) 2: (H86 K87 Y88 F89) 
3 106 11 81 1: (M1 E5 A6 M8 G9 M10 I12 D13 S16) 2: (I81 T82 S85 H86 F89 T92) 
4 47 8 32 2: (K30 K49 D50 K51 D52 A53 V54 D55) 
5 55 6 40 1: (L41 P42 G43 F44 A84 S85 E90 K91) 2: (M1 T2 E5) 
Site Size PLBᶿ Hyd Side Residues 
1 85 1.20 10 66 1: (M1 E5 A6 M8 G9 I12) 2: (I81 T82 S85 H86 F89 T92) 
2 90 0.81 21 74 1: (H86 K91 T92 K95) 2: (I12 F15 S16 S19 G20 S21 E22 Q26 F71) 
3 74 0.23 19 62 1: (I12 F15 S16 S19 S21 Q26 F71) 2: (H86 F89) 
4 34 -0.72 3 27 1: (M1 A6 G9 M10 I12 D13 S16) 2: (H86 F89) 
5 55 -1.52 6 40 1: (L41 P42 G43 F44 A84 S85 E90 K91) 2: (M1 T2 E5) 
B 
A 




Pockets at the dimeric interface identified by each of the algorithms on all 
conformers of 1OZO were comparable, e.g. pocket 3 from Pocket-Finder on conformer 
15 is a subset of pocket 1 on the same conformer from Q-SiteFinder (Figure 2.5). The 
same is true for two pockets identified by Site Finder on the same conformer. In MOE 
2010.09, Site Finder predicted two sites that were subsets of pockets 1 and 8 identified 
by Q-SiteFinder (Figure 2.5). These sites were ranked first and third respectively 





      





Figure 2.5: Overlap between pockets identified by Q-SiteFinder, Site Finder, Pocket-Finder and Fpocket on the dimeric interface of conformer 15 
of the NMR ensemble of S100P. All pockets shown here identified by Fpocket, Site Finder and Pocket-Finder are subsets of pockets 1 and 8 


















2.3.2.2 Binding sites on the dimeric interface of 1OZO 
It has been shown that the biological function of S100P is dependent upon 
dimerization [284, 292, 321, 322]. Hence, it was hypothesised that cromolyn exerted its 
effect on S100P-RAGE interaction by binding at or near to the homodimeric interface, 
thus preventing the protein interacting effectively with its receptor. The significance of 
the dimeric interface was highlighted in a recent report that showed residues that form 
part of the dimer interface of S100P – residues 83-94, and residues 2-14 – as important 
in binding to RAGE [294]. Consequently, only putative sites identified at the dimeric 
interface of the S100P 1OZO NMR ensemble were examined in detail in subsequent 
docking and virtual screening studies.  
The pocket-detection algorithms identified two cavities at the dimeric interface 
for each conformer in the NMR ensemble, one on each side of the protein. However, 
whilst there were similarities between these pockets identified for a given conformer, 
none were identical e.g., pockets identified by Site Finder at the dimeric interface of 
conformer 15 were not identical with respect to either size or amino acid composition 
(Table 2.5). This lack of symmetry at the dimeric interface of members of the NMR 
ensemble of S100P is in contrast to a recent publication by Penumutchu et al. [323] who 
identified two symmetrical pockets on an NMR ensemble of S100P that they resolved 
using the coordinates of 1J55, the crystal structure of S100P. Manipulation of the 
monomeric form of the protein will result in symmetrical dimeric interfaces given that 
this manipulation is a simple superposition of the monomer. S100P is a dynamic protein, 
and modelling a dynamic structure on a static structure has the potential to introduce 




flaws into the system. The NMR ensemble 1OZO is direct experimental evidence 
against the symmetric nature of the S100P dimeric binding site.   
However, a second report published by the same group [294] identified residues 
E5, D13, F44, Y88 and F89 as playing a vital role in S100P-RAGE binding. These 
residues were also identified in the dimeric interface of some of the pockets identified in 
this study. In addition, residues that form the hydrophobic core that is exposed upon 
Ca2+ binding to S100P [141] were also present in sites identified at the dimer interface 
in this study. This hydrophobic core, formed mainly by residues F15, F71, and F74 
[159], has been reported to be important in target interaction in S100P [138, 284]. All 
this evidence points to the S100P NMR ensemble as a valid template in drug design 
studies.  
2.3.2.3 Potential binding sites on the X-ray crystal structure of S100P (1J55) 
The functional dimer form of 1J55 was generated by the UCSF Chimera package 
[299] using the atomic coordinates included in the PDB file of the protein. A 
symmetrical dimer resulted with four bound calcium ions (Figure 2.6). The generated 
dimer formed was an exact and opposite mirror image of the original monomer. Given 
that this symmetry was not observed in any of the structures of the NMR ensemble, 
there is a possibility that the dimeric interface created using the coordinates of 1J55 
could have some limitations and have introduced some errors into the system. Moreover, 
when the resolved dimer was investigated for potential binding sites using Q-SiteFinder, 
identified pockets had smaller volumes compared to those of the NMR conformers 




(Figure 2.7). These pockets were too small to accommodate cromolyn, a known 
inhibitor of the S100P-RAGE interaction, and the ligand to be used for molecular 
docking [195]. The volume of cromolyn is 375 Å3 (calculated from 
http://www.molinspiration.com/cgi-bin/properties).  
Sequence-only superposition of the C-α atoms of the 1J55 monomer with Chain 
A of conformer 15 of 1OZO, the most representative of the NMR ensemble, using the 
Protein Superpose tool in MOE gave a RMSD of 3.75 Å (Figure 2.8). Structural 
superposition of the two models using the Flexible structure Alignment by Changing 
AFPs (Aligned Fragment Pairs) with Twists (FATCAT) [324] however resulted in a 
RMSD of 2.73 Å. Although these values may seem high for models of the same protein 
(and suggest significantly different structures), this apparent discrepancy could be due to 
several factors. Regions of variability (traffic-light colour coded in Figure 2.8) are those 
in the flexible loop regions. These regions have high B-values in the X-ray model, 
demonstrating the uncertainty in the location of these atoms in the crystal lattice. In 
addition, the superposition was only carried out over 88 residues as 1J55 has part of its 
linker region missing as well as the last terminal residue in its model. Also of note is the 
position of helix 2 and length of helix 4 in the apo and Ca2+-bound states of the protein. 
Molecular dynamics (MD) simulations have been used to show a change in the relative 
position of this helix in apo-S100P and Ca2+-bound S100P [325]. The length of helix 4 
is believed to be extended by six residues upon Ca2+ binding compared to the apo state 
[298]. All these factors could contribute to the high RMSD value.   





Figure 2.6: The dimerised structure of 1J55 (Chain A cyan, Chain B red) generated by the 
USCF Chimera software [299] showing four bound calcium ions (green spheres). Red and cyan 
spheres represent water molecules from the crystal structure.  
   





Figure 2.7: Putative binding pockets (magenta spheres) on the dimerised structure of 1J55 
predicted by Q-SiteFinder. The largest predicted pocket (arrow) has a volume of 123 Å3 which 















Figure 2.8: Superposition of C-α atoms of 1J55 with Chain A of conformer 15 of the 1OZO ensemble in MOE. A) Cartoon model of 
monomeric 1J55 (cyan) with bound Ca2+ (green spheres) superposed with Chain A of conformer 15 (red). B) RMSD bar graphs of the 
superposed atoms. Green colours indicate high conformation similarity while red indicate low similarity in backbone conformation.  
A 
B 




2.3.3 Molecular docking of cromolyn to the S100P dimeric interface 
Initial dockings studies were focused on sites located at the dimer interface that 
had a volume close to or larger than the calculated ligand volume e.g. pocket 1 of 
conformers 9 and 15 (Table 2.6). However, in spite of their volume, docking cromolyn 
to these pockets showed that only part of the ligand was found to fit into the cavity, with 
the remainder protruding into solvent (Figure 2.9). Closer examination of the S100P 
conformers showed that for some of them there was more than one potential binding site 
at the dimer interface, and sites that had been identified as separate sites by the pocket-
detection algorithms were actually close enough to be thought of as two lobes of a larger 
binding pocket (Figure 2.10). The pocket-detection algorithms work by identifying 
regions of tight atomic packing (Fpocket, Site Finder), or by using a probe of a certain 
radius (Pocket-Finder), or clusters with favourable binding energy (Q-SiteFinder). It is 
thus feasible that two pockets that are close to each other but are separated by a few 
atoms that do not fall within the algorithms’ criteria for inclusion within a putative site 
will be identified as two separate sites instead of one. Where these pockets exist, they 
were combined to form the larger cavity and the dockings experiments repeated.  
Analysis of all conformers in the 1OZO NMR ensemble showed that only one 
member, conformer 15, was able to yield a combined cavity at the dimeric interface that 
was of sufficiently large volume to accommodate cromolyn, and that this occurred for 
only one of the two cavities at the dimeric interface in the structure. These two sites, 
Pockets 1 and 8 in Table 2.6, were also identified by the other pocket-detection 




algorithms on the same conformer (Table 2.7). As such, only this conformer was carried 
forwards for docking studies. 
 









Predicted site volumes (Å³) 
1 2 3 4 5 6 7 8 9 10 
1 346 331 297 236 228 129 167 163 129 124 
2 366 238 252 252 190 214 170 153 172 129 
3 469 358 326 270 179 179 174 163 136 103 
4 341 259 271 207 211 216 165 119 130 116 
5 327 252 220 279 206 180 153 147 135 110 
6 456 324 235 300 258 206 217 141 128 114 
7 313 204 203 181 194 170 171 154 146 127 
8 321 296 251 255 178 198 144 149 157 163 
9 487 459 340 269 152 156 107 135 115 110 
10 783 275 254 195 180 184 141 114 130 116 
11 388 217 220 149 148 134 131 125 116 129 
12 371 356 297 240 237 200 185 136 148 102 
13 381 253 353 324 207 155 199 164 108 109 
14 255 308 177 189 166 185 161 124 115 145 
15 349 321 285 190 176 202 182 198 167 110 
16 509 386 289 254 224 133 122 106 106 126 
 
 





Figure 2.9: Docked cromolyn in the first predicted pocket of conformer 9 of the S100P 1OZO 










Figure 2.10: Two pockets (cyan and brown) at the dimeric interface of conformer 15 of 1OZO. 
These were initially identified by Q-SiteFinder as distinct individual pockets which, upon closer 
inspection were observed to overlap with one another. As a result, they were combined as one 
large pocket that was used to dock cromolyn.  
 




Table 2.7: Pockets identified by Site Finder, Pocket-Finder and Fpocket on the dimeric interface of conformer 15 of the NMR ensemble 
of S100P were also identified by Q-SiteFinder.  
 









 Chain A Chain B 
Q-SiteFinder 
1 349 M1 T2 E5 A6 M8 G9 I12 F71 S72 I75  F44 V78 A79 A80 I81 T82 S83 A84 S85 H86 K87 Y88 F89 K91 T92 G93 L94 K95  




2 77* M1 E5 A6 M8 G9 M10 I12 D13 S16 I81 T82 S85  H86 F89 T92 
3 106* I12 F15 S16 S19 S21 Q26 F71  H86 L87 Y88 F89 
Pocket-
Finder 
2 76 T82 S83 H86 T92   I12 F15 F71 I75   
3 67 M1 E5 G9 I12   T82 S85 H86 T92   
5 26 T2 L4 E5 M8   I11 V14 E40 L41 F74 V78 I81   
Fpocket 
2 302 M1 E5 G9 I12 S85 H86 F89 T92 
4 653 I12 F15 S16 S19 S21 Q26 F71 H86 F89 




Docking studies of cromolyn into conformer 15 of 1OZO revealed possible 
binding interactions between the protein and ligand at the dimeric interface. Visual 
analyses of the ligand poses showed that in most cases, the first ranked ligand pose did 
not have the optimal binding interactions with the protein. Indeed, the ligand pose which 
was subsequently used to design pharmacophore queries was ranked 18th out of the 36 
poses returned. The observed interactions between the ligand and protein involved three 
residues of Chain B: F89, T82 and T92. There was hydrophobic contact between F89 
with the chromone moiety of the ligand while both threonine residues were involved in 
hydrogen bonding interaction with both carboxylate oxygens at one end of the ligand 
(Figure 2.11).  
The predicted involvement of F89 in binding interactions with the ligand is 
significant as this residue has been reported to provide important hydrophobic contact 
that is crucial in target recognition in S100A1 and S100B [326, 327]. S100P shares a 
sequence identity of approximately 50% and 44% with S100A1 [136] and S100B [159] 
respectively. Thus, evidence of the involvement of this residue in a π-π interaction with 
cromolyn is a credible starting point when designing potential inhibitors against S100P 
as blocking this hydrophobic contact with small molecules could have the potential to 
inhibit S100P binding to its target, RAGE.    
  

















Figure 2.11: Predicted binding interactions between S100P and the ligand cromolyn. A) Docked 
cromolyn (ball and stick in green) in the overlapped sites at the dimeric interface of conformer 
15 of S100P 1OZO NMR ensemble (shown here with the molecular surface and residues 
forming the binding sites). B) Predicted binding interactions between cromolyn and S100P.   
A
B




2.3.4 Pharmacophore generation, virtual screening and hit clustering 
From the observed binding interaction between cromolyn and S100P (Figure 
2.11), a three-point pharmacophore model was derived comprising of an aromatic centre 
(Aro), and two anionic acceptors (Ani&Acc) (Figure 2.12). These features represent the 
hydrophobic contact between F89 and the chromone moiety of cromolyn, and the 
hydrogen bonding between one carboxylate group of the ligand and T82 and T92. This 
was deemed a “stringent” pharmacophore query due to the anionic requirement applied 
to both hydrogen bond acceptor features. This means that “hits” fulfilling the 
pharmacophoric constraints cannot only be hydrogen bond acceptors, but must also be 
anionic. This stringency was evidenced from the number of “hits” obtained when the 
MOE database of lead-like compounds was screened with this query.  
Out of the 653,214 compounds in the database, only 52 came up as ‘“hits”’, 
0.008% of total compounds (Table 2.8). As expected, most of these “hits” were acids, a 
fundamental requirement for fulfilling the anionic constraint of the pharmacophore 
query (Figure 2.13). The average molecular weight of hit compounds was 389 compared 
to 468 for cromolyn. All “hits” possess rings within them, ranging from two to six, 
demonstrating the diversity in their structures.   





Figure 2.12: Pharmacophore model derived from the predicted binding interactions between S100P and cromolyn. A) The three 
pharmacophore features represented by spheres in S100P (with molecular surface). B) Angles between the pharmacophore points. C) 
Distances (in Å) between pharmacophore features. 
A B
C




Table 2.8: “Hits” obtained when the MOE database was screened with a “stringent” 
pharmacophore query. “Hits” sorted according to their commercial vendor ID. Molecular 
descriptors – weight, number of rings, LogP, total polar surface area (TPSA), H-Donors and H-
Acceptors – were calculated using the Descriptor feature in MOE.  
  








Akos LT-1098  X 2900 (6) 2 340.21 4.48 65.97 0 1 
Akos LT-1098  X 4644 (7) 2 271.32 3.23 65.97 0 1 
Art-Chem UZI/6188182 (8) 4 332.31 2.56 119.19 2 3 
Asinex ASN 03791583 (9)  4 405.43 5.08 83.73 0 3 
Asinex BAS 02011727 (10) 4 441.85 3.86 139.76 1 3 
Asinex BAS 02380039 (11) 3 408.46 4.36 103.71 1 4 
Biofocus 144_5936_7270_6684 (12) 4 376.44 3.03 78.26 0 2 
Biofocus 144_5940_7270_6684 (13) 4 406.46 3.02 87.49 0 3 
Chem T&I BOBM0003527 (14) 4 377.33 1.49 127.17 1 5 
Chem T&I UZI/4036985 (15) 2 342.44 3.56 69.23 1 1 
Chembridge 5241336 (16) 3 433.45 2.57 166.33 1 4 
Chembridge 5311676 (17) 3 403.42 2.62 157.10 2 4 
Chembridge 5862836 (18) 3 440.27 5.38 90.82 1 3 
Chembridge 6640941 (19) 3 368.39 4.48 103.18 1 3 
Chembridge 6688677 (20) 3 430.85 5.02 120.25 1 4 
Chembridge 6897450 (21) 4 414.37 4.15 126.07 0 2 
Chembridge 7230553 (22) 3 434.21 3.75 115.84 1 4 
Chembridge 7266811 (23) 3 413.79 3.41 115.84 1 4 
Chembridge 7356270 (24) 6 439.40 3.73 123.33 0 2 
Chembridge 7778804 (25) 3 389.36 4.20 118.59 1 2 
Chembridge 7926943 (26) 3 359.37 2.13 110.84 1 3 
Chemdiv 1805-1431 (27) 4 398.40 4.21 112.33 1 4 
Chemdiv 6049-3009 (28) 5 439.49 6.00 90.17 2 2 
Chemstar CHS 2401453 (29) 3 404.36 7.21 136.64 1 2 
Comgenex CGX-3084890 (30) 2 358.42 2.80 96.28 1 3 
Enamine T0508-3103 (31) 2 335.34 4.51 117.41 2 3 
Enamine T0509-5138 (32) 3 412.24 2.20 113.94 2 3 
Enamine T0514-7139 (33) 3 431.84 1.65 141.18 2 5 
FCHC 29368 (34) 4 383.39 6.79 97.19 1 3 




Table 2.8 cont.: “Hits” obtained when the MOE database was screened with a stringent 
pharmacophore query. “Hits” sorted according to their commercial vendor ID. Cromolyn is 
included at the bottom for comparison. Molecular descriptors – weight, number of rings, LogP, 
total polar surface area (TPSA), H-Donors and H-Acceptors – were calculated using the 















InterBioScreen  STOCK5S-92825 (35) 3 432.45 3.42 151.45 2 6 
InterBioScreen STOCK3S-82963 (36) 4 386.39 2.10 112.30 1 4 
InterBioScreen STOCK5S-29098 (37) 4 419.46 2.37 114.26 1 4 
InterBioScreen STOCK5S-52328 (38) 3 372.40 2.58 104.76 1 3 
InterBioScreen STOCK5S-64425 (39) 3 365.37 2.67 122.72 3 3 
InterBioScreen STOCK5S-65135 (40) 3 424.52 1.88 110.18 0 4 
InterBioScreen STOCK5S-78564 (41) 4 396.38 1.92 109.11 0 3 
InterBioScreen STOCK5S-87979 (42) 3 386.41 2.19 145.55 0 3 
InterBioScreen STOCK5S-88540 (43) 3 373.43 2.65 114.65 0 4 
Labotest LT00103793 (44) 3 347.35 3.87 92.70 2 2 
Labotest LT00786495 (45) 2 372.38 3.98 127.41 1 2 
Life Chemicals F3074-0048 (46) 3 387.44 2.97 102.26 1 4 
Lithuania 1008485 (47) 3 439.51 5.25 91.26 0 4 
Maybridge HTS 05485 (48) 3 327.32 1.97 99.72 2 3 
Maybridge S 11067 (49) 3 346.41 3.84 93.95 1 3 
Otava 7018770072 (50) 3 409.42 2.54 120.28 2 4 
Peakdale 3002075 (51) 4 314.32 3.49 70.84 0 2 
Pharmeks PHAR103163 (52) 5 395.40 3.79 102.01 2 4 
Princeton Biomolecular OSSK_552866 
(53) 
2 383.41 0.96 150.82 2 3 
Princeton Biomolecular OSSK_562305 
(54) 
4 409.42 4.87 98.33 2 2 
Scientific Exchange R-093770 (55) 2 326.36 2.17 105.91 1 3 
Specs AE-641/01104012 (56) 3 428.30 3.71 119.17 0 3 
Specs AH-487/15148047 (57) 5 401.42 4.83 88.16 0 2 
AVERAGE 3 389 3 111 1 3 
Cromolyn (4) 4 466 -1.08 171.55 1 9 





Figure 2.13: Some of the “hits” identified from the MOE database. Most of these “hits” were acidic because the HBA groups on the 









The second “relaxed” pharmacophore query derived from the binding 
interactions between conformer 15 and cromolyn has the same geometric constraints as 
the “stringent” pharmacophore query but different pharmacophoric features. These 
features were defined as HBA and an aromatic centre. Screening the MOE database with 
this “relaxed” pharmacophore query resulted in a total of 4,619 “hits” (0.7%), again 
demonstrating the rigidity the anionic feature conferred on the first pharmacophore. 
There were 4,789 “hits” from the ZINC lead-like database giving a total of 9,408 “hits” 
from both databases. Clustering of these “hits” based on their chemical similarities 
defined as a 9-atom maximum common substructure [303] produced 299 clusters 
altogether with 77 singletons (Table 2.9).  
2.3.4.1 Hit selection for biological screening 
Due to budgetary constraints and compound availability, only a small number of 
“hits” were purchased for biological testing. The first set of 13 compounds purchased 
(Figure 2.14) came from the 52 “hits” obtained from the virtual screening of the MOE 
database using the “stringent” pharmacophore query and were pragmatically selected 
with respect to their price and availability. Key_Organcis_12T_0223 (58) identified in a 
previous screen by Kirton (unpublished) alongside two of its analogues (58a and 58b), 
and compound 7, one of the “hits” identified from the MOE database (Table 2.8) were 
synthesised in-house (discussed in Chapter 3). Hence, a total of 17 hit compounds were 
subsequently tested against S100P-expressing and non-S100P expressing pancreatic 
cancer cells (Chapter 3). 




The second set of compounds purchased for testing came from members of 
individual clusters from the less stringent screening of the MOE database. To ensure 
diversity, 52 compounds with the best S score from each cluster were procured (Table 
2.10, Figure 2.15).   




Table 2.9: Total number of “hits” and clusters obtained from screening the MOE and ZINC 





Figure 2.14: The first set of compounds from the MOE “stringent” virtual screening that were 
subjected to biological screening against pancreatic cancer cells. Compound 58 and two of its 
analogues, 58a and 58b, and compound 7, were synthesised in-house making a total of 17 
compounds that were subsequently subjected to biological screening.     
Database 
Total # of 
compounds  
Total # of 
“hits” 
Clusters Singletons 
MOE  653,214 4,619 129 24 
ZINC  765,278 4,789 170 53 






















Table 2.10: “Hits” purchased from the virtual screening of the MOE database using the less 
“stringent” pharmacophore query and objective selection criteria. Molecular descriptors – 
weight, number of rings, LogP, total polar surface area (TPSA), H-Donors and H-Acceptors – 
were calculated using the Descriptor feature in MOE.  
  
Molecule ID Rings 
Molecular 





LT-1074 X 2785 90 (59) 3 251.3 3.02 66.49 2 1 
LT-1167 X 603 (60) 3 309.2 2.58 55.88 5 0 
LT-1167 X 815 (61) 3 356.3 1.36 108.48 4 1 
Chembridge 6376403 (62) 4 375.4 4.19 66.46 3 1 
Chembridge 6656937 (63) 3 416.9 5.20 103.18 3 1 
Chembridge 7948674 (64) 3 284.3 2.14 59.81 3 2 
Chembridge 7967237 (65) 3 292.3 2.57 59.81 4 1 
Chembridge 7971920 (66) 5 407.4 4.10 110.67 6 3 
Chembridge 7988575 (67) 2 381.4 1.00 131.93 3 1 
Chembridge 7993610 (68) 4 362.4 3.02 96.45 3 1 
ASN 06346992 (69) 2 264.3 1.29 91.94 3 0 
ASN 06747799 (70) 4 387.4 1.68 105.37 6 1 
BAS 00243347 (71) 2 294.3 3.51 107.09 3 1 
BAS 02943034 (72) 4 432.6 5.77 58.33 0 0 
BAS 03609804 (73) 3 398.4 0.95 98.73 5 1 
Bionet 10G-910 (74) 2 323.7 4.08 53.02 4 3 
Bionet 8M-521S (75) 4 313.4 2.37 107.56 2 1 
PHAR058776 (76) 2 313.1 3.49 90.37 4 1 
PHAR087402 (77) 4 346.4 3.64 91.08 4 1 
STOCK1S-56176 (78) 3 398.9 5.45 61.53 5 1 
STOCK1S-87136 (79) 2 278.3 1.54 67.98 4 0 
STOCK2S-82643 (80) 2 251.3 -0.35 111.08 5 0 
STOCK3S-05798 (81) 2 238.3 -2.47 96.43 1 0 
STOCK3S-50234 (82) 2 365.4 3.07 109.28 5 2 
STOCK3S-56652 (83) 3 326.4 2.59 100.29 7 0 
STOCK3S-76708 (84) 2 307.3 1.21 80.10 2 0 
STOCK3S-82963 (85) 4 386.4 2.10 112.30 2 1 
STOCK5S-26863 (86) 2 304.3 -0.01 118.64 2 0 
  




Table 2.10 cont.: “Hits” purchased from the virtual screening of the MOE database using the 
less stringent pharmacophore query and objective selection criteria. Molecular descriptors – 
weight, number of rings, LogP, total polar surface area (TPSA), H-Donors and H-Acceptors – 
were calculated using the Descriptor feature in MOE.  
 
Molecule ID Rings 
Molecular 





STOCK5S-43994 (87) 2 275.2 -1.10 114.26 4 1 
STOCK5S-58409 (88) 2 261.3 1.69 88.28 3 2 
STOCK5S-74616 (89) 3 425.5 1.95 116.17 3 0 
STOCK5S-79215 (90) 3 413.5 1.75 106.94 4 1 
STOCK5S-88609 (91) 3 359.4 2.35 114.65 3 0 
STOCK5S-92145 (92) 3 343.4 2.48 105.42 6 2 
STOCK5S-59895 (93) 4 389.5 0.18 101.63 5 0 
STOCK5S-33478 (94) 5 395.5 3.05 74.04 4 0 
F2009-0120 (95) 3 371.4 1.25 104.27 4 0 
F0532-0705 (96) 4 388.5 4.49 61.20 3 0 
F2510-0310 (97) 3 346.4 1.40 78.38 5 1 
AE-848/11422545 (98) 4 372.4 3.13 106.37 5 1 
AO-623/14653070 (99) 2 299.3 1.25 118.08 5 0 
AK-968/15610255 (100) 2 345.4 3.80 82.12 7 1 
AO-080/43378361 (101) 2 370.4 3.96 87.69 2 1 
AQ-405/42300151 (102) 6 379.4 6.42 62.05 6 1 
Peakdale 1001920 (103) 4 418.5 3.86 69.16 1 0 
Peakdale 1002562 (104) 2 290.3 -0.10 78.27 2 0 
Peakdale 1003002770 
(105) 2 
235.2 -0.89 114.06 
5 2 
HTS 01757 (106) 3 383.45 3.72 82.44 6 0 
HTS 08111 (107) 2 292.32 1.10 93.21 5 4 
KM 07099 (108) 4 359.39 2.84 95.18 2 1 
SEW 00462 (109) 3 324.82 2.91 64.70 4 0 
SPB 03404 (110) 3 362.80 3.84 90.47 5 0 
AVERAGE 3 341.74 2.39 90.95 1 4 
 
  





Figure 2.15: Structure of “hits” purchased from the virtual screening of the MOE database using 

































Figure 2.15 cont.: Structure of “hits” purchased from the virtual screening of the MOE database 






























2.3.4.2 Rescoring “hits” generated from virtual screening studies in “native” 
S100P 
The NMR ensemble of S100P which was used in this project as a template for 
structure-based drug design studies has three mutations: T6A, C85S and A92T. To 
assess the impact of these mutations on the “hits” obtained from the virtual screening 
studies, the 52 purchased “hits” were rescored in the “native” conformer 15 of 1OZO 
and their S score compared to their original S score. Except for three “hits”, compounds 
96, 99 and 104, all the other “hits” returned negative S scores similar to those obtained 
in the original 1OZO conformer 15 (Figure 2.16). The positive S score for these three 
“hits” could be indicative of unfavourable interaction with the native protein. It is 
possible that there may be some penalties – i.e. high binding energy – for potential 
clashes with the protein surface, although there is no evidence of such clashes from 
observation of the compounds’ interaction with the protein (Figure 2.17). In comparison, 
“hits” like compounds 74 and 80 seemed to show favourable interaction with the native 
protein than the mutated conformer 15 of the NMR ensemble. While the pharmacophore 
was a useful constraint in the virtual screening, the interaction of the protein and these 
“hits” goes beyond the three pharmacophoric points. A correlation between the 
predicted binding affinity and the actual activity from biological screening can only be 
made once all the compounds are screened and these two factors are compared. 
   





Figure 2.16: Comparison of S score of the 52 purchased “hits” obtained from using the original S100P NMR conformer 15 (old) 
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Figure 2.16 cont.: Comparison of S score of the 52 purchased “hits” obtained from using the original S100P NMR conformer 15 
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Figure 2.17: Predicted binding interaction between compounds 96, 99 and 104 with “native” 
S100P. All three “hits” had positive S score when rescored in the “native” protein.  
104
9996





Publically available 3D experimental structures of S100P, 1J55 and 1OZO 
were analysed for suitability for use in structure-based drug design (SBDD) studies. 
The NMR ensemble 1OZO was selected over the X-ray crystal structure because it 
represented the biologically active dimeric form of S100P compared to the X-ray 
crystal structure. In addition, all the residues were resolved albeit with three 
mutations.  
Using computational methods, it was found that only one conformer 
(conformer 15) of the NMR ensemble of S100P was suitable for use as template for 
SBDD studies. Both geometric- and energy-based pocket-detection algorithms 
identified potential cavities at the dimeric interface of this conformer adequate to 
accommodate cromolyn during docking studies. Using observed interactions 
between ligand and protein as a template, a pharmacophore query was designed and 
used as a constraint for subsequent virtual screening studies. Seventeen compounds 
from the generated “hits” form a diverse collection of chemical compounds that will 
be screened against pancreatic cancer cells (Chapter 3) in the hope of identifying a 
potential lead therapeutic candidate against this lethal cancer.  
Despite the mutations present in the NMR structures, there was little 
difference between the predicted binding affinities of “hits” with the “mutated” 
S100P NMR conformer and the “native” protein, again confirming the usefulness of 












CHAPTER 3: Synthesis and Biological Evaluation of “Hits” 










Having identified virtual screening “hits” that have the potential to interact with 
the S100P dimeric interface (Chapter 2, Section 2.3.4), two compounds – 7 and 58 
(Figure 3.1) – were synthesised, characterised and subjected to biological screening 
against the pancreatic cancer cell lines BxPC-3 and Panc-1. This chapter details the 
syntheses and biological evaluation of these two hit compounds. In addition to the two 
synthesised compounds, the biological evaluation of 13 commercially available 
compounds identified during the virtual screen (Figure 2.14) is also reported in this 
chapter.   
Biological screening of the “hits” was carried out in collaboration with Dr 
Tatjana Crnogorac-Jurcevic at Barts Cancer Centre, Queen Mary, University of London. 
The biological screening, and the initial evaluation of the data, was carried out by Nasir 
Mahmoud [328]; interpretation of the results was carried out by the author.  
The results from the syntheses and biological screening are discussed in Sections 
3.2 and 3.3 respectively. The experimental details of the syntheses are given at the end 
of this chapter in Section 3.5. 
  






The synthesis of two compounds identified by the virtual screening studies in 
Chapter 2, that were prohibitively expensive (7) and unavailable for purchase (58) are 
described below. Compound 7 is a dibenzyl derivative while 58 is a substituted benzoic 
acid (benzoxazin-2-yl)ethyl ester. In addition, two analogues of 58 (58a and 58b, Figure 
3.1) were also synthesised. 
In total, the syntheses of the above four compounds are discussed in this chapter. 
Viable synthetic routes and identification of readily available starting materials 
(RASMs) were identified using retrosynthetic disconnection approaches [329, 330]. 
Once readily available starting materials were determined, published synthetic routes 
were identified using Reaxys®, (version 1.7.8; www.elsevier.com/reaxys), which were 
followed and adapted where applicable. Where there were no published records for 
synthetic routes, logical synthetic routes were designed and implemented.  
The four synthesised compounds were combined with the 13 “hits” purchased 
from the virtual screening studies (Chapter 2), to give 17 compounds in total. These 
compounds are structurally and/or chemically dissimilar to cromolyn, the compound 
with limited bioavailability previously reported to inhibit S100P binding to RAGE 
[195]. Hence, if any of the compounds demonstrate inhibition of cell proliferation and/or 
cell invasion in the biological assays they will provide novel starting points for drug 
discovery investigations.  





The 17 compounds were assessed for biological activity in separate screening 
studies that examined cell proliferation and cell invasion in two pancreatic cancer cells – 
S100P-expressing BxPC-3 and Panc-1 which does not produce S100P.  
  








Figure 3.1: Structure of cromolyn (4) and the two “hits” from the virtual screening studies (7 
and 58) together with the analogues (58a and 58b) of compound 58. The known inhibitor of the 









3.2 RESULTS AND DISCUSSION 
3.2.1 Synthesis of 4-({[(2-methoxyphenyl)methyl]amino}methyl)benzoic acid: 
compound 7 
Retrosynthetic analysis was applied to identify potential precursors to compound 
7. Following functional group conversions (FGI) of the amino linker to the imine, and 
the carboxylic acid group to the ester, the C=N or the N-C bond could be disconnected 
in the direction of either a or b (Scheme 3.1).   
 
Scheme 3.1. Possible disconnections on compound 7 to identify starting materials. 
 
The respective synthetic equivalents for synthons (i) and (iii), and (ii) and (iv) are an 
amine and an aldehyde respectively. The first attempt at synthesising the target molecule 
7 was carried out via route a. The corresponding synthetic equivalents for this 
disconnection were 4-(aminomethyl)benzoate for (i), after functional group 
interconversion and 2-methoxybenzaldehyde for (ii) (Scheme 3.2).   






Scheme 3.2: Retrosynthetic analysis on compound 7 to identify simple precursor molecules via 
route a. (TM: target molecule, FGI: functional group interconversion, RASMs: readily available 
starting materials).  
  





2-Methoxybenzaldehyde was condensed with 4-(aminomethyl)benzoate, the 
corresponding methyl ester of 4-(aminomethyl)benzoic acid via a nucleophilic addition 
reaction at the carbonyl centre, with the subsequent elimination of a water molecule. 
The nucleophilic nitrogen of the amine group of 4-(aminomethyl)benzoate attacks the 
electrophilic carbon of the aldehyde to form a carbinolamine intermediate (Scheme 3.3) 
[331]. Dehydration of this intermediate generates the imine 111 as a pale yellow oil in 
95% yield. As this was a slow and reversible reaction, anhydrous MgSO4 was added to 
“mop up” the water by-product formed thus driving the synthesis in the direction of the 
required product. The structure of the imine was confirmed by the presence of the imine 
proton as a singlet downfield at δ 8.8 ppm in the 1H-NMR (Section 3.5.2).  
 






Scheme 3.3: Mechanism for the formation of the imine 111 via a carbinolamine intermediate. 





The isolated imine 111 was reduced using sodium borohydride to give the 
corresponding amine 112 as pale yellowish oil in 70% crude yield (Scheme 3.4). The 
amine was confirmed on proton NMR by the absence of the imine proton at δ 8.8 ppm 
and the presence of both pairs of methylene protons on either side of the amine group as 
singlets at δ 3.74 and 3.61 ppm (Section 3.5.2.1). Compound 112 could be synthesised 
from 6 in a one-pot reductive amination reaction where the aldehyde is condensed with 
the amine to form the imine, which is subsequently reduced using a reducing agent. 
However, the use of sodium borohydride, the reducing agent used here, is unsuitable in 
this case as it would have also reduced the aldehyde to its corresponding alcohol.  
The final step in the synthesis of the target compound 7 involved functional 
group interconversion; the ester group of 112 was hydrolysed under basic conditions to 
give the desired acid 7 as a pale yellow solid with a yield of 71% from the final reaction 
step (Scheme 3.5 and 3.6). The absence of the carbon peak and the three methyl proton 
peaks of the ester from both 13C and 1H-NMR spectra respectively, and the presence of a 
broad OH peak at 3368 cm-1 confirmed the formation of the acid product (Section 
3.5.2.2).  
The second route b (Scheme 3.1) was not employed as route a succeeded in 
generating the target compound 7.  















Scheme 3.5: Base hydrolysis of compound 112 to give the required acid 7. 
  



















3.2.2 Synthesis of 2-(6-nitro-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-2-yl)ethyl 4-
iodobenzoate: compound 58 and analogues 
Retrosynthetic analysis of 2-(6-nitro-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-2-
yl)ethyl 4-iodobenzoate (58) identified two main synthons (v) and (vi) from the 
disconnection of the ester bond (Scheme 3.7). The synthetic equivalents for (v) and (vi) 
were an acyl chloride and an alcohol respectively, which react in an addition elimination 
resulting in a substitution reaction to form the ester compound 58. Further retrosynthetic 
analysis on the alcohol 113 identified two additional bonds that can be logically 
disconnected; the amide bond between the carbonyl group and the amine, and the bond 
between C8 and the ether oxygen. A suitable synthetic equivalent for synthon (vii) is 
found in 2-amino-4-nitrophenol. The synthetic equivalent for the remaining synthon 
(viii) with the two electropositive carbon centres is α-bromo-γ-butyrolactone (Scheme 
3.8). The presence of a carbonyl group and a bromine atom in this compound ensures 
that the carbons directly attached to them are electron deficient, thus providing an 
appropriate synthetic equivalent.  
Having identified these starting materials, it was simple to put together a 
synthetic route to get to the target molecule i.e. synthesis of the alcohol (113) before 
reacting this with the acyl chloride to obtain the target molecule 58. The use of the acyl 
chloride instead of the corresponding carboxylic acid, in the second step proceeds via an 
irreversible reaction. This is advantageous in driving the synthesis to completion [332].   







Scheme 3.7: Retrosynthetic analysis on compound 58 to identify readily available starting 
materials. Compound 113 was synthesised first prior to synthesising the target molecule.  
 







Scheme 3.8: Retrosynthetic analysis on compound 113 to identify readily available starting materials (RASMs). 
 





The alcohol 113 (Scheme 3.8) was synthesised by adapting the method of 
Frechette and Beach [333]. α-Bromo-γ-butyrolactone was reacted with 2-amino-4-
nitrophenol in anhydrous tetrahydrofuran to afford 113 in 72% crude yield as a brick-red 
solid after workup. The reaction was carried out under reflux conditions, and is believed 
to proceed via attack of the nucleophilic oxygen of the 2-amino-4-nitrophenol on the 
electron deficient α-carbon centre of the carbonyl compound, formed by the departing 
bromine [333]. Close proximity of the carbonyl and aromatic amine groups leads to 
formation of the intermediate 113a (Scheme 3.9) with subsequent ring-opening of the 
tetrahydrofuran ring giving the benzoxazine crude product as a brick-red solid in 72% 
yield. Recrystallisation from ethyl acetate gave 113 as yellow fluffy crystals with a 
melting point of 169-170 °C and a final yield of 56%. The structure of the product was 
confirmed by 1H-NMR by the presence of the chiral C-H proton of the morpholinone 
ring at δ 4.85 which is absent in either of the starting materials  (Section 3.5.3). 
 






Scheme 3.9: Synthesis of compound 113. (Adapted from Frechette and Beach [333]). 
 





To obtain the required compound 58, the intermediate 113 was reacted with 
4-iodobenzoyl chloride in an acylation reaction to form the ester. This reaction was 
initially attempted in dichloromethane (DCM) but solubility issues with the alcohol 
resulted in incomplete reactions with no product isolated. When tetrahydrofuran 
(THF) was substituted for DCM, the reaction proceeded to completion but the crude 
product contained a mixture of the acid chloride, the required ester product and 
impurities. The ester product was recovered via column purification, in a final yield 
of 8%. The chloro and tert-butyl analogues (58a and 58b respectively) were obtained 
in a similar manner, with yields of 5 and 36% respectively after column purification 
(Table 3.1). The crude products of both 58 and 58a were dark sticky brown and 
cream solids respectively, whereas 58b was a brown oil. Column chromatography 
using diethyl ether as eluent afforded 58, 58a and 58b as a pale yellow, a greenish-
yellow and a cream solid respectively with narrow melting points ranges (Table 3.1). 
All products were characterised by 1H- and 13C-NMR, IR and LC-MS (Sections 
3.5.4, 3.5.4.1 and 3.5.4.2). All three compounds exhibited the characteristic C=O 
stretch of the ester functional group at around 1700 cm-1 in addition to the C=O 
stretch of the amide around 1680 cm-1 in infra-red spectra (Sections 3.5.4, 3.5.4.1, 
and 3.5.4.2). 
  











Compound R Yield (%) Melting point (°C) 
58 I 8  188-190 
58a Cl 5 218-220 
58b t-Bu  36  88-90  
 
  





3.3 BIOLOGICAL EVALUATION OF “HITS” 
Purchased compounds and those synthesised in-house were screened for 
activity against BxPC-3 (ATCC® CRL-1687™) and Panc-1 (ATCC® CRL-1469™) 
human pancreatic cancer cells (American Type Culture Collection, Teddington, 
Middlesex, UK). BxPC-3 cells have been reported to express endogenous S100P 
[121, 177, 334], the therapeutic target protein for which this research aims to design 
inhibitors against its interaction with RAGE. Alternatively, Panc-1 cells are non-
S100P expressing cells [177, 334], making them an ideal S100P-negative control. 
The use of an S100P-negative control should help explain if any observed activity 
against these cells is S100P-related or not. The presence or absence of endogenous 
S100P in both cell types has been previously reported [121, 177, 192, 290]. 
Proliferation studies were carried out using the MTS (3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) colorimetric 
assay. MTS is based on the presence of mitochondrial dehydrogenase enzymes in 
metabolically active viable cells that reduce the salt to a soluble coloured formazan 
dye product which is then read spectrophotometrically [335]. Although specifically 
designed to measure metabolic activity, results from an MTS assay are sometimes 
correctly or incorrectly used to indirectly infer the proliferative activity of cells, as 
less active cells are more likely to be less proliferative. The assay is also used loosely 
to describe cell viability, although it has been argued that a multiplex of different 
assays that also measure other properties such as cytotoxicity from the same 
experimental well give an overall picture of cell viability than a single assay [336, 
337]. 





3.3.1 Effect of cromolyn (4), siS100P on proliferation and invasion of 
pancreatic cancer cells 
Prior to testing the anti-proliferative effect of the screening compounds on 
pancreatic cancer cells, it was found that silencing the S100P gene in BxPC-3 cells 
has little to no effect on their proliferation (Figure 3.2, [328]). 
This result is however in contrast to findings published by Arumugam et al. 
[177] who reported that S100P stimulates pancreatic cancer cell proliferation and 
survival. Their work showed a correlation between high levels of S100P and 
pancreatic cancer cell proliferation, survival, migration, and invasion in both in vitro 
and in vivo models. The effect of knock-down S100P on the proliferation of BxPC-3 
is marginal (Figure 3.2) after 72 h compared to control, and non-existent at 24 and 































Figure 3.2: Effect of knock-down S100P in BxPC-3 cell proliferation. BxPC-3 cells were 
stably transfected with non-target control siRNA or siS100P. Cells were plated at an equal 
density and cultured from 24-74 h before cell numbers were determined using the MTS 
assay. Results are expressed as mean + SEM. Cell viability was expressed as a percentage 
for each treatment group relative to the negative control (1% v/v DMSO in culture media) 
according to the following equation: Growth (%) = OD490(sample)/OD490(control) x 100. P-
value was determined relative to control using un-paired t-test. None of the differences were 
significant.  
  





Interestingly, cromolyn (4), the small anti-allergy molecule that has been 
reported to bind to S100P and inhibit its interaction with RAGE [195, 334], was also 
found to have little effect on the proliferation of BxPC-3 cells at concentrations up to 
1 mM [328]. An effect is only observed at higher concentrations of 2 mM, although 
this was not statistically significant (Figure 3.3). On its own, cromolyn (4) does not 
exert a significant effect on the proliferation of these cells. An increase in anti-
proliferative activity is only observed in combination with gemcitabine [195], the 
current therapeutic agent used in the treatment of pancreatic cancer.  
Knocked-down S100P was found to significantly reduce invasion of BxPC-3 
cells compared to control (Figure 3.4). This effect is in agreement with published 
data that indicate that pancreatic, breast, colon and prostate cancer metastasis is 
mediated via an S100P-related mechanism [177, 181, 182, 226, 289, 338].  
No anti-proliferative or anti-invasive effects were observed in Panc-1 cells 



































Figure 3.3: Anti-proliferative effect of cromolyn (4) on BxPC-3 cells. Cells (1.0 x 103 
cells/well) were cultured in the presence or absence of cromolyn and cell proliferation was 
analysed using the MTS assay after 24, 48 and 72 h. Results are expressed as mean + SEM. 
Cell viability was expressed as a percentage for each treatment group relative to the negative 
control (1% v/v DMSO in culture media) according to the following equation: Growth (%) = 
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Figure 3.4: Effect of S100P on BxPC-3 invasion. A) BxPC-3 cells stably transfected with 
control siRNA or S100P siRNA were placed in serum-free culture media and added into the 
upper compartment of an invasion chamber. After 48 h, cells in the upper chamber were 
removed and cells that had invaded onto the lower surface of the membrane were stained 
using Giemsa stain. Cells in three different areas were counted for invasion studies. Results 
are expressed as mean + SEM (***p<0.001). B) Non-target control siRNA. C) siS100P. 
Photographs of representative membranes for cells after Giemsa staining viewed at x10 
objective lens [328].   





3.3.2 Effect of screening compounds on proliferation and invasion of 
pancreatic cancer cells 
Of the 17 compounds examined, seven compounds (Table 3.2) were 
investigated for effect on both anti-proliferative (BxPC-3 and Panc-1) and anti-
invasive (BxPC-3) properties. As no invasion was observed for Panc-1 cells, the 
compounds were not screened for anti-invasive effects on these cells. A summary of 
the data for the compounds investigated on BxPC-3 cell line for anti-invasive effects, 
and on both Panc-1 and BxPC-3 cell lines for anti-proliferative effects is presented in 
Table 3.2.  
All compounds were tested for anti-invasion activity against BxPC-3. 
However, four compounds (7, 58, 58a and 58b), were not tested for anti-proliferative 
activity on the same cell lines, while seven (compounds 7, 16, 22, 26, 38, 39, 40) 
were not tested on Panc-1 cells for the same activity (Table 3.2). Of the seven 
compounds screened for both anti-invasive and anti-proliferative properties, five 
compounds, 17, 18, 20, 24, 43, showed activity against invasion of BxPC-3 cells 
(Figure 3.5). At 100 μM, both 15 and 24 had a significant effect relative to their 
respective controls (p<0.05, Figure 3.5). Interestingly, compound 24 had an effect at 
100 μM that is comparable to cromolyn (4) at the same concentration (Figure 3.5D). 
At 500 μM all five compounds showed a considerable anti-invasive effect (p<0.001) 
compared to controls. This effect however may be attributed to the high 
concentration of these compounds which could be detrimental to the survival of the 
cells.   









  Invasion Proliferation 
Compound BxPC-3 BxPC-3 Panc-1 
7 Tested ND1 ND1 
16 Tested Tested ND1 
17 Tested Tested Tested 
18 Tested Tested Tested 
20 Tested Tested Tested 
22 Tested Tested ND1 
23 Tested Tested Tested 
24 Tested Tested Tested 
26 Tested Tested ND1 
36 Tested Tested Tested 
38 Tested Tested ND1 
39 Tested Tested ND1 
40 Tested Tested ND1 
43 Tested Tested Tested 
58 Tested ND1 Tested 
58a Tested ND1 Tested 
58b Tested ND1 Tested 
1ND: Not determined. Due to time constraints, some compounds were not tested on either or both cells for 
anti-proliferative activity. 
  






Figure 3.5: Effect of compounds screened on invasion of BxPC-3 pancreatic cancer cells. 
A) Compound 17. B) Compound 18. C) Compound 20. D) Compound 24. E) Compound 43. 
Compounds were added to serum-free medium in the upper compartment of an invasion 
chamber along with the BxPC-3 cells (2.5 x 104 cells/well), media with FBS (10% v/v) was 
added to lower chamber. After 48 hours, cells in the upper chamber were removed and cells 
that had invaded onto the lower surface of the membrane were stained Giemsa stain and 
cells in 5 different fields were counted for invasion studies. Results are expressed as the 
mean + SEM. P value of <0.05 (*), <0.01(**) and <0.001(***) was determined relative to 

















































































































Similar to cromolyn, many of the compounds examined did not show an 
effect on the proliferation of BxPC-3 cells. Compounds 18, 20 and 26 had an effect 
at 500 μM, although the cells’ response appear to be similar at all three time points 
for both compounds 20 and 26 (Figure 3.6). Again, similar to the response of the 
cells for the invasion assay at this concentration (Figure 3.5), it is not known if the 
effect observed here is due to the cells dying from being too stressed after being 
exposed to an environment of such high compound concentration.  
Of the compounds examined for activity on the proliferation of Panc-1 cells, 
five compounds showed an effect at 500 μM (Figure 3.7). Compound 18 exerted a 
similar effect on the proliferation of both cells at 500 μM. Compound 58b, the tert-
butyl analogue of compound 58, showed a significant concentration dependent effect 
on proliferation of Panc-1 cells at 100 and 500 μM (p<0.05 and 0.001 respectively) 
compared to control, although the cells seem to be recovering over time (Figure 
3.7E).  
The lack of anti-proliferative effect from these compounds on Panc-1 cells is 
not surprising as they are designed to interact with S100P. However, the lack of 
difference between their anti-proliferative effects on both cell lines is further 
evidence that S100P may not play a role in pancreatic cancer cell proliferation, 
contrary to published reports [151, 177].   






Figure 3.6: Effect of compounds screened on proliferation of BxPC-3 cells. A) Compound 
18. B) Compound 20. C) Compound 26. Cells (1.0 × 10 3 cells/well) were cultured in the 
presence or absence of screening compounds and cell proliferation analysed using the MTS 
assay after 24, 48, and 72 h. Results are expressed as the mean + SEM. P value of <0.05 (*), 
<0.001(**) and <0.001(***) relative to control using 2-Way ANOVA. Cell viability was 
expressed as a percentage for each treatment group relative to the negative control (1% v/v 
DMSO in culture media) according to the following equation: Growth (%) = OD490(sample)/ 

















































































Figure 3.7: Effect of compounds screened on proliferation of Panc-1 cells. A) Compound 
18. B) Compound 20. C) Compound 36. D) Compound 58. E) Compound 58b. Cells (1.0 × 
10 3 cells/well) were cultured in the presence or absence of screening compounds and cell 
proliferation analysed using the MTS assay after 24, 48, and 72 h. Results are expressed as 
the mean + SEM. P value of <0.05 (*), <0.001(**) and <0.001(***) relative to control using 
2-Way ANOVA. Cell viability was expressed as a percentage for each treatment group 
relative to the negative control (1% DMSO v/v in culture media) according to the following 









































































































































The effect of the screened compounds on proliferation of both cell lines 
indicates that the mechanism by which these compounds are exerting their effect on 
the cells is not mediated by S100P. If the mechanism were S100P-dependent, it is 
expected that compounds that demonstrated an inhibition to the invasive ability of 
BxC-3 cells would also demonstrate a similar inhibitive effect on the proliferative 
capability of these cells. In contrast, no effect on both migration and proliferation 
would be observed with the S100P-negative cell line, Panc-1. This effect was not 
observed for any of the compounds examined. Since most of the compounds showed 
a comparable effect on proliferation of BxPC-3 cells to that of cromolyn (4), it could 
be that proliferation of these cells is independent of S100P, but more work needs to 
be performed to conclusively confirm this observation as it is contrary to current 
published data.  
However, five compounds were identified that show activity against the 
invasion of BxPC-3 cells consistent with the experimental findings that S100P is 
involved in metastatic disease progression [177, 181, 226]. These five compounds, 
17, 18, 20, 24, and 43, will serve as good templates on which to design anti-
metastatic compounds against pancreatic cancer.  
 
  






Four compounds, 7, 58 (its analogues 58a and 58b), were synthesised, isolated 
and characterised. They formed part of the 17 compounds from the virtual screening 
studies that were screened for activity against the invasion and proliferation of 
pancreatic cancer cells.  
Biological evaluation of the 17 hit compounds has identified five compounds 
that show promise with respect to inhibiting the invasion potential of BxPC-3 cells. 
Since these cells secrete endogenous S100P, this inhibitory effect is promising as 
there is scope to further exploit these compounds to increase potency against this 
novel therapeutic target. One such compound of interest is compound 24. At 100 
μM, it demonstrated an inhibitory effect comparable to that of cromolyn (4) at the 
same concentration. As this was one of the compounds originally purchased, the aim 
will be to synthesise, purify, characterised and retest it against these cells for 
reproducibility (Chapter 4).  
The results from the proliferation assay studies are inconclusive as to the 
involvement of S100P in pancreatic cancer cell proliferation. Since compounds that 
show inhibitory activity against invasion of BxPC-3 cells did not reproduce similar 
effects on proliferation of the same cells, or the opposite results on Panc-1 cells, it is 
difficult to conclude that proliferation in pancreatic cancer is S100P-mediated based 
on these results, despite literature evidence to the contrary [151, 177].   





3.5 EXPERIMENTAL  
3.5.1 General methodology: Synthesis and Instrumentation 
Reagents for the chemical synthesis unless specified were purchased from 
Sigma-Aldrich (Gillingham, Dorset, UK) and were used without further purification. 
All solvents were purchased from Fisher Scientific (Loughborough, UK). Where 
necessary, solvents were dried using activated 3 Å (methanol, ethanol, 
dichloromethane) and 4 Å (diethyl ether) molecular sieves.  
1H-NMR and 13C-NMR spectra were recorded on a JEOL ECA/54/SSS (400 
or 600 MHz) spectrometer using (TMS) as internal standard. Deuterated solvents 
used for compound analysis are indicated with individual compound data. Raw 
NMR data were processed with ACD/NMR Processor Academic Edition Version 
12.01 (Advanced Chemistry Development, Inc., Toronto, Canada, 
www.acdlabs.com, 2014). Chemical shifts are given in ppm relative to 
tetramethylsilane and J values (where given) are in Hz. Spectral splitting patterns are 
given as singlet (s), doublet (d), doublet of doublets (dd), triplet (t), quadruplet (q), 
quartet of quartets (qq), multiplet overlapped (m), broad (br).  
Infrared spectra were recorded in Scimitar 800 FT-IR spectrometer (Varian 
Inc.), Nicolet 6700 FT-IR Smart iTR (Thermo Scientific) spectrometer using a 
Golden GateTM Diamond ATR adapter, or using a Perkin Elmer FT-IR/FIR 
Spectrometer Frontier (Version 10.03.07), with samples prepared as thin films on the 
universal ATR sampling accessory.  





Liquid chromatography–mass spectrometry (LC-MS)  was determined using 
a Varian 1200L Quadrupole LC/MS/MS system equipped with Electrospray 
Ionisation (ESI) (Agilent Technologies, USA) and using a Varian Pursuit 50 mm x 
4.6 mm 5 micron pore size C18 reverse phase column. Samples were run at a flow 
rate of 0.25 mL/min for 20 minutes using water/formic acid (0.1% v/v): 
acetonitrile/formic acid (0.1% v/v) mobile phases. The gradient at which the samples 
were ran is as follows: 
0:00 minutes: 80% formic acid and water/formic acid and acetonitrile 
10:00 minutes: 10% formic acid and water/formic acid acetonitrile 
16:00 minutes: 10% formic acid and water/formic acid acetonitrile 
16:30 minutes: 80% formic acid and water/formic acid acetonitrile 
20:00 minutes: 80% formic acid and water/formic acid acetonitrile 
The Mass Spectrometer acquires both positive and negative ions from masses 50 Da 
to 1000 Da. 
Thin-layer chromatography (TLC) was carried out using Macherey-Nagel 60 
Å (250 μm thick) flexible polyester sheet silica gel plates pre-coated with fluorescent 
indicator UV254 (TLC-sheets POLYGRAM
® SIL G/UV254, Fisher, Loughborough, 
UK). Dichloromethane (DCM) was used as the mobile phase unless otherwise stated. 
Column chromatography for compounds 55, 55a and 55b was carried out using 
silica gel (high-purity grade, pore size 60 Å, 230-400 mesh particle size, 40-63 μm 
particle size, for flash chromatography, Sigma-Aldrich, Gillingham, Dorset, UK) in a 
30 cm long column using diethyl ether (Et2O) as eluent. Samples were dry-loaded by 
dissolving in either dichloromethane (DCM; 58 and 58b)) or chloroform (58a) 
before adsorbing unto silica gel.   





Melting points (M.p.) were measured in open capillaries using a Griffin 
melting point apparatus and are uncorrected. Where known, melting points from 
published literature are shown next to that determined for each compound in this 
study. 
All structures, unless otherwise specified, were generated and named using 
ChemDraw Ultra 14. (PerkinElmer, Massachusetts, US). 
  





3.5.2 Synthesis of Methyl 4-{[(E)-[(2-
methoxyphenyl)methylidene]amino]methyl}benzoate (111). (Adapted 





Methyl (4-aminomethyl)benzoate was obtained from its hydrochloride salt by 
stirring the salt with sodium carbonate in water and extracting the ester in diethyl 
ether. The extracted benzoate (0.21 g, 1.3 mmol, 1 eq) was reacted with 2-
methoxybenzaldehyde (0.17 g, 1.3 mmol, 1 eq) in dry DCM (3 mL) in the presence 
of a drying agent (anhydrous MgSO4). The reaction mixture was stirred overnight for 
a total reaction time of 22 h. The flask contents were filtered through K2CO3 and the 
solvent removed under vacuum to afford 111 as a yellow oil which was used in the 
next step without further purification. Yield 0.34 g, 95%; 1H-NMR (600 MHz, 
DMSO-d6)  (ppm) 8.80 (1 H, s, 1 HC=N), 7.89 - 7.92 (2 H, m, para-Ar-H), 7.85 (1 
H, dd, J = 7.7, 1.7 Hz, Ar-H), 7.41 - 7.45 (3 H, m, 2 para-Ar-H, Ar-H), 7.08 (1 H, d, 
J = 8.5 Hz, Ar-H), 6.94 - 6.98 (1 H, m, Ar-H), 4.82 (2 H, s, CH2), 3.83 (3 H, s, CH3 
ester), 3.81 (3 H, s, CH3 ether). 13C-NMR (150 MHz, DMSO-d6)  (ppm) 166.69 
(C=O ester), 159.08 (C=N), 158.19 (CO ether), 146.09 (Ar-C), 132.96 (Ar-CH), 
129.83 (para-Ar-CH), 128.60 (Ar-C), 128.54 (para-Ar-CH), 127.19 (Ar-CH), 





124.29 (Ar-C), 121.10 (Ar-CH), 112.41 (Ar-CH), 64.32 (CH2), 56.20 (CH3 ether), 
52.58 (CH3 ester).  
3.5.2.1 Reduction of 111 to Methyl 4-({[(2-
methoxyphenyl)methyl]amino}methyl) benzoate (112). 




The imine 111 (0.3 g, 1.1 mmol, 1 eq) was reduced to the amine under a 
nitrogen atmosphere using sodium borohydride (0.05 g, 1.3 mmol, 1.1 eq). Briefly, 
the imine was added to methanol (5 mL) and stirred at room temperature before 
cooling to 0 °C in an ice bath. Sodium borohydride (NaBH4) was added in aliquots 
and the mixture stirred for another 0.5 h. After this time methanol was removed 
under vacuum and the residue diluted with Et2O (30 mL) and saturated NaHCO3 (30 
mL). The organic layer was extracted with Et2O (2 x 20 mL). The combined organic 
layers were dried over MgSO4, the mixture was filtered and the solvent removed in 
vacuo to give the amine 112 as a pale yellowish oil, yield 0.23 g, 70%. 1H-NMR 
(600 MHz, DMSO-d6)  (ppm) 7.86 - 7.89 (2 H, d, J = 8.0 Hz, para-Ar-H), 7.46 (2 
H, d, J = 8.0 Hz, para-Ar-H), 7.30 (1 H, d, J = 7.3 Hz, Ar-H), 7.18 (1 H, m, Ar-H), 





6.91 (1 H, d, J = 8.3 Hz, Ar-H), 6.88 (1 H, m, Ar-H), 3.81 (3 H, s, CH3 ester), 3.74 
(2 H, s, CH2), 3.72 (3 H, s, CH3 ether), 3.61 (2 H, CH2). 13C-NMR (150 MHz, 
DMSO-d6)  (ppm)  166.76 (C=O ester), 157.51 (CO ether), 147.45 (Ar-C), 129.58 
(para-Ar-CH), 129.17 (Ar-CH), 128.80 (Ar-C), 128.53 (para-Ar-CH), 128.41 (Ar-
CH), 128.27 (Ar-C), 120.61 (Ar-CH), 110.94 (Ar-CH), 61.07 (CH2), 55.71 (CH3), 
52.50 (CH2), 47.29 (CH3 ester).  
3.5.2.2 Hydrolysis of 112 to 4-({[(2-
Methoxyphenyl)methyl]amino}methyl)benzoic acid (7)  
 
 
The amine 112 (0.22 g, 0.78 mmol) was stirred under reflux in MeOH/THF 
mixture (1:1 v/v) and NaOH (1 M, 1.5 mL) for 1.5 h, then left overnight at room 
temperature whilst stirring. After a total reaction time of 20.5 h, the reaction was 
quenched with de-ionised water (2 mL) and the organic solvents removed under 
vacuum. HCl (1 M) was added to the concentrated residue to adjust the pH. A 
precipitate was formed at pH 7 which was filtered off, using a Hirsch funnel, to 
afford 7 as a pale yellow solid, yield 0.15 g, 71%. M.p. 190-192 °C. 1H-NMR (600 
MHz, MeOH-d3)  (ppm) 7.95 - 7.99 (2 H, m, para-Ar-H), 7.43 (2 H, d, J = 8.3 Hz, 
para-Ar-H), 7.40 (1 H, dd, J = 7.6, 1.7 Hz, Ar-H), 7.31 (1 H, dd, J = 7.6, 1.7 Hz, Ar-





H), 7.05 (1 H, d, J = 8.3 Hz, Ar-H), 6.98 (1 H, td, J = 7.4, 1.0 Hz, Ar-H), 4.18 (2 H, 
s, CH2), 4.13 (2 H, s, CH2), 3.86 (3 H, s, CH3). 13C-NMR (150 MHz, MeOH-d3)  
(ppm) 172.57 (C=O acid), 158.05 (CO ether), 138.37 (Ar-C), 133.70 (Ar-C), 131.23 
(Ar-CH), 131.15 (Ar-CH), 129.67 (para-Ar-CH), 129.00 (para-Ar-CH), 120.63 (Ar-
CH), 119.67 (Ar-C), 110.69 (Ar-CH), 54.72 (CH3), 50.42 (CH2), 46.20 (CH2). IR 
vmax/cm-1: 3368.08 (OH stretch), 2920.39 (CH stretch), 2850.51 (CH stretch), 
2188.30, 1716.84 (C=O stretch), 1604.93 (NH bend). LC-MS (ESI) found m/z [M + 
H]+: 272, C16H17NO3 requires 271. 
  





3.5.3 Synthesis of 2-(2-Hydroxyethyl)-6-nitro-3,4-dihydro-2H-1,4-benzoxazin-










2-Amino-4-nitrophenol (3.00 g, 19.48 mmol, 1 eq) and potassium carbonate 
(4.03 g, 29.22 mmol, 1.5 eq) were stirred in anhydrous tetrahydrofuran (THF, 40 
mL) at room temperature (r.t.) for 50 minutes under a nitrogen gas atmosphere. α-
Bromo-γ-butyrolactone (3.86 g, 23.38 mmol, 1.2 eq) was added dropwise and the 
resulting mixture heated under reflux for 5.5 h. The reaction was quenched with 80 
mL ice-cold deionised water and the solvent removed under vacuum. The aqueous 
portion was cooled on ice before filtering off the solid to afford 113 as a brick-red 
solid. Recrystallisation from ethyl acetate gave fluffy yellow crystals, yield 2.61 g 
(56%). M.p. 169-170 °C (lit. 173 °C [333]); Rf 0.81 (ethyl acetate: cyclohexane: 
ethanoic acid, 5:4:1 v/v/v). 1H-NMR (600 MHz, DMSO-d6)  (ppm) 11.01 (1 H, br. 
s., NH), 7.81 (1 H, dd, J = 8.3, 2.3 Hz, Ar-H), 7.70 (1 H, d, J = 2.3 Hz, Ar-H), 7.14 
(1 H, d, J = 8.3 Hz, Ar-H), 4.85 (1 H, dd, J = 9.2, 4.6 Hz, CH), 4.65 (1 H, t, J = 5.5 
Hz, OH), 3.45 - 3.62 (2 H, m, CH2), 1.79 - 2.03 (2 H, m, CH2). 13C-NMR (150 
MHz, MeOH-d3)  (ppm) 166.97 (C=O amide), 148.29 (Ar-CO), 142.81 (Ar-
CNO2), 127.55 (Ar-CNH), 119.36 (Ar-CH), 116.83 (Ar-CH), 110.78 (Ar-CH), 74.33 





(aliphatic-CHO), 56.75 (aliphatic-CH2), 33.46 (aliphatic-CH2). IR vmax/cm-1: 3596 
(OH stretch), 3187 (CH stretch), 3118 (CH stretch), 3047 (CH stretch), 2955 (CH 
stretch), 2882 (CH stretch), 1696 (C=O amide), 1605 (C=C aromatic stretch), 1516 
(NO2 asymmetrical stretch), 1491 (CH2 bend), 1394 (NO2 symmetrical stretch), 1331 
(C-O stretch). LC-MS (ESI) found m/z [M – H]+: 237, C10H10N2O5 requires 238. 
3.5.4 Synthesis of 2-(6-Nitro-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-2-yl)ethyl 





Compound 113 (1.0 g, 4.2 mmol, 1 eq), triethylamine (1.4 mL, 0.4 g/mL, 5.0 
mmol, 1.2 eq) and 4-dimethylaminopyridine (DMAP, 0.30 g, 2.1 mmol, 0.5 eq) were 
stirred under a nitrogen atmosphere in anhydrous tetrahydrofuran (THF, 120 mL) at 
room temperature for at least 30 minutes. The mixture was then cooled in an ice bath 
to 0 °C and 4-iodobenzoyl chloride (1.12 g, 4.20 mmol, 1 eq) was added, in portions, 
with stirring, to the mixture. The mixture was then heated under reflux for a total 
reaction time of 5 h. After completion of the reaction as judged by TLC, the reaction 
mixture was poured into a flask containing 100 mL deionised ice-cold H2O. The 





aqueous phase was extracted with DCM three times (2x 30 mL, 1x 20 mL). The 
combined organic phases were washed with 10% HCl (2.74 M, 40 mL) to remove 
the triethylamine base, followed by saturated sodium hydrogen carbonate (NaHCO3, 
40 mL). The extracted organic layer was dried over anhydrous magnesium sulphate 
(MgSO4), filtered, and the solvent removed under vacuum to afford 58 as a sticky 
brown solid. Column chromatography (diethyl ether) afforded the pure ester as a 
pale yellow solid, yield 0.15 g, 8%. M.p. 188-190 °C; Rf 0.43 (diethyl ether). 1H-
NMR (600 MHz, DMSO-d6)  (ppm) 11.10 (1 H, s, NH), 7.86 - 7.89 (2 H, m, para-
Ar-H), 7.79 (1 H, dd, J = 8.7, 2.8 Hz, Ar-H), 7.67 (1 H, d, J = 2.3 Hz, Ar-H), 7.63 - 
7.68 (2 H, m, para-Ar-H), 7.10 (1 H, d, J = 8.9 Hz, Ar-H), 5.03 (1 H, dd, J = 7.6, 
4.6 Hz, CH), 4.42 (2 H, t, J = 6.3 Hz, CH2 aliphatic), 2.24 - 2.39 (2 H, m, CH2). 13C-
NMR (150 MHz, DMSO-d6)  (ppm) 174.53 (C=O amide), 165.72 (C=O ester), 
154.57 (Ar-CO), 145.67 (CNO2), 138.26 (para-Ar-CH), 131.41 (para-Ar-CH), 
129.01 (Ar-C), 127.81 (Ar-C), 119.67 (Ar-CH), 117.34 (Ar-CH), 111.17 (Ar-CH), 
101.12 (Ar-I), 74.56 (CH), 61.19 (CH2 aliphatic), 30.07 (CH2 aliphatic). IR vmax/cm-
1: 3607 (NH stretch), 3257 (CH stretch), 3088 (CH stretch), 1704 (C=O ester), 1673 
(C=O amide), 1633, 1606 (C=C aromatic stretch), 1588, 1517 (NO2 asymmetrical 
stretch), 1495 (CH2 bend), 1473, 1393 (NO2 symmetrical stretch). LC-MS (ESI) 
found m/z [M – H]-: 467 C17H13IN2O6 requires 468. 





3.5.4.1 Synthesis of 2-(6-Nitro-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-2-yl)ethyl 
4-chlorobenzoate (58a)  
 
 
Compound 113 (0.52 g, 2.2 mmol, 1 eq), Et3N (0.4 mL, 0.7 g/mL, 2.6 mmol, 
1.2 eq), DMAP (0.1 g, 1.1 mmol, 0.5 eq), 4-chlorobenzoyl chloride (0.38 g, 0.28 
mL, 2.2 mmol, 1 eq). Procedure identical to the synthesis of compound 58. Column 
chromatography (diethyl ether) afforded 58a as a greenish-yellow solid, yield 0.042 
g, 5%. M.p. 218-220 °C; Rf 0.82 (diethyl ether). 1H-NMR (600 MHz, DMSO-d6)  
(ppm) 11.09 (1 H, s, NH), 7.88 - 7.93 (2 H, m, para-Ar-H), 7.80 (1 H, dd, J = 8.9, 
2.75 Hz, Ar-H), 7.67 (1 H, d, J = 2.8 Hz, Ar-H), 7.53 - 7.58 (2 H, m, para-Ar-H), 
7.11 (1 H, d, J = 8.9 Hz, Ar-H), 5.04 (1 H, dd, J = 7.6, 4.47 Hz, CH), 4.43 (2 H, t, J 
= 6.2 Hz, CH2 aliphatic), 2.25 - 2.40 (2 H, m, CH2 aliphatic). 13C-NMR (150 MHz, 
DMSO-d6)  (ppm) 165.69 (C=O amide), 165.31 (C=O ester), 148.66 (Ar-CO), 
142.52 (CNO2), 138.85 (para-Ar-CH), 131.59 (para-Ar-CH), 129.44 (Ar-C), 128.92 
(Ar-C), 128.24 (Ar-C), 119.74 (Ar-CH), 117.37 (Ar-CH), 111.15 (Ar-CH), 74.57 
(CH), 61.23 (CH2 aliphatic), 30.07 (CH2 aliphatic). IR vmax/cm-1: 3275 (NH stretch), 
1716 (C=O ester), 1687 (C=O amide), 1524 (NO2 asymmetrical stretch), 1488 (CH2 





bend), 1378 (NO2 symmetrical stretch). LC-MS (ESI) found m/z [M – H]-: 375, 
C17H13ClN2O6 requires 376. 
3.5.4.2 Synthesis of 2-(6-Nitro-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-2-yl)ethyl 




Compound 113 (0.5 g, 2.1 mmol, 1 eq), Et3N (0.35 mL, 0.73 g/mL, 2.5 
mmol, 1.2 eq), DMAP (0.13 g, 1.1 mmol, 0.5 eq), 4-tert-butylbenzoyl chloride (0.41 
g, 0.41 mL, 2.1 mmol, 1 eq). Procedure identical to the synthesis of compound 58. 
Column chromatography (diethyl ether) afforded 58b as a pale brown solid, yield 
0.31 g, 37%. M.p. 88-90 °C; Rf 0.82 (diethyl ether) 0.84. 1H-NMR (600 MHz, 
DMSO-d6)  (ppm) 11.11 (1 H, s, NH), 7.81 - 7.84 (2 H, m, para-Ar-H), 7.78 (1 H, 
dd, J = 8.9, 2.8 Hz, Ar-H), 7.66 (1 H, d, J = 2.8 Hz, Ar-H), 7.47 - 7.50 (2 H, m. 
para-Ar-H), 7.11 (1 H, d, J = 8.9 Hz, Ar-H), 5.03 (1 H, dd, J = 7.6, 4.47 Hz, CH), 
4.41 (2 H, t, J = 6.2 Hz, CH2 aliphatic), 2.25 - 2.38 (2 H, m, CH2 aliphatic), 1.29 (9 
H, s, CH3). 13C-NMR (150 MHz, DMSO-d6)  (ppm) 166.06 (C=O ester), 165.68 
(C=O amide), 156.91 (Ar-C), 148.65 (Ar-CO), 142.49 (CNO2), 129.63 (para-Ar-
CH), 128.21 (Ar-C), 127.35 (Ar-C), 126.03 (para-Ar-CH), 119.70 (Ar-CH), 117.34 





(Ar-CH), 111.13 (Ar-CH), 74.59 (CH), 60.70 (CH2 aliphatic), 35.37 (C-tBu), 31.33 
(CH3), 30.20 (CH2 aliphatic). IR vmax/cm-1: 3251 (NH stretch), 1700 (C=O ester), 
1685 (C=O amide), 1502 (NO2 asymmetrical stretch), 1365 (NO2 symmetrical 













CHAPTER 4: Synthesis and Biological Evaluation of 









ChemBridge 7356270 (24) was one compound from the initial screening studies 
that showed promising inhibitory activity against the invasion of the S100P-expressing 
pancreatic cancer cells BxPC-3. At 100 μM, the compound exerted an effect on BxPC-3 
cells that is comparable to the proposed S100P-RAGE interaction inhibitor cromolyn at 




Figure 3.5D: Effect of compound 24 on the invasion of BxPC-3 cells. At 100 μM, compound 24 
showed a significant effect on the invasion of these cells relative to the non-treated control. This 
effect is comparable to that of cromolyn at the same concentration. *P<0.05; ***P<0.001. 
(Mahmoud [328]). 
  


























Compound 24 showed a weak but significant effect (p<0.001) on proliferation of 
BxPC-3 cells at the highest concentration of 500 μM after exposure to the compound for 
24 h (Chapter 3). This anti-proliferation effect was not observed on Panc-1 cells on 
exposure for 24 h. The effect of cromolyn on proliferation of BxPC-3 were not 
reproducible by Mahmoud [328] and in earlier work carried out in Dr Crnogorac-
Jurcevic’s laboratory (unpublished results) at Queen Mary University of London 
(QMUL). Work by the same laboratory also found that siS100P had little effect on the 
proliferation of BxPC-3 (Chapter 3) casting doubt on the role of S100P in the 
proliferation of pancreatic cancer cells [328]. It could therefore be possible that 
inhibition of S100P could affect pancreatic cancer cell migration/invasion and survival 
without significantly affecting proliferation.   
In this chapter, the design, synthesis and characterisation of ChemBridge 
7356270 (24) and its analogues will be discussed. Two synthetic routes to the target 
compound are presented, followed by biological screening studies of five analogues, 
including compound 24, against pancreatic cancer cells. Preliminary findings from chick 
chorioallantioc membrane (CAM) assay studies, used to assess the effect of the 
compounds on angiogenesis, are also presented.  
The experimental work detailing the syntheses and biological screening, and 
analytical data pertaining to the analogues synthesised form the final section of the 
chapter. 





The discovery of compound 24 as a potential lead candidate for a therapeutic 
agent against pancreatic cancer is promising. Given the lethality of this cancer, any 
compound that shows even marginal potency against the disease opens up many 
possibilities for further optimisation on the chemical structure in order to improve its 
therapeutic effect.  
Structurally, compound 24 is quite distinct from cromolyn (4) and its analogue 
C5-OH (5) (Figure 4.1), sharing a maximum common substructure Tanimoto similarity 
coefficient of 0.17 and 0.16 with both compounds respectively [282, 342]. Compounds 4 
and 5 have been reported to inhibit the growth and invasion of pancreatic cancer cells 
via disruption of the S100P-RAGE interaction [195, 197]. This structural diversity 
between 24 and 4 and 5 bodes well in the search for novel inhibitors of S100P as it 
ensures exploitation of the chemical space that could be targeted in pancreatic cancer 
therapy. 
Although compound 24 is commercially available, this will be first time, to the 
best knowledge of this author, that its synthesis, purification and characterisation are 
discussed. The approach used to design synthetic routes for the compound will be 
shown. The compound’s in vitro activity, as well as four of its analogues, against target-
specific and non-specific pancreatic cancer cells will also be discussed.  
  







Figure 4.1: Compound 24 is structurally different from cromolyn (4) and its analogue C5OH 








4.2 RESULTS AND DISCUSSION 
4.2.1 Strategy for the synthesis of compound 24  
Retrosynthetic analysis on 3-(9-nitro-12,14-dioxo-9,10-dihydro-9,10-
[3,4]epipyrroloanthracen-13-yl)benzoic acid (24) identified four synthons (ix), (x), (xi) 
and (xii) (Scheme 4.1). Disconnection of the two O=C-N bonds on the pyrrolidine-2,5-
dione moiety led to 3-aminobenzoic acid being identified as the appropriate synthetic 
equivalent for synthon (ix), and 9-nitroanthracene-maleic anhydride cycloadduct as the 
synthetic equivalent for (x). Further disconnection of the cycloadduct resulted in maleic 
anhydride and 9-nitroanthracene as the corresponding synthetic equivalents for the 
generated synthons (xi) and (xii) respectively (Scheme 4.1). Having determined the 
simplest readily available starting materials (RASMs) to the target molecule 24, two 
synthetic routes a and b were identified using Reaxys® (version 1.7.8; Elsevier; 2012, 
www.elsevier.com/reaxys, Scheme 4.2). Both routes involve the reaction of maleic 
anhydride either with ethyl aminobenzoate initially, followed by 9-nitroanthracene 
(route a) or alternatively with 9-nitrotoanthracene initially, followed by the 
aminobenzoic acid (route b). The first step of route a involves an addition/elimination 
reaction to yield the intermediate 115, which will subsequently react with 9-
nitroanthracene in a Diels–Alder cycloaddition to give 24. Alternatively, route b starts 
with the Diels–Alder cycloaddition reaction between maleic anhydride and 9-
nitroanthracene to form the cycloadduct 119 (Scheme 4.2). The final step in this route 
involves a simultaneous addition/elimination reaction with the amine to form the target 
compound 24 (Section 4.2.3).   





Scheme 4.1: Retrosynthetic analysis on target molecule (TM) 24 to identify readily available 
starting materials (RASMs). 
  














Scheme 4.2: Overview of the synthetic routes identified for 24. (FGI: functional group interconversion). 
 




4.2.2 Route a  
In the first approach (Scheme 4.3), the ethyl ester of 3-aminobenzoic acid was 
reacted with maleic anhydride to obtain 114. The acid 114 was then dehydrated to give 
the maleimide 115. Using the ester instead of the acid in the first step circumvented 
solubility problems encountered in subsequent steps when 3-aminobenzoic acid was 
used as the initial reagent. The first synthetic step was carried out at room temperature to 
yield the intermediate product 114 and the second under simple reflux conditions to give 
intermediate 115. Yields for intermediates 114 and 115 were reproducible, and the 
intermediates were not purified prior to the next synthetic step being carried out 
(Scheme 4.3). The next stage of the synthesis involved heating the maleimide 115 under 
reflux with 9-nitroanthracene in a Diels–Alder cycloaddition, to give the ester 
cycloadduct 116 of the target compound.  
Diels–Alder synthesis is an important [4+2] cycloaddition reaction that is 
commonly employed to generate new cycloadducts by reacting a diene, a compound 
with two conjugated carbon double bonds, in its cis conformation, with a dienophile 
[343-346]. The reaction was initially described by Otto Diels and Kurt Alder in 1928 
[347], for which they were awarded a Nobel Prize in 1950. The Diels–Alder reaction has 
been widely applied in synthesis to give highly regioselective and stereogenic 
compounds [348-350]. Its simplicity has made it an ideal and important route for 
forming new unsaturated six-membered rings and the use of catalysts has seen the 
production of highly enantioselective products [351-353].  




The first attempt at synthesising the target compound 24 via the Diels–Alder 
reaction was carried out by adapting the method of Bova et al. [354] but was not 
successful. In this method, the maleimide 115 was reacted with 9-nitroanthracene under 
reflux in xylene but no product was isolated. Microwave-assisted synthesis with and 
without solvent proved ineffective. Both toluene and xylene, the two non-polar solvents 
used, are poor microwave energy absorbers [355] and could not therefore attain a high 
enough temperature required to facilitate the reaction. It was hoped that the use of 
microwave-assisted synthesis using such solvents would allow the direct transfer of 
microwave energy to the reactants thus allowing the reaction to occur. The use of silica 
gel in Diels–Alder reactions using microwave energy has been previously reported with 
moderate yields [356, 357]. However, when the Diels–Alder reaction between 115 and 
9-nitroanthracene was carried out with silica gel using the microwave, no product was 
isolated, the starting diene was recovered suggesting no reaction had occurred.  
  






Scheme 4.3: First synthetic route (route a) for compound 24. 
  




While 9-nitroanthracene has been cited in literature for many Diels–Alder 
reactions [358-360], the poor reactivity between this diene and the maleimide 115 could 
be attributed to the former’s poor electron density due to the electron withdrawing effect 
of the nitro group on the π system. Electron-withdrawing groups on position C9 of 
anthracene have been reported to slow the rate of the Diels-Alder reaction [361]. It is 
also possible that the bulky N-aryl group of 115 was sterically interfering with the π 
system of the diene. Similar interactions between ortho-substituents of the N-aryl group 
and the π system have been previously reported to have a stabilising or destabilising 
effect on the π system [362]. Absence of the electron withdrawing effect of the nitro 
group was evident when anthracene was used as the diene. Anthracene reacted well with 
115 under reflux conditions to give the anthracene-maleimide cycloadduct ester 117 
(Scheme 4.4). Hydrolysis of the ester to the acid did not go to completion, but gave a 
mixture of both the acid and ester. No attempts were made to separate the two as a 
simpler route to forming the target compound (route b) had been identified. 
 
Scheme 4.4: Reaction of anthracene with 115 to give the anthracene-maleimide cycloadduct 
ester 117. 




4.2.3 Route b 
A second approach to generate the target compound was employed after the first 
attempt (Scheme 4.3) failed to generate the required product 24. In the second route, 
maleic anhydride was first reacted with 9-nitroanthracene under reflux as described by 
Wade [363] to give the Diels–Alder cycloadduct 119 (Scheme 4.5). The successful 
reaction between maleic anhydride and 9-nitroanthracene demonstrates the possibility 
that failure of the latter to react with the dienophile 115 (route a, Scheme 4.3) could be 
due to the steric inference of the N-aryl group of the dienophile with the π system of the 
diene in addition to the possible electron withdrawing effect of the nitro group of the 
diene on the π system.   
The cycloadduct product 119 was confirmed as the desired intermediate by the 
appearance of three distinct signals for the three chemically different protons in the 1H-
NMR as a result of the formation of a new 6-membered ring (Section 4.5.2.1). Since 
these signals were different from the singlet observed for the olefinic protons of maleic 
anhydride, their appearance in the 1H-NMR spectrum served as a benchmark in 
confirming the success or otherwise of the Diels–Alder cycloaddition reaction.   
In the final step of this route, the cycloadduct 119 was reacted directly with 3-
aminobenzoic acid in glacial acetic acid [364] to give the desired product 24 as a white 
solid in 80% yield (Scheme 4.5). 1H- and 13C-NMR, IR and LC-MS analyses all 
confirmed the product as compound 24 (Section 4.5.2.1.1).   





Scheme 4.5: Synthesis of compound 24 via route b. 
 
4.2.4 Analogues of compound 24 
Once the target compound was confirmed as compound 24, route b was 
employed to synthesise analogues by varying three main groups R, Rʹ and X on the 





Figure 4.2: General structure of analogues of compound 24 that were synthesised by varying the 
X, R and Rʹ groups. 
 




In the first instance, analogues were synthesised using 9-nitroanthracene (X = NO2) as 
the diene in the Diels–Alder reaction. The substituents on the amine (Scheme 4.2) were 
varied between positions 3 and 4 of the phenyl ring. Ortho-substituted amines were not 
considered for synthesis because of the potential interaction between the ortho-
substituent on the N-aryl phenyl ring and the π system of one of the benzene rings of the 
dihydroanthracene group if the latter adopts a conformation perpendicular to the 
succinimide group [362]. In addition, docking studies showed that an ortho substituent 
on the N-phenyl ring could prevent that part of the compound from interacting with the 
“smaller putative site” of S100P (Figure 4.3). A total of 19 analogues were synthesised 
with X = NO2 (24a-24s), and meta- and para-substituted amines in addition to 
compound 24 (Table 4.1, Section 4.5.2.1.1). 
The next set of analogues were synthesised using anthracene (X = H) as the 
diene replacing 9-nitroanthracene. Each analogue synthesised with the nitro group had a 
corresponding analogue without the group (Table 4.2, Section 4.5.2.2.1). Twenty 
compounds were synthesised from the anthracene-maleic anhydride cycloadduct (121-
121s) bringing to 40 the total number of analogues synthesised including compound 24. 
It was not surprising to find some of the synthesised anthracene-maleic anhydride 
derived analogues, 121, 121d, 121e, 121j, 121n, 121n, 121p, 121q, and 121r in the 
literature [365-368] as this cycloadduct is commonly encountered in many Diels–Alder 
reactions [369-371]. These analogues were previously synthesised to study their 
photoactivatability ([365], 121e, 121n, 121p, 121q, 121r) or their inclusion behaviour 
([366], 121, 121d, 121e, 121n) but not for their biological activity. 





Figure 4.3: Ortho-substituted analogue of compound 24. A) Modelling of the interaction of the ortho-substituted analogue of compound 24 
(in green) shows the effect of ortho- substitution preventing interaction with the putative binding pockets of S100P (arrows). B) Predicted 








Table 4.1: Analogues of compound 24 where X = NO2. Yields (from the Diels–Alder step), 
melting point (M.p.) and compound appearance are shown.  
 
 
Compound  R R' Yield* (%) M.p. (°C) Appearance 
24 CO2H H 80 271-272 white crystals 
24a CO2Et H 84 202-203 white flakes 
24b F H 81 241-243 cream flakes 
24c Cl H 82 230-232 cream solid 
24d NO2 H 93 240-242 pale yellow powder 
24e H H 72 110-112 cream flakes, static 
24f† CH3 H 91 209-211 cream powder 
24g† MeO H 72 262-265 brown solid 
24h† Me2N H 97 213-215 cream powder 
24i† CN H 97 310-311 cream powder 
24j H CO2H 80 344-345 cream flakes 
24k H CO2Et 78 255-256 white flakes 
24l H F 88 223-225 cream solid 
24m H Cl 91 270-273 cream flakes, static 
24n H NO2 78 316-318 fluffy cream powder 
24o† H CH3 75 258-262 white solid 
24p† H MeO 85 249-250 grey-purple solid 
24q† H Me2N 74 265-266 light grey powder 
24r H I 84 305-308 white crystalline powder 
24s H t-Bu 82 238-240 cream solid 
†Compounds synthesised by Kulikowska [372] and Grewal [373] as part of their final year project for the 
degree of Master of Pharmacy, University of Hertfordshire. *Yields shown are from the reaction of 
maleic-anthracene adduct and the amine.  




Table 4.2: Analogues of compound 24 where X = H. Yields (from the Diels–Alder step), 
melting point and compound appearance are shown. 
 
Compound  R R' Yield* (%) Mp (°C) Appearance 
121 CO2H H 95 285-288 white solid 
121a CO2Et H 96 205-207 pale pink powder 
121b F H 87 228-230 white flakes 
121c Cl H 92 238-240 cream flakes 
121d NO2 H 95 282-285 white powder 
121e H H 83 211-215 white solid 
121f† CH3 H 61 199-200 cream solid 
121g† MeO H 91 200-201 sand-coloured solid 
121h† Me2N H 93 228-230 cream solid 
121i† CN H 99 262-264 white solid 
121j H CO2H 86 354-355 white powder 
121k H CO2Et 92 220-222 white powder 
121l H F 96 250-253 pinkish solid 
121m H Cl 94 275-278 fluffy white powder 
121n H NO2 83 294-295 cream crystals 
121o† H CH3 94 220-222 white powder 
121p† H MeO 87 240-243 light purple solid 
121q† H Me2N 96 243-245 light purple powder 
121r H I 89 303-307 white solid 
121s H t-Bu 93 268-271 white solid 
†Compounds synthesised by Kulikowska [372] and Grewal [373] as part of their final year project for the 
degree of Master of Pharmacy, University of Hertfordshire. *Yields shown are from the reaction of 
maleic-anthracene adduct and the amine.   




Similar to compound 24, analogues with the X = NO2 substituent (Table 4.1) 
exhibited three distinct signals upfield in their 1H-NMR spectra due to asymmetry from 
the nitro group, which coupled to one another. Where defined, the first signal appeared 
as a doublet of doublets (dd) in the region δ = 3.53-3.76 ppm with coupling constants of 
~ 9.0 and 3.0 Hz. This signal comes from proton Hb of the succinimide moiety (Figure 
4.4) and is split into a doublet of doublets by protons Ha and Hc respectively (Section 
4.5.2.1.1). The large J coupling constant (J ~ 9.0 Hz) comes from the adjacent vicinal 
proton Ha of the succinimide moiety whose signal, a doublet, lies downfield between δ = 
4.4-4.6 ppm. Proton Hc of 9,10-dihydroanthrancene appears as a doublet when the peak 
is defined, at around δ 5.0-5.1 ppm with a coupling constant of J~3.0 Hz from proton 
Hb. These coupling constant values are comparable to those reported for similar 9-
substituted Diels–Alder anthracene-cycloadducts [360]. 
Anthracene-derived analogues (121-121s), where X = H, in comparison to the 
corresponding nitro derivatives, only had two proton peaks from protons Ha and Hb 
(Figure 4.4) on their 1H-NMR spectra from the newly formed six-membered ring of the 
Diels–Alder cycloadduct (Section 4.5.2.2) due to symmetry. These signals are in 
agreement with similar anthracene-maleic anhydride-derivatives published in the 
literature [365, 366, 369, 370, 374]. Both peaks appear as multiplets, with the first peak 
occurring between δ = 3.34-3.51 ppm. This signal originates from protons Ha on the 
succinimide moiety. The second signal lies upfield between δ = 4.85-4.89 and comes 
from protons Hb of the newly formed 5,10-dihydroanthracene cycloadduct. No coupling 




constants were available for these signals as they appeared as multiplets (Section 
4.5.2.2.1). 
In the 13C-NMR spectra of the 9-nitroanthracene analogues (24-24s), the two 
succinimide carbonyl carbon atoms appear as two signals between δ = 175 and 172 
ppm, whereas in the anthracene-derived analogues (121-121s), they are appear as a 
single signal in the same region due to symmetry (Section 4.5.2.2.1). In compounds 24-
24s, there are 18 aromatic carbon signals (6 carbon signals per aromatic ring) on the 13C-
NMR spectra. In comparison, compounds 121-121s exhibited 12 carbon signals (6 from 
the N-substituted phenyl ring and 6 from the aromatic anthracene rings) in their 13C-
NMR spectra due to symmetry.  
 
Figure 4.4: Signals from Ha, Hb and Hc. Three distinct signals were observed for protons Ha, Hb 
and Hc in the 1H-NMR spectra of all analogues with X = NO2 (compounds 24-24s), while only 
two distinct signals were observed for the corresponding analogues where X = H (compounds 
121-121s).   




Infrared (IR) analysis of all the nitro analogues (X = NO2, 24-24s) show distinct 
sharp NO2 peaks at around 1550 cm
-1 (asymmetric stretch) and 1340 (±50) cm-1 
(symmetric stretch). Melting points for the analogues varied, with 24j (X = NO2, R = H, 
Rʹ = CO2H) and its corresponding analogue 121j (X = H, R = H, Rʹ = CO2H) recording 
the highest melting points between 354-355 °C (Table 4.1 and 4.2 respectively). Both 
compounds are para- substituted and exhibited a considerable difference, greater than 
50 °C, in their melting points compared to the meta- substituted isomers. This difference 
is not surprising as the presence of symmetry in organic compounds has been reported to 
correlate with high melting points [375, 376]. The high melting point in symmetrical 
molecules is believed to be due to the more compact arrangement of the molecules in 
the crystal lattice which in turn requires higher energy to disrupt [376, 377]. Indeed, of 
the 32 analogues synthesised that have both para- and meta-isomers, all but three of the 
para-isomers, 24b, 24g, and 121d, have higher melting points than their corresponding 
meta- substituted counterparts. It is not known what is responsible for this disparity in 
the melting points of the three isomers, but cases where meta- or ortho- substituted 
isomers have a higher melting point than their para-substituted have been reported 
[378].  
Although most of the analogues are not easily ionisable, except for those with 
acidic groups such as compounds 24, 24j, 121 and 121j, liquid chromatography-mass 
spectrometry (LC-MS) analysis was still able to pick up the molecular ion, either in 
negative or positive mode. In the LC-MS spectra of intermediates 119 and 120, an m/z 




of + 31 was observed for both (Sections 4.5.2.1 and 4.5.2.2). These compounds were 
dissolved in methanol and the m/z indicates formation of a methanol-adduct. 
4.2.5 Analogue synthesis for high-throughput biological screening 
The rationale behind the synthesis of the above analogues was to create a library 
of compounds similar to compound 24 that could be used in high-throughput biological 
screening. By varying the R and Rʹ groups on the phenyl ring, the effect of substituents 
in position 3 or 4 on biological activity could be compared and contrasted for further 
studies such as during structure-activity relationship (SAR) studies. By replacing the 
carboxylic acid group in 24 with groups such as H, CO2Et, Cl, F, MeO, CN, NO2, I, t-
Bu, and Me2N, a variety of groups with different physicochemical properties to the acid 
are sampled. For example, replacing the CO2H group with a CH3 group removes the 
potential for hydrogen bonding and potential ionic interactions between the compound 
and the target protein. However, the presence of the hydrophobic CH3 group could 
enhance hydrophobic interactions with a lipophilic region of the protein that would 
otherwise not have been possible with the acid group. Substitution at the para- position 
provides a series of compounds that could be compared with their meta- substituent 
counterparts, to assess whether substituent position on the phenyl ring impacts on 
biological activity. For SAR purposes, the para-substituted substituents synthesised lie 
in different quadrants of the Craig plot (Figure 4.5) compared to the carboxylic acid 
group. The Craig plot [379] is a two-dimensional map that correlates two 
physicochemical properties, the Hammett substituent constant (σ) and the substituent 
hydrophobicity constant (π), for para-substituted groups on a phenyl ring. The Hammett 




substituent constant provides a measure of a substituent’s electronic properties while the 
substituent’s π-value provides its hydrophobicity relative to hydrogen [201]. This 
information is useful as a guide to synthesising more compounds based on biological 
activity and calculation of which properties may need improving. Sixteen of the 
analogues synthesised (24l-24s, 121l-121s) have substituents which are included in the 
Craig plot (highlighted in Figure 4.5) which should aid in future SAR calculations.  
By synthesising analogues with different substituents and physicochemical 
properties, it is hoped that high-throughput biological screening will facilitate the 
process of identifying which groups of compounds could be progressed for further 
optimisation studies in the search for a therapeutic agent against pancreatic cancer.  
  





Figure 4.5: Craig plot showing σ and π values for para-substituted phenyl substituents. Sixteen 
of the synthesised analogues (24l-24s, 121l-121s) have substituents which are included in the 
Craig plot. These substituents (highlighted in yellow) have σ and π properties that vary from the 
carboxylic acid group (circled in red). (Graph adapted from Patrick [201]).  
 
  




4.2.6 Selecting analogues for biological screening 
Five compounds including the “hit” compound 24 were selected, from the 40 
synthesised, for biological screening against pancreatic cancer cells (Figure 4.6, Table 
4.3). Compound 24a is the ester analogue of 24, and has a similar molecular weight to 
cromolyn; compound 24e on the other hand lacks a substituent on the phenyl ring, and 
was selected to examine the absence of the carboxylic acid group on biological activity. 
Compound 24j, the para-substituted analogue of 24, is selected to examine the effect of 
substituent position on biological activity, and compound 121, which lacks a NO2 group, 
was selected to assess whether this group is necessary for activity.  
 
  




Table 4.3: Physicochemical properties of cromolyn and compounds selected for biological 
screening. MW: Molecular Weight, tPSA: total Polar Surface Area, Log S: aqueous solubility, 
clog P: octanol-water partition coefficient, pKa: acid dissociation constant. Properties calculated 
in MOE 
 
Compound MW tPSA Log S clog P pKa 
Cromolyn 468.37 165.89 -4.24 1.48 2.58 
24 440.41 126.49 -5.21 2.80 3.84 
24a 468.13 115.49 -5.93 3.74 - 
24e 396.40 89.19 -5.26 2.74 - 
24j 440.41 126.49 -5.34 2.80 3.71 




Figure 4.6: Compounds selected for biological screening. Highlighted in red are the differences 
between analogues and “hit” compound 24.  
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4.3 BIOLOGICAL SCREENING  
4.3.1 Growth of pancreatic cancer cells 
The response of pancreatic cancer cells BxPC-3 and Panc-1 (Figure 4.7) in 
growth culture medium was assessed prior to screening the effect of compound 24 and 
analogues against them. A study of the growth of both cell lines for optimal cell 
proliferation studies was carried out using a 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS)-based assay 
(Promega, Southampton, UK). This assay exploits the presence of a mitochondrial 
dehydrogenase enzyme in metabolically active viable cells that reduces the salt to a 
coloured soluble formazan dye product which is then determined spectrophotometrically 
[335]. In short, a high absorbance reading corresponds to a higher metabolic activity, 
which can also be interpreted as an increase in cell numbers. This will be discussed 
further in the sections below. 
It was found that both cell lines grow optimally when seeded at a density of 1 x 
104 cells/well in 96-well plates (Figure 4.8). At this density, the cells grew exponentially 
for a period of 120 hours (5 days) before reaching a plateau and entering the death phase 
around day 7 (Figure 4.8). Furthermore, at a density of 1 x 104 cells/well, most of the 
cells were attached overnight (~23 hours, Figure 4.9). These cells are adherent cell lines 
and as such need to attach to grow. For screening purposes, seeding at 1 x 104 cells/well 
seemed to provide the best seeding density for attachment during the exponential growth 
phase. The growth characteristics of the cells when seeded at 1 x 103 cells/well are 




similar to that at 1 x 104 cells/well. However, due to the lower cell number per surface 
area per well, the cells at the former density took longer to attach and divide compared 
to the latter (Figure 4.9), which is most likely due to the limited cell-to-cell interaction 
and signalling at the lower concentration. At a density of 1 x 105 cells/well, both BxP-3 
and Panc-1 cells showed a rapid decline in cell number (i.e. metabolic activity) possibly 
due to cell death caused by the cells competing for limited nutrients in 100 μL of growth 
medium, lack of growing area that they require for adherence as well as exposure to a 
cocktail of by-products/metabolites/intracellular enzymes excreted by the other growing 
or dead cells (Figure 4.8 and 5).  
In conjunction with the MTS assay, the CytoTox-ONE™ Homogeneous 
Membrane Integrity Assay (Promega, Southampton, UK) was used to determine 
viability of both cell lines during their growth. However, the results obtained were found 
to be, inconclusive. This assay relies on the release of the enzyme lactate dehydrogenase 
(LDH) from compromised cell membranes of dead cells into the culture medium which 
is then measured fluorometrically [380]. The presence of foetal bovine serum (FBS, 
10% v/v) in the growth medium has been reported to interfere with this particular assay 
due to endogenous LDH in FBS [381, 382] yielding a high signal-to-noise ratio. In this 
study, the signal-to-noise ratio was still high even after accounting for background noise 
from media-only controls. As the assay was carried out in multiplex with the MTS 
assay, which performed satisfactorily in the presence of FBS, lowering the serum 
concentration to optimise it for LDH release studies would require assessing the 




response of the cells to such conditions which would be counter to the serum 
concentration for optimal cell growth as recommended by the vendor.    
In addition to possible serum interference, phenol red present in culture media 
has also been reported to interfere with the LDH assay [383]. Indeed, many papers have 
reported carrying out LDH studies using serum-free/reduced serum and phenol red-free 
culture medium [384-386]. This is an avenue that could be pursued in future if using this 
assay to determine the cytotoxicity of the compounds screened.    





Figure 4.7: Pancreatic cancer cells BxPC-3 and Panc-1 adhered at the bottom of T-75 cm2 
flasks. Cells were cultured in complete growth medium supplemented with FBS (10% v/v), 
Penicillin/Streptomycin (200 U) solution, and L-glutamine (2 mM). Images taken with a 
GXCAM-9 digital microscope C-mount camera (GT Vision, Suffolk, UK) mounted on an 










Figure 4.8: Batch growth curve for pancreatic cancer cells over a period of two weeks. A) 
BxPC-3 cells. B) Panc-1 cells. Cells were plated in 96-well plates at a density of 1000, 10,000 
and 100,000 cells/well (100 μM) in complete cell culture growth medium. Samples were 
assessed using the MTS reagent (Promega) according to the manufacturer’s instructions before 
reading absorbance at 492 nm using a Multiskan Ascent 96/384 plate reader (Thermo 






























































Figure 4.9: Representative images of attachment of pancreatic cancer cells 48 h after seeding in 
96-well plates for batch growth curve studies. After reading MTS absorbance for proliferation 
studies, cells were washed with Phosphate Buffered Saline (PBS), fixed with paraformaldehyde 
(3.7% w/v) at room temperature for 15 minutes followed by another wash with PBS. After 
fixation they were permeabilised with Triton X-100 (0.01% v/v) for 15 minutes, washed with 
PBS before staining the cytoplasm and nuclei with May-Grünwald (0.25% v/v) and Giemsa 
(0.4% v/v) stains respectively. Images taken with a GXCAM-9 digital microscope C-mount 
camera (GT Vision, Suffolk, UK) mounted on an Olympus CKX41 microscope at x20 









4.3.2 Effect of cromolyn (4), compounds 24, 24a, 24e, 24j and 121 on pancreatic 
cancer cells 
4.3.2.1 Proliferation studies 
Cromolyn (4) has been reported to inhibit proliferation of pancreatic cancer cells 
by binding to S100P cells in both in vitro and in vivo models [195, 334, 387]. To 
determine this effect, pancreatic cancer cells BxPC-3 and Panc-1 were incubated with 4 
at different concentrations and the effect on proliferation assessed using the MTS assay. 
Compound 4 was found to have no meaningful statistical effect on the proliferation of 
both these cell lines at low concentrations (1, 10 and 100 μM) compared to the no-
treatment control (p>0.05, Figure 4.10). At the high concentration of 1000 μM, there 
was a significant effect on proliferation of both cell lines (p<0.05) although, on closer 
observation, this effect seems to be constant over the 72 h period. This effect could be a 
result of general toxicity of the compound to the cells from such a high concentration 
rather than a specific anti-proliferative effect. These findings are similar to results by 
Mahmoud [328] but contrary to those of Arumugam et al. [195]. The latter group 
observed no effect on the proliferation of Panc-1 cells from 4, but Panc-1 cells 
transfected with S100P were found to be inhibited by the compound at 100 μM after 48 
h. In the same work, they also reported that 4 inhibited proliferation of BxPC-3 cells at 
10 and 100 μM (p = 0.002 and p<0.001 respectively). Since the current studies were not 
carried out in exactly the same way as Arumugam et al.’s work, it is not known if the 
discrepancies observed herein are due to disparate methodologies.   





Figure 4.10: Effect of cromolyn (4) on proliferation of pancreatic cancer cells BxPC-3 (A) and 
Panc-1 (B). Cells were seeded overnight (1 x 104 cells/well in 100 μL) in 96-well plates in 
complete medium supplemented with FBS (10% v/v), L-glutamine (2 mM) and 
Penicillin/Streptomycin (200 U) solution. Cromolyn was added to the wells and cell 
proliferation assessed using the MTS assay after 24, 48, and 72 h. Results are expressed as mean 
+ SEM of three independent experiments with n = 12. P value of <0.05(*) was determined 
relative to control using 2-Way ANOVA. Post-test comparisons were made using Bonferroni 































































In Arumugam et al.’s proliferation studies, they plated 96-well plates at a density 
of 1 x 103 cells/well, compared to 1 x 104 cells/well used in the present study, and they 
measured the effect of 4 on the cells’ proliferation after 48 h [195]. Other than the 
differences in seeding density, the discrepancies in the effect of 4 on these cells between 
this work and Arumugam et al.’s is something that warrants further investigation.  
When compound 24 was screened for anti-proliferation properties on BxPC-3 
cells, there was a significant inhibition of growth relative to control at all three 
concentrations (1, 10 and 100 μM) after 72 h (p<0.0001, Figure 4.11). However, a 
similar effect was also observed on the Panc-1 cells, casting doubt upon a solely S100P-
mediated effect. Compound 24a, which has an ester group in place of the carboxyl 
group, had a more pronounced anti-proliferative effect on BxPC-3 cells after 24 h 
compared to compound 24 (Figure 4.12A). This initial decrease in cell metabolic 
activity may be due to exposure of the cells to a foreign stimulus resulting in a lower 
proliferative ability. After 48 h, the cells appear to be recovering albeit only slightly 
compared to the control. A dose-dependent decrease in proliferation was observed for 
all three concentrations (1, 10 and 100 μM) after 72 h with the highest effect seen at 100 
μM. This concentration-dependent effect of 24a was absent on Panc-1 cells, although 
the compound still interestingly exerted an effect on proliferation at all three 
concentrations (1, 10 and 100 μM) relative to control (Figure 4.13A).  





Figure 4.11: Effect of compound 24 on proliferation of pancreatic cancer cells BxPC-3 (A) and 
Panc-1 (B). Cells were seeded overnight (1 x 104 cells/well in 100 μL) in 96-well plates in 
complete medium supplemented with FBS (10% v/v), L-glutamine (2 mM) and 
Penicillin/Streptomycin (200 U) solution. Compound 24 was added to the wells and cell 
proliferation assessed using the MTS assay after 24, 48, and 72 h. Results are expressed as mean 
+ SEM of three independent experiments with n = 12. P value of <0.0001 (****) was 
determined relative to control using 2-Way ANOVA. Post-test comparisons were made using 
































































A similar dose-dependent effect on proliferation of BxPC-3 was seen with 24e 
after 72 h (Figure 4.12B). This analogue lacks a substituent on the phenyl ring when 
compared to 24 and 24a. Interestingly, the effect on proliferation of Panc-1 cells closely 
resembled that exerted by 24a, the ester analogue. At 24 h, the anti-proliferative effect 
on Panc-1 cells was striking but the cells seem to be recovering after 72 h albeit 
marginally relative to control (Figure 4.13B).  
The regioisomer of compound 24, compound 24j, with the carboxyl group in the 
para position produced a more pronounced anti-proliferative effect on BxPC-3 cells at 1 
and 10 μM compared to 24 where the acid group is in the meta position (Figure 4.12C). 
Although still viable, as assessed by trypan blue counting, no metabolic activity was 
observed for the BxPC-3 cells at 1 μM after 72 h, making 24j the most potent inhibitor 
at this concentration in comparison to 24, 24a and 24e. Similar effects were observed on 
the proliferation of Panc-1 cells calling into question whether the mechanism by which 
this compound is acting is S100P-mediated (Figure 4.13C).   
Compound 121, which lacks the NO2 group, inhibited proliferation of BxPC-3 
cells at low concentrations, 1 and 10 μM, relative to control (Figure 4.12D). Again, 
similar to compounds 24, 24a, 24e and 24j, inhibition was also observed against Panc-1 
cells (Figure 4.13D). 




Figure 4.12: Effect of hit compounds on proliferation of BxPC-3 cells. A) Compound 24a. B) Compound 24e. C) Compound 24j. D) 
Compound 121. Cells were seeded overnight (1 x 104 cells/well in 100 μL) in 96-well plates in complete medium supplemented with 
FBS (10% v/v), L-glutamine (2 mM) and Penicillin/Streptomycin (200 U) solution. Compounds were added to the wells and cell 
proliferation assessed using the MTS assay after 24, 48, and 72 h. Results are expressed as mean + SEM of three independent 
experiments with n = 12. P value of <0.0001 (****) was determined relative to control using 2-Way ANOVA. Post-test comparisons 






















































































































Figure 4.13: Effect of hit compounds on proliferation of Panc-1 cells. A) Compound 24a. B) Compound 24e. C) Compound 24j. D) 
Compound 121. Cells were seeded overnight (1 x 104 cells/well in 100 μL) in 96-well plates in complete medium supplemented with 
FBS (10% v/v), L-glutamine (2 mM) and Penicillin/Streptomycin (200 U) solution. Compounds were added to the wells and cell 
proliferation assessed using the MTS assay after 24, 48, and 72 h. Results are expressed as mean + SEM of three independent 
experiments with n = 12. P value of <0.0001 (****) was determined relative to control using 2-Way ANOVA. Post-test comparisons 






















































































































Despite the effect of these compounds on the proliferation of Panc-1 cells, which 
casts doubt on an S100P-mediated effect on BxPC-3 cells, it is encouraging that the 
compounds are exerting some anti-proliferative effects at low concentrations of 1 and 10 
μM relative to control. What will be interesting to see is how the cells respond to the 
compounds at nanomolar concentrations, a task that was not carried out in this study due 
to time limitations, as this would provide an opportunity to further optimise them to 
improve their potency. Ideally, high potency is desired for a drug candidate at low 
concentrations in order to avoid unwanted and potentially adverse side effects. Low-
concentration dosing could also be beneficial to solubility and stability of the 
compounds, important properties that are useful further down the drug development and 
formulation stages [388].  
There were some solubility issues in the aqueous-based culture media for 
compounds 24a, 24e and 24j at 100 and 1000 μM (Figure 4.14). Although soluble in 
dimethyl sulfoxide (DMSO), a precipitate was observed for all three compounds at 100 
and 1000 μM once they were added to wells containing the cells in culture media. These 
precipitates sometimes resulted in erroneously high MTS absorbance readings, for e.g. 
compound 24a at 100 μM for Panc-1 cells (Figure 4.13B). To identify the source of the 
abnormally high MTS readings at these concentrations, the compounds were added to 
culture media (both RPMI and DMEM) in the absence of cells in 96-well plates before 
adding the MTS reagent and reading the absorbance. As suspected, there were high 
absorbance readings after addition of the MTS reagent to these three compounds in 
culture medium (Figure 4.15). Visual analysis of images of 24j taken before and after 




addition of the MTS reagent showed what appeared to be salt deposits on the crystals of 
the compound, suggesting formation of a complex between the reagent and the 
compound (Figure 4.15B and C). Since these solubility issues were only encountered at 
high concentrations (100 and 1000 μM), these concentration values will be omitted in 
future studies.  
  





Figure 4.14: Precipitation of compounds (red arrows) when added to BxPC-3 cells (white 
arrows) in RPMI-1640 culture medium in 96-well plates. A) 24a. B) 24e. C) 24j. Images taken 
with a GXCAM-9 digital microscope C-mount camera (GT Vision, Suffolk, UK) mounted on an 
Olympus CKX41 microscope at x4 magnification (objective lens).    









Figure 4.15: Solubility issues encountered with compounds 24a, 24e and 24j. A) Absorbance 
reading for the compounds in RPMI-1640 culture medium (in the absence of cells) following the 
addition of the MTS reagent. B) Compound 24j in RPMI-1640 medium before addition of the 
MTS reagent (x40). C) Compound 24j in RPMI-1640 after addition of MTS reagent showing 

































4.3.2.2 Membrane integrity studies 
Cell membrane integrity studies carried out using CytoTox-ONE™ 
Homogeneous Membrane Integrity Assay (Promega, Southampton, UK), were 
inconclusive for all the compounds (24, 24a, 24e, 24j and 121) examined. There was a 
high signal-to-noise ratio at all concentrations even after subtracting values obtained 
with media-only controls for background absorbance. As discussed previously (Section 
4.3.1), the high interference observed here could be due to many factors including the 
presence of foetal bovine serum and the phenol red dye in the culture medium, both of 
which have been reported to interfere with the lactate dehydrogenase (LDH) enzyme in 
the assay. 
Results from the membrane integrity studies, together with those from the MTS 
assay studies, would have provided an insight into how the compounds were exerting 
their effect on the cells. If the compounds were cytotoxic, cell membranes of both cell 
lines would be compromised and a high fluorescence reading would be expected from 
the LDH assay studies, the cells were viable at the start of the experiment as confirmed 
by the Trypan blue exclusion assay and therefore had intact cell membranes at the start 
of the experiment. The inconclusive results from the LDH assay investigations indicate 
that no conclusions can be drawn on the cytotoxicity or otherwise of these compounds. 
Further work to optimise this assay, or use of a different assay is necessary in the future 
in order to clarify the situation. Despite this setback with the cytotoxicity studies, the 
MTS results suggest that the compounds may be cytostatic, i.e. inhibition of cell growth 
by inhibiting the cells’ metabolic ability. This cytostatic property is promising at this 




stage of the drug discovery process as it indicates possible alternative strategies for 
compound efficacy optimisation against pancreatic cancer cells. Indeed, in the absence 
of a cure, cytostatic anti-cancer drugs used to stabilise the disease may be the way 
forward with lethal, incurable cancers such as pancreatic cancer [389].  
4.3.2.3 Chick Chorioallantoic Membrane (CAM) Assay  
Angiogenesis plays a crucial role in cancer growth and progression by providing 
a rich network of blood vessels that supply oxygen and nutrients to the proliferating 
cells [390-392]. Inhibition of tumour angiogenesis therefore offers another therapeutic 
avenue of targeting cancer cell proliferation, migration and metastasis. Indeed, many 
anti-cancer drugs that are developed to inhibit tumour growth, migration and invasion 
do so by indirectly inhibiting proangiogenic factors [393, 394].  
The chick chorioallantioc membrane (CAM) assay was employed to assess the 
effect of screening compounds on blood vessel formation. Traditionally, this assay has 
served as a useful model to study angiogenesis [395, 396], tumour growth and migration 
[397-400]. Compounds 24, 24a, 24e, 24j and 121 were tested for anti-angiogenic 
properties adapting the method described in [401]. The compounds were added to the 
chorioallantioc membranes of 4-day old developing embryos via a cut window through 
the shell and incubated until day 10 when representative images are taken to assess 
angiogenesis. Of the five compounds tested, preliminary observations show only 
compound 24 appeared to affect angiogenesis (Figure 4.16). However, this effect was 
not reproducible as it was difficult to retain viable embryos by day 10 of the 




investigation despite efforts to minimise injury to the embryo during the study. As a 
result of the high attrition rate associated with this assay, insufficient data was generated 
for statistical analysis, even for compound 24. Approximately 95% of embryos treated 
with the compounds on day 4 after first incubation did not make it to day 10, when they 
were assessed for anti-angiogenic effects. Due to time limitations, the experiment was 
only repeated twice, and on both occasions, most of the embryos had died by day 10. 
Despite this setback, the initial results obtained with compound 24 demonstrate the 
feasibility of this assay to study angiogenesis, a crucial process in tumour development. 
Once optimised in future studies, this assay, together with the proliferation and 
cytotoxicity assays, should provide a comprehensive understanding of how the screened 
compounds are affecting pancreatic cancer cell lines.  
  





Figure 4.16: Chick chorioallantioc membrane (CAM) assay for compound 24. A) Developing 
embryo on day 4 following incubation showing the developing blood vessels. B) Compound 24 
(10 μM 20 μL pre-absorbed on filter paper) on the CAM membrane of a 10-day old embryo.   
A
B





Compound 24 and 39 analogues were successfully synthesised, isolated and 
characterised following a two-step synthetic route involving a Diels–Alder 
cycloaddition and an addition/elimination reaction. Compounds structures and purity 
were confirmed by characterisation via 1H- and 13C-NMR, melting point analysis, and 
LC-MS spectrometry. By varying the substituents in positions 3 and 4 of the phenyl ring 
of compound 24, as well as removing the nitro group, it is hoped that the diverse 
collection of analogues synthesised will provide a library of compounds that could be 
used in high throughput biological screening studies against pancreatic cancer cells. The 
results from these screens will be valuable in the development of a structure-activity 
relationship (SAR) model for these compounds in their optimisation for increased 
potency. 
Five compounds, including compound 24, were advanced for biological 
screening against the proliferation of pancreatic cancer cells. Compound 24 was found 
to inhibit proliferation of both BxPC-3 and Panc-1 cells at all concentrations of 1, 10 
and 100 μM (p<0.0001). Its ester analogue, 24a, also inhibited proliferation of both cell 
lines at all three concentrations. The same pattern of inhibition was observed for 24e (no 
substitution on the phenyl ring system), 24j (4-CO2H) and 121 (no NO2 group). 
Interestingly, all four analogues seemed to have a greater effect on proliferation of both 
cell lines compared to 24. Since all five compounds showed inhibitory activity at 1 μM 
relative to control (p<0.0001), it will be interesting to see their effect at sub-micromolar 
concentrations. Testing the compounds at sub-micromolar concentrations will also allow 




the assessment of their IC50 values, an important property that will be useful when 
optimising them for potency.  
Early indications from the biological screening, although not definitively 
conclusive, suggest that these compounds have the potential to contribute to pancreatic 
cancer therapy. Preliminary results demonstrate that the five compounds examined 
affect the proliferative capability of pancreatic cancer cells to an extent. Given that there 
are 35 more analogues yet to be examined, the prospect of finding more hits with even 
better activity than the five compounds investigated remains high. The five compounds 
examined all have the potential for further optimisation to improve potency in the next 
stage of the drug discovery process, in the hope that one or more candidates will emerge 
as a lead therapeutic candidate for the treatment of pancreatic cancer.  
  





4.5.1 General Methodology: Synthesis and Instrumentation 
Similar procedure as described in Section 3.5.1.  
4.5.1.1 Synthesis of compound 24: Route a 
4.5.1.1.1 Synthesis of (Z)-4-((3-(ethoxycarbonyl)phenyl)amino)-4-oxobut-2-enoic 






A pale brown solution of maleic anhydride (0.61 g, 6.20 mmol) and ethyl-3-
aminobenzoate (1.01 g, 6.11 mmol) in acetone (30 mL) was stirred at room temperature 
for 4.5 h until a precipitate formed. The precipitate was filtered off to give 114 as a 
fluffy cream powder, yield 1.49 g, 93%, which was used in the next step without further 
purification. M.p. 154-155 °C. 1H-NMR (400 MHz, acetone-d6)  (ppm) 10.64 (br. s, 
1H, OH), 8.27 - 8.41 (1 H, m, Ar-H), 7.99 (1 H, m, Ar-H ), 7.77 - 7.92 (1 H, m, Ar-H), 
7.53 (1 H, t, J = 8.0 Hz, Ar-H), 6.69 (1 H, d, J = 12.6 Hz, alkenyl-H), 6.39 (1 H, d, J = 




12.6 Hz, alkenyl-H), 4.36 (1 H, q, J = 7.1 Hz, CH2), 1.36 (3 H, t, J = 7.1 Hz, CH3).  13C-
NMR (100 MHz, acetone-d6)  (ppm) 178.34 (C=O acid), 174.11 (C=O ester), 173.49 
(C=O amide), 134.60 (alkenyl-CH), 132.49 (alkenyl-CH), 131.52 (Ar-C), 129.35(Ar-C), 
126.56, 125.99 (Ar-C), 124.82 (Ar-C), 121.28 (Ar-C), 60.91 (CH2), 13.75 (CH3). IR 
vmax/cm-1: 3303 (N-H stretch), 3223 (OH stretch), 3158, 3124, 3093 (C-H stretch), 1720 
(C=O stretch, acid), 1678 (C=O stretch, ester), 1627 (C=O amide), 1106 (C-O stretch), 
1018 (C-N stretch). LC-MS (ESI) found m/z [M – H]-: 262, C13H13NO5 requires 263. 
4.5.1.1.2 Synthesis of ethyl 3-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzoate 






Sodium acetate (0.03 g, 0.31 mmol) was added to a stirred solution of 4-((3-
(ethoxycarbonyl)phenyl)amino)-4-oxobut-2-enoic acid (114) (0.35 g, 1.33 mmol) in 
acetic anhydride (20 mL) and the contents heated under reflux at 140 °C for 0.5 h. The 
pale yellow solution was cooled to room temperature while stirring for another 2 h. The 
mixture was poured into ice-cold sodium hydrogen carbonate (10% w/v, 40 mL) in an 




ice-bath while stirring vigorously until a precipitate formed. The precipitate was 
extracted with Et2O (1x 75 mL, 1x 50 mL, 1x 25 mL). The combined ethereal extracts 
were dried over anhydrous MgSO4, filtered, Et2O removed under vacuum and the 
product was precipitated from the remaining acetic anhydride solution by the addition of 
ice-cold distilled water. The precipitate was filtered under suction and dried to give 115 
as pale orange flakes. The product was used in the next step without further purification. 
Yield 0.23 g, 66%. M.p. 109-110 °C. 1H-NMR (400 MHz, DMSO-d6)  (ppm) 7.91 - 
8.02 (2 H, m, Ar-H), 7.59 - 7.72 (2 H, m, Ar-H), 7.21 (2 H, s, alkenyl-H), 4.34 (2 H, q, J 
= 7.14 Hz, CH2), 1.33 (3 H, t, J = 7.14 Hz, CH3). 13C-NMR (100 MHz, DMSO-d6)  
(ppm) 170.32 (2 C=O amide), 165. 61 (C=O ester), 135.34 (2 C, olefinic), 132.60 (Ar-
C), 131.94 (Ar-C), 131.20 (Ar-C), 129.99 (Ar-C), 128.77 (Ar-C), 127.74 (Ar-C), 61.65 
(CH2), 14.71 (CH3). IR vmax/cm-1: 3091, 2993 (C-H stretch), 1716, 1707 (C=O stretch), 
1020 (C-O stretch). LC-MS (ESI) found m/z [M – H]-: 244, C13H11NO4 requires 245. 
4.5.1.1.3 Attempted synthesis of ethyl 3-(9-nitro-12,14-dioxo-9,10-dihydro-9,10-









9-Nitroanthracene (0.22 g, 1.00 mmol) was added to a stirred solution of 115 
(0.25 g, 1.00 mmol) in xylene (15 mL). The contents were heated under reflux for 3 
days after which the reaction was cooled to room temperature with stirring. The mixture 
was then placed in an ice-bath while stirring for 45 minutes. After this time the solvent 
was removed under vacuum to yield 116 as a sticky orange solid, which proton NMR 
analysis indicated the material to be mainly unreacted diene. No further analysis was 
carried out on the product.  








Ethyl 3-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzoate (0.10 g, 0.50 mmol), 9-
nitroanthrocene (0.18 g, 0.80 mmol) and xylene (4 mL) were placed in a 5 mL round 
bottom vial fitted with a magnetic stirrer. The contents were subjected to microwave 
(MW) irradiation in a Biotage Microwave Synthesizer (Biotage Limited, Hengoed, 




Wales, UK) for 3 h at low absorption, at a temperature of 220 °C and 400 W. When the 
reaction was complete (monitored by TLC using hexane:t-butyl methyl ether, 4:1, v/v), 
the mixture was cooled to room temperature then placed in an ice-bath with stirring, 
which resulted in the formation of a precipitate. The precipitate was filtered analysis of 
which by proton NMR indicated the presence of unreacted 9-nitroanthracene.   
4.5.1.3 Replacing substituted diene (9-NO2) with unsubstituted diene (9-H) 








The diene anthracene (0.25 g, 1.39 mmol) was added to a stirred solution of 115 
(0.17 g, 0.70 mmol) in xylene (15 mL). The contents were heated under reflux at 140 °C 
for ~4 h. After this time, the reaction mixture was cooled to room temperature then 
placed in an ice-bath to precipitate out 117 as cream flakes. Yield 0.13 g, 44%. M.p. 
203-205 °C. 1H-NMR (400 MHz, acetone-d6)  (ppm) 8.06 - 8.09 (1 H, m, Ar-H), 7.92 




- 7.94 (1 H, m, Ar-H), 7.43 - 7.53 (4 H, m, Ar-H), 7.20 - 7.24 (4 H, m, Ar-H), 7.17 - 
7.18 (1 H, m, Ar-H), 6.77 - 6.80 (1 H, m, Ar-H), 4.89 - 4.90 (2 H, m, CH 
dihydroanthracene), 4.34 (2 H, q, J = 7.3 Hz, CH2), 3.47 (2 H, m, CH succinimide), 
1.36 (3 H, t, J = 7.0 Hz, CH3). 13C-NMR (100 MHz, acetone-d6)  (ppm) 175.62 (2 
C=O amide), 164.91 (C=O ester), 141.97 (Ar-C), 139.68 (Ar-C), 131.40 (Ar-C), 131.30 
(Ar-C), 129.12 (Ar-C), 129.02 (Ar-C), 128.17 (Ar-C), 127.85 (Ar-C), 126.85 (Ar-C), 
126.61 (Ar-C), 125.51 (Ar-C), 124.38 (Ar-C), 60.95 (CH2 aliphatic), 47.25 (2 CH 
dihydroanthracene), 45.83 (2 CH succinimide), 13.75 (CH3). IR vmax/cm-1: 3052, 2988, 
2961 (C-H stretch), 1775, 1718, 1706 (C=O stretch, amide and ester). LC-MS (ESI) 
found m/z [M + H]+: 424, C27H21NO4 requires 423. 
4.5.1.5 Attempted synthesis of 3-(12,14-dioxo-9,10-dihydro-9,10-
3,4]epipyrroloanthracen-13-yl)benzoic acid (118) 
 




Compound 117 (0.05 g, 0.13 mmol) was dissolved in dichloromethane/ethanol 
(9:1 v/v) and stirred for 5 minutes at room temperature to give a pale yellow solution. 
Sodium hydroxide (2 mL, 1 M) was added while stirring resulting in a cloudy yellow 
solution. After 75 minutes of stirring at room temperature, the mixture was heated under 
reflux at 45 °C for 4 h after which a white precipitate was formed. The reaction was 
cooled to room temperature, the precipitate was filtered off and the residue taken up in 
deionised water (10 mL). The aqueous solution was extracted with diethyl ether (2x 20 
mL) which was discarded. The aqueous phase was retained, acidified with HCl (1 M) to 
pH 2-3, and extracted with ethyl acetate (2x 20 mL, 1x 10 mL). The combined organic 
phases were dried over anhydrous magnesium sulphate, filtered, and the solvent 
removed to afford 118 as a white powder, yield 0.04 g, 77%. The product contained 
both the starting ester as well as some of the acid. No purification was carried out as the 









4.5.2 Route b 
4.5.2.1 Synthesis of 9-nitro-9,10-dihydro-9,10-[3,4]furanoanthracene-12,14-dione 










Maleic anhydride (0.46 g, 4.71 mmol) was added to a stirred solution of 9-
nitroanthracene (1.03 g, 4.61 mmol) in xylene (25 mL) and the mixture heated under 
reflux at 140-143 °C until all the diene disappeared as indicated by TLC (DCM). The 
reaction mixture was cooled to room temperature before placing on ice with stirring. A 
precipitate separated out upon cooling, which was filtered, washed with ice-cold xylene 
to give the desired Diels-Alder cycloadduct 119 as a pale yellow powder which was 
used in the next step without further purification. Rf 0.78 (Et2O). Yield 0.97 g, 65%. 
M.p. 239-240 °C (lit. 244-245 °C, [370]). 1H-NMR (400 MHz, DMSO-d6) δ (ppm) 
7.65 - 7.69 (1 H, m, Ar-H), 7.50 - 7.58 (2 H, m, Ar-H), 7.37 - 7.44 (3 H, m, Ar-H), 7.32 
- 7.37 (1 H, m, Ar-H), 7.05 (1 H, dd, J = 7.5, 0.5 Hz, Ar-H), 5.11 (1 H, d, J = 3.0 Hz, 
CH dihydroanthracene), 4.66 (1 H, d, J = 9.3 Hz, CH succinimide), 3.94 (1 H, dd, J = 
9.3, 3.2 Hz, CH succinimide). 13C-NMR (100 MHz, DMSO-d6) δ (ppm) 170.32 (C=O 




carboxyl), 168.99 (C=O carboxyl), 139.47 (Ar-C), 137.17 (Ar-C), 136.93 (Ar-C), 
134.15 (Ar-C), 129.49 (Ar-C), 129.44 (Ar-C), 128.40 (Ar-C), 128.17 (Ar-C), 126.11 
(Ar-C), 125.60 (Ar-C), 123.37 (Ar-C), 120.81 (Ar-C), 93.24 (CNO2), 51.14 (CH 
dihydroanthracene), 49.25 (CH succinimide), 44.79 (CH succinimide). IR vmax/cm-1: 
2988, 2969 (C-H stretch), 1781 (C=O stretch), 1556 (NO2 asymmetric), 1361 (NO2 
symmetric). LC-MS (ESI) found m/z [M – H + MeOH]-: 352, C18H11NO5 requires 321. 
4.5.2.1.1 Synthesis of 3-(9-nitro-12,14-dioxo-9,10-dihydro-9,10-
[3,4]epipyrroloanthracen-13-yl)benzoic acid, [R = CO2H, Rʹ=H] (24) and analogues. 





Compound R R' Compound R R' 
24 CO2H H 24j H CO2H 
24a CO2Et H 24k H CO2Et 
24b F H 24l H F 
24c Cl H 24m H Cl 
24d NO2 H 24n H NO2 
24e H H 24o† H CH3 
24f† CH3 H 24p† H MeO 
24g† MeO H 24q† H Me2N 
24h† Me2N H 24r H I 
24i† CN H 24s H t-Bu 
†Compounds synthesised by Kulikowska [372] and Grewal [373] as part of their final year project for the 
degree of Master of Pharmacy, University of Hertfordshire. 




General procedure for the synthesis of 24-24s 
The corresponding 3- or 4-substituted aniline (1.2-1.7 eq) was added to a stirred 
solution of the maleic anhydride-9-nitroanthracene cycloadduct (119, 1eq) in glacial 
acetic acid (10 mL). The reaction mixture was heated under reflux at 120 °C for 2-3 h 
then cooled to room temperature. In some reactions, a precipitate formed upon cooling 
to room temperature (24, 24b, 24d, 24f, 24j, 24m, 24n, 24r) while none was present for 
others (24a, 24c, 24e, 24g, 24h, 24i, 24k, 24l, 24o, 24p, 24q, 24s). De-ionised water 
was added to quench all the reactions resulting in the formation of a precipitate in all 
cases. The precipitates were washed with ice-cold de-ionised water and dried under 
suction to yield the desired products. Yields shown are from the final Diels-Alder step, 
not from overall synthesis. Where known, reference melting points are shown next to 
that determined for the respective compound.  
Synthesis of 3-(9-nitro-12,14-dioxo-9,10-dihydro-9,10-[3,4]epipyrroloanthracen-13-
yl)benzoic acid (24) [R = CO2H, Rʹ = H].  
Compound 119 (0.07 g, 0.22 mmol, 1 eq) was combined with the 3-
aminobenzoic acid (0.20 g, 1.5 mmol, 6.7 eq) in 10 mL glacial acetic acid according to 
the procedure above. Recrystallisation in glacial acetic acid afforded 24 as white 
crystals, yield 1.07g, 96%. M.p. 272-273 °C. 1H NMR (600 MHz, acetone-d6)  (ppm) 
7.92 - 7.99 (1 H, m, Ar-H), 7.67 - 7.76 (2 H, m, Ar-H), 7.32 - 7.51 (6 H, m, Ar-H), 7.25 
(1 H, m, Ar-H), 7.08 (1 H, m, Ar-H), 6.68 - 6.85 (1 H, m, Ar-H), 5.05 (1 H, d, J = 2.7 




Hz, CH dihydroanthracene), 4.60 (1 H, d, J = 8.9 Hz, CH succinimide), 3.74 (1 H, dd, J 
= 8.9, 3.4 Hz, CH succinimide). 13C-NMR (150 MHz, acetone-d6)  (ppm) 174.05 
(C=O), 172.93 (C=O), 166.63 (C=O acid), 139.79 (Ar-C), 137.60 (Ar-C), 137.45 (Ar-
C), 134.37 (Ar-C), 132.20 (Ar-C), 131.61 (Ar-C), 130.99 (Ar-C), 129.68 (Ar-C), 129.13 
(Ar-C), 128.78 (Ar-C), 128.48 (Ar-C), 127.97 (Ar-C), 127.52 (Ar-C), 127.47 (Ar-C), 
125.47 (Ar-C), 124.71 (Ar-C), 123.79 (Ar-C), 120.55 (Ar-C), 93.69 (CNO2), 49.41 (CH 
dihydroanthracene), 47.91 (CH succinimide), 45.78 (CH succinimide). IR vmax/cm-1: 
3535 (OH stretch), 1783, 1706 (C=O stretch), 1552 (NO2 asymmetric), 1398 (NO2 
symmetric), 1202 (CO stretch). LC-MS (ESI) found m/z [M – H]-: 439, C25H16NO6 
requires 440.  
Synthesis of ethyl 3-(9-nitro-12,14-dioxo-9,10-dihydro-9,10-
[3,4]epipyrroloanthracen-13-yl)benzoate (24a) [R = CO2Et, Rʹ = H].  
Compound 119 (0.05 g, 0.22 mmol, 1 eq), ethyl 3-aminobenzoate (0.03 g, 0.18 
mmol, 1.2 eq) in 10 mL glacial acetic acid according to the procedure described above. 
Recrystallisation in glacial acetic acid afforded 24a as white flakes, yield 0.06 g, 85%. 
M.p. 202-203 °C.1H-NMR (400 MHz, acetone-d6) δ (ppm) 7.94 - 7.96 (1 H, m, Ar-H), 
7.68 - 7.75 (2 H, m , Ar-H), 7.35 - 7.52 (6 H, m, Ar-H), 7.16 - 7.17 (1 H, m, Ar-H), 7.08 
- 7.11 (1 H, m, Ar-H), 6.79 - 6.81 (1 H, m, Ar-H), 5.07 (1 H, d, J = 3.4 Hz, CH 
dihydroanthracene), 4.62 (1 H, d, J = 8.8 Hz, CH succinimide), 4.33 (2 H, q, J = 7.1 Hz, 
CH2 aliphatic), 3.75 - 3.77 (1 H, dd, J = 8.8, 3.1 Hz, CH succinimide), 1.40 (3 H, t, J = 
7.1 Hz, CH3). 13C-NMR (150 MHz, acetone-d6) δ (ppm) 174.06 (C=O), 172.93 (C=O), 




164.76 (C=O ester), 139.76 (Ar-C), 137.58 (Ar-C), 137.48 (Ar-C), 134.39 (Ar-C), 
132.23 (Ar-C), 131.52 (Ar-C), 131.16 (Ar-C), 129.46 (Ar-C), 129.22 (Ar-C), 128.79 
(Ar-C), 128.49 (Ar-C), 127.70 (Ar-C), 127.53 (Ar-C), 127.47 (Ar-C), 125.48 (Ar-C), 
124.72 (Ar-C), 123.81 (Ar-C), 120.55 (Ar-C), 93.69 (CNO2), 61.02 (CH2 aliphatic), 
49.44 (CH dihydroanthracene), 47.94 (CH succinimide), 45.78 (CH succinimide), 13.72 
(CH3). IR vmax/cm-1: 2984, 2903 (CH stretch), 1782 (C=O stretch), 1710 (C=O stretch), 
1551 (NO2 asymmetric), 1363 (NO2 symmetric), 1209 (CO stretch). LC-MS (ESI) found 
m/z [M + H]+: 469, C27H20NO6 requires 468.  
Synthesis of 13-(3-fluorophenyl)-9-nitro-9,10-dihydro-9,10-
[3,4]epipyrroloanthracene-12,14-dione (24b) [R = F, Rʹ = H].  
Compound 119 (0.07 g, 0.23 mmol, 1 eq), 3-fluoroaniline (0.03 g, 0.27 mmol, 
1.2 eq) in 10 mL glacial acetic acid according to the procedure described above. 
Recrystallisation in glacial acetic acid afforded 24b as a cream solid, yield 0.08 g, 81%. 
M.p. 241-243 oC. 1H-NMR (400 MHz, DCM-d2)  (ppm) 7.74 (1 H, d, J = 6.8 Hz, Ar-
H), 7.54 (1 H, d, J = 7.0 Hz, Ar-H), 7.01 - 7.46 (8 H, m, Ar-H), 6.35 (1 H, d, J = 7.7 Hz, 
Ar-H), 6.12 - 6.31 (1 H, m, Ar-H), 4.93 (1 H, d, J = 3.1 Hz, CH dihydroanthracene), 
4.45 (1 H, d, J = 9.0 Hz, CH succinimide), 3.56 (1 H, dd, J = 9.0, 3.1 Hz, CH 
succinimide). 13C-NMR (100 MHz, DCM-d2)  (ppm) 173.73 (C=O), 172.37 (C=O), 
163.65 (Ar-CF), 138.96 (Ar-C),  137.13 (Ar-C), 136.49 (Ar-C), 133.93 (Ar-C), 130.34 
(Ar-C), 128.88 (Ar-C), 128.66 (Ar-C), 127.80 (Ar-C), 127.68 (Ar-C), 125.36 (Ar-C), 
124.36 (Ar-C), 123.90 (Ar-C), 122.24 (Ar-C), 120.91 (Ar-C), 116.18 (Ar-C),  115.97 




(Ar-C), 113.79 (Ar-C), 93.42 (CNO2), 49.03 (CH dihydroanthracene), 47.77 (CH 
succinimide), 45.99 (CH succinimide). IR vmax/cm-1: 3075, 3040, 3015, 2973, 2890 (CH 
stretch), 1706 (C=O stretch), 1551 (NO2 asymmetric), 1383 (NO2 symmetric). LC-MS 
(ESI) found m/z [M + H]+: 415, C24H15FNO4 requires 414.  
Synthesis of 13-(3-chlorophenyl)-9-nitro-9,10-dihydro-9,10-
[3,4]epipyrroloanthracene-12,14-dione (24c) [R = Cl, Rʹ = H].  
Compound 119 (0.08 g, 0.23 mmol, 1 eq) was combined with 3-chloroaniline 
(0.04 g, 0.28 mmol, 1.2 eq) in 10 mL glacial acetic acid according to the procedure 
described above. Recrystallisation in glacial acetic acid afforded 24c as a cream solid, 
yield 0.08 g, 82%. M.p. 230-232 oC. 1H-NMR (400 MHz, DMSO-d6)  (ppm) 7.71 (1 
H, d, J = 7.2 Hz, Ar-H), 7.61 - 7.66 (1 H, m, Ar-H), 7.31 - 7.51 (7 H, m, Ar-H), 7.06 (1 
H, d, J = 7.1 Hz, Ar-H), 6.40 - 6.52 (2 H, m, Ar-H), 5.07 (1 H, d, J = 3.0 Hz, CH 
dihydroanthracene), 4.49 (1 H, d, J = 8.8 Hz, CH succinimide), 3.69 (1 H, dd, J = 8.7, 
3.2 Hz, CH succinimide). 13C-NMR (100 MHz, DMSO-d6)  (ppm) 174.63 (C=O), 
173.44 (C=O), 134.30 (Ar-C), 133.04 (Ar-C), 131.38 (Ar-C), 1245 (Ar-C), 125.51 (Ar-
C), 129.29 (Ar-C), 128.99 (Ar-C), 128.03 (Ar-C), 127.95 (Ar-C), 126.84 (Ar-C), 125.96 
(Ar-C), 125.83 (Ar-C), 125.67 (Ar-C), 125.47 (Ar-C), 123.80 (Ar-C), 122.72 (Ar-C), 
120.75 (Ar-C), 120.65 (Ar-C), 93.74 (CNO2), 49.63 (CH dihydroanthracene), 48.01 (CH 
succinimide), 45.29 (CH succinimide). IR vmax/cm-1: 3115, 2981, 2966 (CH stretch), 
1717 (C=O stretch), 1547 (NO2 asymmetric), 1383 (NO2 symmetric). LC-MS (ESI) 
found m/z [M + H]+: 431, C24H15ClNO4 requires 430.   





[3,4]epipyrroloanthracene-12,14-dione (24d) [R = NO2, Rʹ = H].  
Compound 119 (0.06 g, 0.20 mmol, 1 eq) was combined with 3-nitroaniline 
(0.04 g, 0.30 mmol, 1.5 eq) in 10 mL glacial acetic acid according to the procedure 
described above. Recrystallisation in glacial acetic acid afforded 24d as a pale yellow 
powder, yield 0.08 g, 93%. M.p. 240-242 oC.1H-NMR (400 MHz, DCM-d2)  (ppm) 
8.15 (1 H, m, Ar-H), 7.68 - 7.78 (1 H, m, Ar-H), 7.47 - 7.59 (2 H, m, Ar-H), 7.26 - 7.46 
(6 H, m, Ar-H), 7.06 - 7.16 (1 H, m, Ar-H), 6.94 - 6.98 (1 H, m, Ar-H), 4.95 (1 H, d, J = 
3.0 Hz, CH dihydroanthracene), 4.50 (1 H, dd, J = 8.9, 1.3 Hz, CH succinimide), 3.61 - 
3.63 (1 H, m, CH succinimide). 13C-NMR (150 MHz, DCM-d2)  (ppm) 173.55 
(C=O), 172.23 (C=O), 148.41 (Ar-CNO2), 138.77 (Ar-C), 136.96 (Ar-C), 136.39 (Ar-
C), 133.86 (Ar-C), 132.37 (Ar-C), 132.01 (Ar-C), 130.10 (Ar-C), 128.96 (Ar-C), 128.80 
(Ar-C), 127.93 (Ar-C), 127.76 (Ar-C), 125.41 (Ar-C), 124.40 (Ar-C), 123.93 (Ar-C), 
123.72 (Ar-C), 121.67 (Ar-C), 120.95 (Ar-C), 93.42 (CNO2), 49.13 (CH 
dihydroanthracene), 47.88 (CH succinimide), 46.04 (CH succinimide). IR vmax/cm-1: 
3094, 3080, 3049, 2976, 2971, 2959, 2887, (CH stretch), 1775, 1709 (C=O stretch), 
1548, 1529 (NO2 asymmetric), 1386, 1341 (NO2 symmetric).  LC-MS (ESI) found m/z 
[M + H]+: 442, C24H15N3O6 requires 441.   
 





dione (24e) [R = H, Rʹ = H].  
Compound 119 (0.11 g, 0.33 mmol, 1 eq) was combined with aniline (0.04 g, 
0.39 mmol, 1.2 eq) in 10 mL glacial acetic acid according to the procedure described 
above. Recrystallisation in glacial acetic acid afforded 24e as cream-coloured flakes, 
yield 0.09 g, 72%. M.p. 111-112 °C. 1H-NMR (400 MHz, DMSO-d6) δ (ppm) 7.71 (1 
H, d, J = 7.3 Hz, Ar-H), 7.62 - 7.67 (1 H, m, Ar-H), 7.30 - 7.50 (8 H, m, Ar-H), 7.05 (1 
H, d, J = 7.6 Hz, Ar-H), 6.42 - 6.47 (2 H, m, Ar-H), 5.07 (1 H, d, J = 2.6 Hz, CH 
dihydroanthracene), 4.50 (1 H, dd, J = 8.8, 1.5 Hz, CH succinimide), 3.66 - 3.68 (1 H, 
m, CH succinimide). 13C-NMR (100 MHz, DMSO-d6) δ (ppm) 174.96 (C=O), 173.75 
(C=O), 139.98 (Ar-C), 137.67 (Ar-C), 137.67 (Ar-C), 134.27 (Ar-C), 131.84 (Ar-C), 
129.58 (2 para-Ar-C), 129.38 (Ar-C), 129.27 (Ar-C), 128.98 (Ar-C), 127.99 (Ar-C), 
127.92 (Ar-C), 126.99 (2 para-Ar-C), 125.94 (Ar-C), 125.42 (Ar-C), 123.79 (Ar-C), 
120.73 (Ar-C), 93.76 (CNO2), 49.54 (CH dihydroanthracene), 47.95 (CH succinimide), 
45.28 (CH succinimide). IR vmax/cm-1: 3070, 2972, 2903 (CH stretch), 1783, 1713 
(C=O stretch), 1597, 1550 (NO2 asymmetric), 1387 (NO2 symmetric). LC-MS (ESI) 
found m/z [M + H]+: 397, C24H16N2O4 requires 396. 
Synthesis of 9-nitro-13-(m-tolyl)-9,10-dihydro-9,10-[3,4]epipyrroloanthracene-
12,14-dione (24f) [R = CH3, Rʹ = H].  
Compound 119 (0.50 g, 1.56 mmol, 1 eq), m-toluidine (0.17 g, 1.59 mmol, 1 eq) 
in 20 mL glacial acetic acid according to the procedure described above. 




Recrystallisation in glacial acetic acid afforded 24f as a cream solid, yield 0.58 g 91%. 
M.p. 209-211 °C. 1H-NMR (400 MHz, DMSO-d6)  (ppm) 7.68 - 7.73 (1 H, m, Ar-H), 
7.62 - 7.67 (1 H, m, Ar-H), 7.46 - 7.50 (1 H, m, Ar-H), 7.39 - 7.45 (3 H, m, Ar-H), 7.33 
- 7.39 (1 H, m, Ar-H), 7.22 (1 H, m, Ar-H), 7.15 (1 H, m, Ar-H), 7.05 (1 H, m, Ar-H), 
6.23 (1 H, m, Ar-H), 6.19 (1 H, s, Ar-H), 5.06 (1 H, d, J = 3.0 Hz, CH 
dihydroanthracene), 4.48 (1 H, d, J = 8.7 Hz, CH succinimide), 3.65 (1 H, dd, J = 8.8, 
3.1 Hz, CH succinimide), 2.21 (3 H, s, CH3). 13C-NMR (100 MHz, DMSO-d6)  (ppm) 
175.00 (C=O), 173.80 (C=O), 139.97 (Ar-C), 139.09 (Ar-C), 137.70 (Ar-C), 137.54 
(Ar-C), 134.29 (Ar-C), 131.82 (Ar-C), 129.99 (Ar-C), 129.37 (Ar-C), 129.26 (Ar-C), 
128.95 (Ar-C), 127.99 (Ar-C), 127.91 (Ar-C), 127.48 (Ar-C), 125.97 (Ar-C), 125.41 
(Ar-C), 124.09 (Ar-C), 123.82 (Ar-C), 120.73 (Ar-C), 93.76 (CNO2), 49.53 (CH 
dihydroanthracene), 47.96 (CH succinimide), 45.28 (CH succinimide), 21.23 (CH3). IR 
vmax/cm-1: 3079, 3039, 2982, 2921 (CH stretch), 1787 (C=O), 1716 (C=O), 1549 (NO2 
asymmetric), 1382 (NO2 symmetric). LC-MS (ESI) found m/z [M – H]-: 409, 
C25H18N2O4 requires 410.   
Synthesis of 13-(3-methoxyphenyl)-9-nitro-9,10-dihydro-9,10-
[3,4]epipyrroloanthracene-12,14-dione (24g) [R = MeO, Rʹ = H].  
Compound 119 (0.52 g, 1.62 mmol, 1 eq) was combined with 3-methoxyaniline 
(0.24 g, 1.95 mmol, 1.2 eq) in 20 mL glacial acetic acid according to the procedure 
described above. Recrystallisation in glacial acetic acid afforded 24g as a brown 
granules, yield 0.50 g, 72%. M.p. 262-265 °C. 1H-NMR (600 MHz, DMSO-d6)  




(ppm) 7.65 - 7.68 (1 H, m, Ar-H), 7.59 - 7.62 (1 H, m, Ar-H), 7.43 - 7.46 (1 H, m, Ar-
H), 7.36 - 7.41 (3 H, m, Ar-H), 7.32 (1 H, m, Ar-H), 7.22 (1 H, t, J = 8.2 Hz, Ar-H), 
7.00 - 7.03 (1 H, m, Ar-H), 6.88 (1 H, dd, J = 8.4, 2.6 Hz, Ar-H), 6.04 (1 H, m, Ar-H), 
5.80 (1 H, t, J = 2.2 Hz, Ar-H), 5.02 (1 H, d, J = 3.1 Hz, CH dihydroanthracene), 4.44 (1 
H, d, J = 8.8 Hz, CH succinimide), 3.61 - 3.63 (3 H, m, CH3), 3.60 - 3.61 (1 H, m, CH 
succinimide). 13C-NMR (150 MHz, DMSO-d6)  (ppm) 174.78 (C=O), 173.59 (C=O), 
159.94 (Ar-CO), 139.91 (Ar-C), 137.68 (Ar-C), 137.49 (Ar-C), 134.28 (Ar-C), 132.87 
(Ar-C), 130.38 (Ar-C), 129.22 (Ar-C), 128.91 (Ar-C), 127.95 (Ar-C), 127.86 (Ar-C), 
125.92 (Ar-C), 125.38 (Ar-C), 123.80 (Ar-C), 120.25 (Ar-C), 119.22 (Ar-C), 115.06 
(Ar-C), 112.66 (Ar-C), 93.74 (CNO2), 55.87 (CH3), 49.51 (CH dihydroanthracene), 
47.93 (CH succinimide), 45.28 (CH succinimide). IR vmax/cm-1: 3070, 2952, 2833 (CH 
stretch), 1783, 1716 (C=O), 1550 (NO2 asymmetric), 1386 (NO2 symmetric).  
Synthesis of 13-(3-(dimethylamino)phenyl)-9-nitro-9,10-dihydro-9,10-
[3,4]epipyrroloanthracene-12,14-dione (21h) [R = Me2N. Rʹ = H].  
Compound 119 (0.50 g, 1.56 mmol, 1 eq) combined with N, N-dimethyl-m-
phenylenediamine (0.39 g, 1.86 mmol, 1.2 eq) in 20 mL glacial acetic acid according to 
the procedure described above. Recrystallisation in glacial acetic acid afforded 24h as a 
cream solid, yield 0.66 g, 97%. M.p. 213-215 °C. 1H-NMR (400 MHz, DMSO-d6)  
(ppm) 7.70 (1 H, m, Ar-H), 7.63 - 7.67 (1 H, m, Ar-H), 7.46 - 7.50 (1 H, m, Ar-H), 7.38 
- 7.44 (3 H, m, Ar-H), 7.32 - 7.38 (1 H, m, Ar-H), 7.11 (1 H, m, Ar-H), 7.03 - 7.07 (1 H, 
m, Ar-H), 6.65 (1 H, m, Ar-H), 5.79 (1 H, m, Ar-H), 5.43 (1 H, t, J = 2.2 Hz, Ar-H), 




5.05 (1 H, d, J = 3.1 Hz, CH dihydroanthracene), 4.47 (1 H, d, J = 8.8 Hz, CH 
succinimide), 3.62 (1 H, dd, J = 8.8, 3.1 Hz, CH succinimide), 2.78 (6 H, s, 2 CH3). 13C-
NMR (100 MHz, DMSO-d6)  (ppm) 175.02 (C=O), 173.81 (C=O), 151.25 (Ar-CN), 
140.00 (Ar-C), 137.75 (Ar-C), 137.59 (Ar-C), 134.33 (Ar-C), 132.78 (Ar-C), 129.83 
(Ar-C), 129.24 (Ar-C), 128.88 (Ar-C), 127.98 (Ar-C), 127.85 (Ar-C), 125.96 (Ar-C), 
125.39 (Ar-C), 123.85 (Ar-C), 120.71 (Ar-C), 114.45 (Ar-C), 113.07 (Ar-C), 110.63 
(Ar-C), 93.79 (CNO2), 49.49 (CH dihydroanthracene), 47.93 (CH succinimide), 45.31 
(CH succinimide), C in CH3 overlapped with solvent peaks. IR vmax/cm-1: 3075, 2911, 
2822 (CH stretch), 2358 (CN), 1788, 1717 (C=O), 1548 (NO2 asymmetric), 1389, 1354 
(NO2 symmetric). LC-MS (ESI) found m/z [M – H]-: 438, C26H21N3O4 requires 439.   
Synthesis of 3-(9-nitro-12,14-dioxo-9,10-dihydro-9,10-[3,4]epipyrroloanthracen-13-
yl)benzonitrile (24i) [R = CN, Rʹ = H].  
Compound 119 (0.50 g, 1.56 mmol, 1 eq) was combined with 3-
aminobenzonitrile (0.22 g, 1.86 mmol, 1.2 eq) in 20 mL glacial acetic acid according to 
the procedure described above. Recrystallisation in glacial acetic acid afforded 24i as a 
cream solid, yield 0.64 g, 98%. M.p. 310-3.11 °C. 1H-NMR (600 MHz, DMSO-d6)  
(ppm) 7.82 (1 H, m, Ar-H), 7.68 (1 H, dd, J = 7.5, 1.0 Hz, Ar-H), 7.55 - 7.62 (2 H, m, 
Ar-H), 7.44 - 7.48 (1 H, m, Ar-H), 7.36 - 7.41 (3 H, m, Ar-H), 7.33 (1 H, m, Ar-H), 7.02 
(1 H, M, Hz, Ar-H), 6.86 - 6.88 (1 H, m, Ar-H), 6.75 (1 H, m, Ar-H), 5.05 (1 H, d, J = 
3.1 Hz, CH dihydroanthracene), 4.48 (1 H, d, J = 8.768 Hz, CH succinimide), 3.69 (1 H, 
dd, J = 8.8, 3.1 Hz, CH succinimide). 13C-NMR (150 MHz, DMSO-d6)  (ppm) 




174.50 (C=O), 173.31 (C=O), 139.76 (Ar-C), 137.59 (Ar-C), 137.33 (Ar-C), 134.22 
(Ar-C), 133.28 (Ar-C), 132.44 (Ar-C), 131.82 (Ar-C), 131.26 (Ar-C), 130.15 (Ar-C), 
129.28 (Ar-C), 129.01 (Ar-C), 128.02 (Ar-C), 127.94 (Ar-C), 125.95 (Ar-C), 125.44 
(Ar-C), 123.77 (Ar-C), 120.74 (Ar-C), 118.02 (CN), 112.56 (Ar-C), 93.71 (CNO2), 
49.63 (CH dihydroanthracene), 47.99 (CH succinimide), 45.27 (CH succinimide). IR 
vmax/cm-1: 3101, 3064, 2995, 2924 (CH stretch), 2231 (CN stretch), 1788, 1716 (C=O), 
1547 (NO2 asymmetric), 1387 (NO2 symmetric). LC-MS (ESI) found m/z [M + H]
+: 
420, C25H15N3O4 requires 421.   
Synthesis of 4-(9-nitro-12,14-dioxo-9,10-dihydro-9,10-[3,4]epipyrroloanthracen-13-
yl)benzoic acid (24j) [R = H, Rʹ = CO2H].  
Compound 119 (0.05 g, 0.16 mmol, 1 eq) was combined with 4-aminobenzoic 
acid (0.03 g, 0.16 mmol, 1 eq) in 10 mL glacial acetic acid according to the procedure 
described above. Recrystallisation in glacial acetic acid afforded 24j as cream-coloured 
flakes, yield 0.06 g 80%. M.p. 343-345 °C.1H-NMR (400 MHz, acetone-d6) δ (ppm) 
7.97 (2 H, d, J = 8.9 Hz, para-Ar-H), 7.69 - 7.78 (2 H, m, Ar-H), 7.47 - 7.51 (1 H, m, 
Ar-H), 7.35 - 7.45 (4 H, m, Ar-H), 7.08 - 7.12 (1 H, m, Ar-H), 6.73 (2 H, d, J = 8.8 Hz, 
para-Ar-H), 5.05 - 5.08 (1 H, m, CH dihydroanthracene), 4.62 (1 H, d, J = 8.9 Hz, CH 
succinimide), 3.76 (1 H, dd, J = 8.9, 3.1 Hz, CH succinimide). 13C-NMR (150 MHz, 
acetone-d6) δ (ppm) 173.91 (C=O), 172.76 (C=O), 165.94 (C=O ester), 139.77 (Ar-C), 
137.58 (Ar-C), 137.41 (Ar-C), 135.70 (Ar-C), 134.33 (Ar-C), 130.86 (2 para-Ar-C), 
130.08 (Ar-C), 128.80 (Ar-C), 128.52 (Ar-C), 127.53 (Ar-C), 127.49 (Ar-C), 126.57 (2 




para-Ar-C), 125.47 (Ar-C), 124.71 (Ar-C), 123.77 (Ar-C), 120.54 (Ar-C), 93.69 
(CNO2), 49.39 (CH dihydroanthracene), 47.89 (CH succinimide), 45.77 (CH 
succinimide). IR vmax/cm-1: 3284 (OH stretch), 3076, 2970, 2903 (CH stretch), 1781, 
1702 (C=O stretch), 1550 (NO2 asymmetric), 1389 (NO2 symmetric). LC-MS (ESI) 
found m/z [M – H]-: 439, C25H16N2O6 requires 440.   
Synthesis of ethyl 4-(9-nitro-12,14-dioxo-9,10-dihydro-9,10-
[3,4]epipyrroloanthracen-13-yl)benzoate (24k) [R = H, Rʹ = CO2Et].  
Compound 119 (0.05 g, 0.16 mmol, 1 eq) ethyl-4-aminobenzoate (0.03 g, 0.21 
mmol, 1.3 eq) in 10 mL glacial acetic acid according to the procedure described above. 
Recrystallisation in glacial acetic acid afforded 24k as white flakes, yield 0.06 g, 78%. 
M.p. 255-256 oC. 1H-NMR (400 MHz, acetone-d6)  (ppm) 7.92 - 7.97 (2 H, m, para-
Ar-H), 7.68 - 7.77 (2 H, m, Ar-H), 7.47 - 7.51 (1 H, m, Ar-H), 7.36 - 7.46 (4 H, m, Ar-
H), 7.10 (1 H, d, J = 6.1 Hz, Ar-H), 6.70 - 6.74 (2 H, m, para-Ar-H), 5.07 (1 H, d, J = 
3.1 Hz, CH dihydroanthracene), 4.62 (1 H, d, J = 8.9 Hz, CH succinimide), 4.32 (2 H, q, 
J = 7.1 Hz, CH2 aliphatic), 3.76 (1 H, dd, J = 8.8, 3.0 Hz, CH succinimide), 1.33 (3 H, t, 
J = 7.1 Hz, CH3). 13C-NMR (150 MHz, acetone-d6)  (ppm) 173.85 (C=O), 172.73 
(C=O), 164.98 (C=O ester), 139.76 (Ar-C), 137.57 (Ar-C), 137.41 (Ar-C), 134.34 (Ar-
C), 130.63 (Ar-C), 129.78 (2 para-Ar-C), 128.79 (Ar-C), 128.51 (Ar-C), 127.53 (Ar-C), 
127.48 (Ar-C), 126.61 (2 para-Ar-C), 125.46 (Ar-C), 124.71 (Ar-C), 123.77 (Ar-C), 
120.54 (Ar-C), 113.38 (Ar-C), 93.68 (CNO2), 60.91 (CH2 aliphatic), 49.39 (CH 
dihydroanthracene), 47.89 (CH succinimide), 45.78 (CH succinimide), 13.65 (CH3). IR 




vmax/cm-1: 2989 (CH stretch), 1785, 1710 (C=O stretch), 1550 (NO2 asymmetric), 1394 
(NO2 symmetric). LC-MS (ESI) found m/z [M + H]
+: 469, C27H20N2O6 requires 468.   
Synthesis of 13-(4-fluorophenyl)-9-nitro-9,10-dihydro-9,10-
[3,4]epipyrroloanthracene-12,14-dione (24l) [R = H, Rʹ = F].  
Compound 119 (0.10 g, 0.31 mmol, 1 eq) was combined with 4-fluoroaniline 
(0.04 g, 0.37 mmol, 1.2 eq) in 10 mL glacial acetic acid according to the procedure 
described above. Recrystallisation in glacial acetic acid afforded 24l as a cream solid, 
yield 0.11 g, 88%. M.p. 238-240 oC. 1H-NMR (600 MHz, acetone-d6)  (ppm) 7.66 - 
7.75 (2 H, m, para-Ar-H), 7.44 - 7.48 (1 H, m, Ar-H), 7.34 - 7.42 (4 H, m, Ar-H), 7.05 - 
7.10 (3 H, m, Ar-H), 6.54 - 6.59 (2 H, m, para-Ar-H), 5.02 (1 H, d, J = 2.7 Hz, CH 
dihydroanthracene), 4.56 (1 H, d, J = 8.9 Hz, CH succinimide), 3.70 (1 H, dd, J = 8.9, 
2.7 Hz, CH succinimide). 13C-NMR (150 MHz, acetone-d6)  (ppm) 174.10 (C=O), 
172.97 (C=O), 163.03 (Ar-CF), 139.80 (Ar-C), 137.61 (Ar-C), 137.48 (Ar-C), 134.40 
(Ar-C), 128.79 (Ar-C), 128.76 (Ar-C), 128.74 (Ar-C), 128.41 (2 para-Ar-C), 128.04 
(Ar-C), 127.51 (2 para-Ar-C), 127.41 (Ar-C), 125.45 (Ar-C), 124.69 (Ar-C), 123.79 
(Ar-C), 120.53 (Ar-C), 115.77 (Ar-C), 115.62 (Ar-C), 93.66 (CNO2), 49.29 (CH 
dihydroanthracene), 47.77 (CH succinimide), 45.75 (CH succinimide). IR vmax/cm-1: 
2981, 2970, 2893 (CH stretch), 1782, 1710 (C=O stretch), 1551 (NO2 asymmetric), 
1395 (NO2 symmetric). LC-MS (ESI) found m/z [M + H]
+: 415, C24H15FN2O4 requires 
441.    





[3,4]epipyrroloanthracene-12,14-dione (24m) [R = H, Rʹ = Cl].  
Compound 119 (0.07 g, 0.23 mmol, 1 eq) was combined with 4-chloroaniline 
(0.05 g, 0.37 mmol, 1.6 eq) in 10 mL glacial acetic acid according to the procedure 
described above. Recrystallisation in glacial acetic acid afforded 24m as a cream solid, 
yield 0.09 g, 90%. M.p. 270-273 oC. 1H-NMR (400 MHz, DCM-d2)  (ppm) 7.70 - 
7.75 (1 H, m, Ar-H), 7.52 - 7.56 (1 H, m, Ar-H), 7.26 - 7.42 (7 H, m, Ar-H), 7.08 - 7.13 
(1 H, m, Ar-H), 6.43 - 6.49 (2 H, m, para-Ar-H), 4.92 (1 H, d, J = 3.1 Hz, CH 
dihydroanthracene), 4.44 (1 H, d, J = 8.9 Hz, CH succinimide), 3.55 (1 H, dd, J = 8.9, 
3.1 Hz, CH succinimide). 13C-NMR (150 MHz, DCM-d2)  (ppm) 173.84 (C=O), 
172.47 (C=O), 138.96 (Ar-C), 137.14 (Ar-C), 136.49 (Ar-C), 134.80 (Ar-C), 133.92 
(Ar-C), 129.62 (Ar-C), 129.29 (2-para-Ar-C), 128.86 (Ar-C), 128.60 (Ar-C), 127.76 
(Ar-C), 127.68 (3 Ar-C), 125.34 (Ar-C), 124.34 (Ar-C), 123.89 (Ar-C), 120.90 (Ar-C), 
93.43 (CNO2), 49.02 (CH dihydroanthracene), 47.76 (CH succinimide), 45.99 (CH 
succinimide). IR vmax/cm-1: 2981, 2971, 2887 (CH stretch), 1781, 1709 (C=O stretch), 
1551 (NO2 asymmetric), 1389 (NO2 symmetric). LC-MS (ESI) found m/z [M + H]
+: 
431, C24H15ClN2O4 requires 430.    
Synthesis of 9-nitro-13-(4-nitrophenyl)-9,10-dihydro-9,10-
[3,4]epipyrroloanthracene-12,14-dione (24n) [R = H, Rʹ = NO2].  




Compound 119 (0.07 g, 0.21 mmol, 1 eq) was combined with 4-nitroaniline 
(0.04 g, 0.29 mmol, 1.4 eq) in 10 mL glacial acetic acid according to the procedure 
described above. Recrystallisation in glacial acetic acid afforded 24n as fluffy cream 
powder, yield 0.07 g, 78%. M.p. 316-318 oC. 1H-NMR (400 MHz, DCM-d2)  (ppm) 
8.12 - 8.16 (2 H, m, para-Ar-H), 7.72 - 7.76 (1 H, m, Ar-H), 7.53 - 7.56 (1 H, m, Ar-H), 
7.30 - 7.44 (5 H, m, Ar-H), 7.10 - 7.14 (1 H, m, Ar-H), 6.78 - 6.83 (2 H, m, para-Ar-H), 
4.94 (1 H, d, J = 3.1 Hz, CH dihydroanthracene), 4.49 (1 H, d, J = 9.0 Hz, CH 
succinimide), 3.60 (1 H, dd, J = 9.0, 3.1 Hz, CH succinimide). 13C-NMR (100 MHz, 
DCM-d2)  (ppm) 170.62 (C=O), 169.30 (C=O), 144.68 (Ar-C), 136.03 (Ar-C), 134.20 
(Ar-C), 133.66 (Ar-C), 133.60 (Ar-C), 131.07 (Ar-C), 126.19 (Ar-C), 125.97 (Ar-C), 
125.11 (Ar-C), 124.99 (Ar-C), 124.30 (2 para-Ar-C), 122.59 (Ar-C), 121.62 (Ar-C), 
121.54 (2 para-Ar-C), 121.11 (Ar-C), 118.17 (Ar-C), 90.62 (CNO2), 46.33 (CH 
dihydroanthracene), 45.06 (CH succinimide), 43.25 (CH succinimide). IR vmax/cm-1: 
3121, 3087, 2978, 2855 (CH stretch), 1781, 1712 (C=O stretch), 1551, 1521 (NO2 
asymmetric), 1344 (NO2 symmetric). LC-MS (ESI) found m/z [M + H]
+: 442, 
C24H15N3O6 requires 441.    
Synthesis of 9-nitro-13-(p-tolyl)-9,10-dihydro-9,10-[3,4]epipyrroloanthracene-
12,14-dione (24o), [R = H, Rʹ = CH3].  
Compound 119 (0.50 g, 1.56 mmol, 1 eq) was combined with p-toluidine (0.19 
g, 1.77 mmol, 1.1 eq) in 20 mL glacial acetic acid according to the procedure described 
above. Recrystallisation in glacial acetic acid afforded 24o as white powder, yield 0.48 




g. 75%. M.p. 258-262 oC. 1H-NMR (400 MHz, DMSO-d6)  (ppm) 7.70 (1 H, dd, J = 
7.3, 1.1 Hz, Ar-H), 7.60 - 7.66 (1 H, m, Ar-H), 7.45 - 7.49 (1 H, m, Ar-H), 7.38 - 7.44 (3 
H, m, Ar-H), 7.33 - 7.38 (1 H, m, Ar-H), 7.14 (2 H, m, J = 8.1 Hz, para-Ar-H), 7.1 (1 H, 
d, J = 7.4 Hz, Ar-H), 6.32 (2 H, m, J = 8.2 Hz, para-Ar-H), 5.06 (1 H, d, J = 3.0 Hz, CH 
dihydroanthracene), 4.47 (1 H, d, J = 8.7 Hz, CH succinimide), 3.64 (1 H, dd, J = 8.8, 
3.1 Hz, CH succinimide), 2.25 (3 H, s, CH3). 13C-NMR (100 MHz, DMSO-d6)  (ppm) 
175.02 (C=O), 173.81 (C=O), 140.00 (Ar-C), 138.99 (Ar-C), 137.67 (Ar-C), 137.56 
(Ar-C), 134.26 (Ar-C), 129.99 (2 para-Ar-C), 129.25 (Ar-C), 129.22 (Ar-C), 128.94 
(Ar-C), 127.98 (Ar-C), 127.88 (Ar-C), 126.69 (2 para-Ar-C), 125.92 (Ar-C), 125.41 
(Ar-C), 123.78 (Ar-C), 120.72 (Ar-C), 93.76 (CNO2), 49.47 (CH dihydroanthracene), 
47.89 (CH succinimide), 45.27 (CH succinimide), 21.21 (CH3). IR vmax/cm-1: 3486, 
3049, 2966, 2918 (CH stretch), 1784, 1719 (C=O stretch), 1553, 1514 (NO2 
asymmetric), 1391 (NO2 symmetric). LC-MS (ESI) found m/z [M – H]-: 409, 
C25H18N2O4 requires 410.    
Synthesis of 13-(4-methoxyphenyl)-9-nitro-9,10-dihydro-9,10-
[3,4]epipyrroloanthracene-12,14-dione (24p) [R = H, Rʹ = MeO].   
Compound 119 (0.50 g, 1.56 mmol, 1 eq) was combined with 4-methoxyaniline 
(0.23 g, 1.87 mmol, 1.2 eq) in 20 mL glacial acetic acid according to the procedure 
described above. Recrystallisation in glacial acetic acid afforded 24p as a grey-purple 
solid, yield 0.56 g, 84%. M.p. 249-250 oC. 1H-NMR (600 MHz, DMSO-d6)  (ppm) 
7.65 - 7.67 (1 H, m, Ar-H), 7.58 - 7.62 (1 H, m, Ar-H), 7.41 - 7.45 (1 H, m, Ar-H), 7.34 




- 7.39 (3 H, m, Ar-H), 7.32 (1 H, td, J = 7.7, 1.20 Hz, Ar-H), 7.01 (1 H, d, J = 7.7 Hz, 
Ar-H), 6.81 - 6.89 (2 H, m, para-Ar-H), 6.26 - 6.34 (2 H, m, para-Ar-H), 5.01 (1 H, d, J 
= 3.1 Hz, CH dihydroanthracene), 4.43 (1 H, d, J = 8.8 Hz, CH succinimide c), 3.68 (3 
H, s, CH3), 3.59 (1 H, dd, J = 8.8, 3.1 Hz, CH succinimide). 13C-NMR (150 MHz, 
DMSO-d6)  (ppm) 175.09 (C=O), 173.87 (C=O), 159.73 (Ar-CO), 139.97 (Ar-C), 
137.54 (Ar-C), 134.27 (Ar-C), 129.20 (Ar-C), 128.87 (Ar-C), 128.12 (2 para-Ar-CH), 
127.93 (Ar-C), 127.82 (Ar-C), 127.30 (Ar-C), 125.88 (Ar-C), 125.34 (Ar-C), 124.31 
(Ar-C), 123.75 (Ar-C), 120.68 (Ar-C), 114.76 (2 para-Ar-CH), 93.74 (CNO2), 55.88 
(CH3), 49.40 (CH dihydroanthracene), 47.81 (CH succinimide), 45.28 (CH 
succinimide). IR vmax/cm-1: 3367, 2960, 2909 (CH stretch), 1782, 1702 (C=O stretch), 
1549 (NO2 asymmetric), 1395 (NO2 symmetric). LC-MS (ESI) found m/z [M + H]
+: 
427, C25H18N2O5 requires 426.    
Synthesis of 13-(4-(dimethylamino)phenyl)-9-nitro-9,10-dihydro-9,10-
[3,4]epipyrroloanthracene-12,14-dione (21q) [R = H, Rʹ = Me2N].  
Compound 119 (0.50 g, 0.1.56 mmol, 1 eq) was combined with N,N-dimethyl-
1,4-diamine (0.25 g, 1.84 mmol, 1.2 eq) in 20 mL glacial acetic acid according to the 
procedure described above. Recrystallisation in glacial acetic acid afforded 24q as light-
grey solid, yield 0.50 g, 73%. M.p. 265-266 oC. 1H-NMR (600 MHz, DMSO-d6)  
(ppm) 7.66 (1 H, dd, J = 7.4, 1.0 Hz, Ar-H), 7.57 - 7.61 (1 H, m, Ar-H), 7.40 - 7.43 (1 
H, m, Ar-H), 7.3 - 7.39 (3 H, m, Ar-H), 7.31 (1 H, td, J = 7.6, 1.3 Hz, Ar-H), 7.00 (1 H, 
d, J = 7.6 Hz, Ar-H), 6.52 - 6.57 (2 H, m, para-Ar-H), 6.15 - 6.19 (2 H, m, para-Ar-H), 




4.99 (1 H, d, J = 3.1 Hz, CH dihydroanthracene), 4.40 (1 H, d, J = 8.8 Hz, CH 
succinimide), 3.55 (1 H, dd, J = 8.8, 3.1 Hz, CH succinimide), 2.81 (6 H, s, 2 CH3). 13C-
NMR (150 MHz, DMSO-d6)  (ppm) 175.32 (C=O), 174.10 (C=O), 150.76 (Ar-CO), 
140.04 (Ar-C), 137.68 (Ar-C), 137.60 (Ar-C), 134.28 (Ar-C), 129.17 (Ar-C), 128.82 
(Ar-C), 127.91 (Ar-C), 127.76 (Ar-C), 127.39 (2 para-Ar-CH), 125.86 (Ar-C), 125.30 
(Ar-C), 123.75 (Ar-C), 120.65 (Ar-C), 119.99 (Ar-C), 112.38 (2 para-Ar-CH), 93.76 
(CNO2), 49.28 (CH dihydroanthracene), 47.71 (CH succinimide), 45.28 (CH 
succinimide), 2 CH3 overlapped with solvent peaks. IR vmax/cm-1: 3074, 2980, 2890, 
2816 (CH stretch), 1703 (C=O stretch), 1545 (NO2 asymmetric), 1362 (NO2 symmetric). 
LC-MS (ESI) found m/z [M + H]+: 440, C26H21N3O4 requires 439.    
Synthesis of 13-(4-iodophenyl)-9-nitro-9,10-dihydro-9,10-
[3,4]epipyrroloanthracene-12,14-dione (24r) [R = H, Rʹ = I].  
Compound 119 (0.11 g, 0.35 mmol, 1 eq) was combined with 4-iodoaniline 
(0.12 g, 0.54 mmol, 1.6 eq) in 10 mL glacial acetic acid according to the procedure 
described above. Recrystallisation in glacial acetic acid afforded 24r as white crystalline 
solid, yield 0.15 g, 84%. M.p. 305-308 oC. 1H-NMR (400 MHz, DMSO-d6)  (ppm) 
7.66 - 7.77 (3 H, m, Ar-CH), 7.59 - 7.65 (1 H, m, Ar-CH), 7.30 - 7.49 (5 H, m, Ar-CH), 
7.05 (1 H, d, J = 7.5 Hz, Ar-CH), 6.23 - 6.32 (2 H, m, para-Ar-CH), 5.06 (1 H, d, J = 
2.6 Hz, CH dihydroanthracene), 4.48 (1 H, d, J = 8.8 Hz, CH succinimide), 3.66 (1 H, 
dd, J = 8.7, 2.6 Hz, CH succinimide). 13C-NMR (100 MHz, DMSO-d6)  (ppm) 
174.65 (C=O), 173.44 (C=O), 139.89 (Ar-C), 138.50 (2 para-Ar-C), 137.60 (Ar-C), 




137.47 (Ar-C), 134.20 (Ar-C), 131.46 (Ar-C), 128.99 (Ar-C), 129.28 (Ar-C), 128.91 (2 
para-Ar-C), 128.01 (Ar-C), 127.94 (Ar-C), 125.90 (Ar-C), 125.41 (Ar-C), 123.73 (Ar-
C), 120.73 (Ar-C), 95.62 (Ar-CI), 93.74 (CNO2), 49.59 (CH dihydroanthracene), 47.97 
(CH succinimide), 45.28 (CH succinimide). IR vmax/cm-1: 2968, 2901 (CH stretch), 
1778, 1706 (C=O stretch), 1550 (NO2 asymmetric), 1387 (NO2 symmetric). LC-MS 
(ESI) found m/z [M + H]+: 523, C24H15IN2O4 requires 522.   
Synthesis of 13-(4-(tert-butyl)phenyl)-9-nitro-9,10-dihydro-9,10-
[3,4]epipyrroloanthracene-12,14-dione (24s) [R = H, Rʹ = t-Bu].  
Compound 119 (0.10 g, 0.32 mmol, 1 eq) was combined with t-butylaniline 
(0.06 g, 0.38 mmol, 1.2 eq) in 15 mL glacial acetic acid according to the procedure 
described above. Recrystallisation in glacial acetic acid afforded 24s as a cream solid, 
yield 0.13 g, 89%. M.p. 238-240 oC. 1H-NMR (400 MHz, DCM-d2)  (ppm) 7.72 - 
7.75 (1 H, m, Ar-CH), 7.51 - 7.55 (1 H, m, Ar-CH), 7.28 - 7.43 (7 H, m, Ar-CH), 7.08 - 
7.12 (1 H, m, Ar-CH), 6.36 - 6.41 (2 H, m, para-Ar-CH), 4.92 (1 H, d, J = 3.1 Hz, CH 
dihydroanthracene), 4.43 (1 H, d, J = 9.0 Hz, CH succinimide), 3.53 (1 H, dd, J = 8.9, 
3.1 Hz, CH succinimide), 1.26 (9 H, s, 3 CH3). 13C-NMR (150 MHz, DCM-d2)  
(ppm) 174.33 (C=O), 172.92 (C=O), 152.38 (Ar-C-C), 139.09 (Ar-C), 137.23 (Ar-C), 
136.57 (Ar-C), 133.95 (Ar-C), 128.82 (Ar-C), 128.58 (Ar-C), 128.42 (Ar-C), 127.72 
(Ar-C), 127.61 (Ar-C), 126.18 (2 para-Ar-C), 125.90 (2 para-Ar-C), 125.37 (Ar-C), 
124.34 (Ar-C), 123.89 (Ar-C), 120.86 (Ar-C), 93.47 (CNO2), 48.98 (CH 
dihydroanthracene), 47.74 (CH succinimide), 45.97 (CH succinimide), 34.65 (t-Bu-C), 




30.92 (3 CH3). IR vmax/cm-1: 2981, 2902, 2875 (CH stretch), 1783, 1714 (C=O stretch), 
1547 (NO2 asymmetric), 1392 (NO2 symmetric). LC-MS (ESI) found m/z [M + H]
+: 
453, C28H24N2O4 requires 452.  





Maleic anhydride (1.00 g, 10 mmol) was added to a stirring solution to 
anthracene (1.82 g, 10.2 mmol) in xylene (25 mL) and the mixture was heated under 
reflux at 140-143 °C until all the diene disappeared as indicated by TLC. The reaction 
mixture was cooled to room temperature before placing on ice while stirring. The 
precipitate was filtered, washed with ice-cold xylene to give the desired Diels-Alder 
cycloadduct 120 as sand-coloured granules, yield 2.69, 95%.  The cycloadduct was used 
in the next step without further purification. Rf 0.87 (Et2O); M.p. 259-260 °C (lit. 261-
263 °C [404]; 265-266 °C [374], 253-256 °C [405]). 1H-NMR (400 MHz, acetone-d6) δ 
(ppm) 7.47 - 7.51 (2 H, m, Ar-CH), 7.33 - 7.38 (2 H, m, Ar-CH), 7.17 - 7.22 (4 H, m, 
Ar-CH), 4.89 - 4.92 (2 H, m, CH dihydroanthracene), 3.73 - 3.75 (2 H, m, CH 
succinimide). 13C-NMR (100 MHz, acetone-d6) δ (ppm) 171.22 (2 C=O), 141.51 (2 
Ar-C), 139.41 (2 Ar-C), 127.23 (2 Ar-C), 126.79 (2 Ar-C), 125.09 (2 Ar-C), 124.48 (2 




Ar-C), 48.24 (2 CH dihydroanthracene), 45.29 (2 CH succinimide). IR vmax/cm-1: 3077, 
3026, 2970 (C-H stretch), 1782 (C=O stretch). LC-MS (ESI) found m/z [M – H + 
MeOH]-: 307, C18H12O3 requires 276.  
4.5.2.2.1 Synthesis of 3-(12,14-dioxo-9,10-dihydro-9,10-[3,4]epipyrroloanthracen-







Compound R R' Compound R R' 
121 CO2H H 121j H CO2H 
121a CO2Et H 121k H CO2Et 
121b F H 121l H F 
121c Cl H 121m H Cl 
121d NO2 H 121n H NO2 
121e H H 121o† H CH3 
121f† CH3 H 121p† H MeO 
121g† MeO H 121q† H Me2N 
121h† Me2N H 121r H I 
121i† CN H 121s H t-Bu 
†Compounds synthesised by Kulikowska [372] and Grewal [373] as part of their final year project for the 
degree of Master of Pharmacy, University of Hertfordshire  
 
 




General procedure for the synthesis of 121-121s 
Maleic anhydride-anthracene cycloadduct (120, 1 eq), and the appropriate 3- or 
4-substituted aniline (1.2-1.5 eq) were stirred under reflux in glacial acetic acid (10 mL) 
between 1-5 h then cooled to room temperature. In some reactions, a precipitate formed 
upon cooling to room temperature (121, 121b, 121c, 121d, 121e, 121j, 121k, 121l, 
121m, 121n, 121r) while none was present for others (121a, 121f, 121g, 121h, 121i, 
121o, 121p, 121q, 121s). De-ionised water (25-40 mL) was added to the reaction 
mixture, which resulted in a precipitate forming. This was filtered, washed with ice-cold 
de-ionised water and dried. Recrystallisation was carried out in glacial acetic acid. 
Yields shown are from the final Diels-Alder step, not from overall synthesis. Although 
analogues 121, 121d, 121e, 121j, 121n, 121r, 121p, and 121q have been previously 
synthesised, their melting points were however not reported by the authors [365-368]. 
Synthesis of 3-(12,14-dioxo-9,10-dihydro-9,10-[3,4]epipyrroloanthracen-13-
yl)benzoic acid (121) [R = CO2H, Rʹ = H].  
Compound 120 (0.08 g, 0.29 mmol, 1 eq) was combined with 3-aminobenzoic 
acid (0.06 g, 0.41 mmol, 1.4 eq) in 10 mL glacial acetic acid according to the procedure 
described above. Compound 121 was obtained as a white solid, yield 0.11 g, 95%. M.p. 
285-288 oC. 1H-NMR (400 MHz, acetone-d6)  (ppm) 7.93 - 7.97 (1 H, m, Ar-H), 7.52 
(1 H, dd, J = 5.4, 3.3 Hz, Ar-H), 7.41 - 7.48 (1 H, m, Ar-H), 7.28 - 7.35 (4 H, m, Ar-H), 
7.21 (4 H, m, Ar-H), 6.73 - 6.79 (1 H, m, Ar-H), 4.88 - 4.91 (2 H, m, CH 
dihydroanthracene), 3.47 (2 H, m, CH succinimide ), 1.95 (1 H, s, OH). 13C-NMR (100 




MHz, acetone-d6)  (ppm) 175.60 (2 C=O), 165.77 (C=O acid), 141.99 (2 Ar-C), 
139.65 (2 Ar-C), 132.79 (Ar-C), 131.44 (Ar-C), 131.12 (Ar-C), 129.34 (Ar-C), 128.93 
(Ar-C), 128.10 (Ar-C), 126.84 (2 Ar-C), 126.60 (2 Ar-C), 125.00 (2 Ar-C), 124.37 (2 
Ar-C), 47.23 (2 CH dihydroanthracene), 45.82 (2 CH succinimide). IR vmax/cm-1: 3321 
(OH stretch), 1774, 1704 (C=O stretch). LC-MS (ESI) found m/z [M – H]-: 394, 
C25H17NO4 requires 395.  
Synthesis of ethyl 3-(12,14-dioxo-9,10-dihydro-9,10-[3,4]epipyrroloanthracen-13-
yl)benzoate (121a) [R = CO2Et, Rʹ = H].  
Compound 120 (0.11 g, 0.41 mmol, 1 eq) was combined with ethyl-3-
aminobenzoate (0.08 g, 0.51 mmol, 1.3 eq) in 15 mL glacial acetic acid according to the 
procedure described above. Compound 121a was obtained as a pale pink powder, yield 
0.17 g, 96%. M.p. 205-207 oC. 1H-NMR (400 MHz, acetone-d6)  ppm 7.89 - 7.96 (1 
H, m, Ar-H), 7.49 - 7.55 (2 H, m, Ar-H), 7.45 (1 H, t, J = 7.9 Hz, Ar-H), 7.30 - 7.37 (2 
H, m, Ar-H), 7.15 - 7.26 (5 H, m, Ar-H), 6.76 - 6.82 (1 H, m, Ar-H), 4.89 (2 H, m, CH 
dihydroanthracene), 4.33 (2 H, q, J = 7.1 Hz, CH2 aliphatic), 3.47 (2 H, dd, J = 2.1, 1.3 
Hz, CH succinimide), 1.36 (3 H, t, J = 7.1 Hz, CH3). 13C-NMR (150 MHz, acetone-d6) 
 (ppm) 175.63 (2 C=O), 164.90 (C=O ester), 132.81 (Ar-C), 131.39 (Ar-C), 132.81 
(Ar-C), 131.39 (Ar-C), 131.29 (Ar-C), 129.12 (Ar-C), 129.02 (2 Ar-C), 127.83 (2 Ar-
C), 126.84 (2 Ar-C), 126.61 (2 Ar-C), 125.01 (2 Ar-C), 124.37 (2 Ar-C), 60.94 (CH2 
aliphatic), 47.24 (2 CH dihydroanthracene), 45.81 (2 CH succinimide), 13.73 (CH3). IR 




vmax/cm-1: 3070, 3042, 2992 (CH stretch), 1775, 1718, 1703 (C=O stretch). LC-MS 
(ESI) found m/z [M + H]+: 424, C27H21NO4 requires 423.  
Synthesis of 13-(3-fluorophenyl)-9,10-dihydro-9,10-[3,4]epipyrroloanthracene-
12,14-dione (121b) [R = F, Rʹ = H].  
Compound 120 (0.10 g, 0.37 mmol, 1 eq) was combined with 3-fluoroaniline 
(0.05 g, 0.44 mmol, 1.2 eq) in 10 mL glacial acetic acid according to the procedure 
described above. Compound 121b was obtained as white flakes, yield 0.12 g, 87%. M.p. 
228-230 oC. 1H-NMR (400 MHz, DCM-d2)  (ppm) 7.41 - 7.45 (2 H, m, Ar-H), 7.17 - 
7.34 (7 H, m, Ar-H), 6.97 - 7.05 (1 H, m, Ar-H), 6.29 - 6.36 (1 H, m, Ar-H), 6.24 (1 H, 
m, Ar-H), 4.83 - 4.89 (2 H, m, CH dihydroanthracene), 3.35 - 3.41 (2 H, m, CH 
succinimide). 13C-NMR (100 MHz, DCM-d2)  (ppm) 175.60 (2 C=O), 163.67 (Ar-
CF), 141.40 (2 Ar-C), 139.01 (2 Ar-C), 133.8 (Ar-C), 130.19 (Ar-C), 127.18 (2 Ar-C), 
126.83 (2 Ar-C), 125.07 (2 Ar-C), 124.38 (2 Ar-C), 122.42 (Ar-C), 115.60 (Ar-C), 
114.15 (Ar-C), 47.13 (2 CH dihydroanthracene), 45.89 (2 CH succinimide). IR vmax/cm-
1: 3083, 3041, 3020, 2974 (CH stretch), 1774, 1702 (C=O stretch). LC-MS (ESI) found 
m/z [M + H]+: 370, C24H16FNO2 requires 369.  
Synthesis of 13-(3-chlorophenyl)-9,10-dihydro-9,10-[3,4]epipyrroloanthracene-
12,14-dione (121c)  [R = Cl, Rʹ = H].  




Compound 120 (0.09 g, 0.31 mmol, 1 eq) was combined with 3-chloroaniline 
(0.05 g, 0.37 mmol, 1.2 eq) in 10 mL glacial acetic acid according to the procedure 
described above. Compound 121c was obtained as a cream solid, yield 0.11 g, 92%. 
M.p. 238-240 oC. 1H-NMR (400 MHz, DMSO-d6)  (ppm) 7.49 - 7.54 (2 H, m, Ar-H), 
7.36 - 7.45 (2 H, m, Ar-H), 7.30 - 7.34 (2 H, m, Ar-H), 7.17 - 7.25 (4 H, m, Ar-H), 6.42 
- 6.49 (2 H, m, Ar-H), 4.87 (2 H, s, CH dihydroanthracene), 3.42 (2 H, m, CH 
succinimide). 13C-NMR (100 MHz, DMSO-d6)  (ppm) 176.24 (2 C=O), 142.05 (2 Ar-
C), 139.86 (2 Ar-C), 133.63 (Ar-C), 133.46 (Ar-C), 131.21 (Ar-C), 129.15 (Ar-C), 
127.22 (2 Ar-C), 126.98 (3 Ar-C), 125.95 (Ar-C), 125.38 (2 Ar-C), 124.98 (2 Ar-C), 
47.29 (2 CH dihydroanthracene), 45.44 (2 CH succinimide). IR vmax/cm-1: 3077 (CH 
stretch), 2960 (CH stretch), 1774, 1708 (C=O stretch). LC-MS (ESI) found m/z [M + 
H]+: 386, C24H16ClNO2 requires 385.  
Synthesis of 13-(3-nitrophenyl)-9,10-dihydro-9,10-[3,4]epipyrroloanthracene-12,14-
dione (121d) [R = NO2, Rʹ = H].  
Compound 120 (0.10 g, 0.38 mmol, 1 eq) was combined with 3-nitroaniline 
(0.08 g, 0.57 mmol, 1.5 eq) in 10 mL glacial acetic acid according to the procedure 
described above. Compound 121d was obtained as a white solid, yield 0.14 g, 95%. Mp 
282-285 oC. 1H-NMR (400 MHz, DCM-d2)  (ppm) 8.11 - 8.15 (1 H, m, Ar-CH), 7.42 
- 7.52 (3 H, m, Ar-H), 7.31 - 7.38 (3 H, m, Ar-H), 7.19 - 7.27 (4 H, m, Ar-CH), 6.92 - 
7.13 (1 H, m, Ar-H), 4.88 (2 H, s, CH dihydroanthracene), 3.40 - 3.44 (2 H, m, CH 
succinimide). 13C-NMR (150 MHz, DCM-d2)  (ppm) 175.41 (2 C=O), 148.40 (Ar-




CNO2), 141.19 (2 Ar-C), 138.89 (2 Ar-C), 132.65 (Ar-C), 132.54 (Ar-C), 129.91 (Ar-
C), 127.30 (2 Ar-C), 126.90 (2 Ar-C), 125.09 (2 Ar-C), 124.41 (2 Ar-C), 123.36 (Ar-C), 
121.77 (Ar-C), 47.21 (2 CH dihydroanthracene), 45.93 (2 CH succinimide). IR vmax/cm-
1: 3081, 3048, 3011, 2957 (CH stretch), 1775, 1710 (C=O stretch), 1530 (NO2 
asymmetric), 1387 (NO2 symmetric). LC-MS (ESI) found m/z [M + H]
+: 397, 
C24H16N2O4 requires 396.  
Synthesis of 13-phenyl-9,10-dihydro-9,10-[3,4]epipyrroloanthracene-12,14-dione 
(121e) [R = H, Rʹ = H].  
Compound 120 (0.05 g, 0.18 mmol, 1 eq) was combined with aniline (0.02 g, 
0.21 mmol, 1.2 eq) in 10 mL glacial acetic acid according to the procedure described 
above. Compound 121e was obtained as a white solid, yield 0.05 g, 83%. Mp 212-215 
oC. 1H-NMR (400 MHz, DMSO-d6)  (ppm) 7.51 (2 H, dd, J = 5.3, 3.3 Hz, Ar-H), 
7.28 - 7.36 (5 H, m, Ar-H), 7.21 (4 H, m, Ar-H), 6.37 - 6.47 (2 H, m, Ar-H), 4.86 (2 H, 
s, CH dihydroanthracene), 3.41 (2 H, s, CH succinimide). 13C-NMR (150 MHz, DCM-
d2)  (ppm) 175.97 (2 C=O), 141.51 (2 Ar-C), 139.07 (2 Ar-C), 131.79 (Ar-C), 128.97 
(2 para-Ar-C), 128.70 (Ar-C), 127.09 (2 Ar-C), 126.76 (2 para-Ar-C), 126.61 (2 Ar-C), 
125.05 (2 Ar-C), 124.33 (2 Ar-C), 47.13 (2 CH dihydroanthracene), 45.89 (2 CH 
succinimide). IR vmax/cm-1: 3069, 3038, 2969 (CH stretch), 1776, 1710 (C=O stretch). 
LC-MS (ESI) found m/z [M + H]+: 352, C24H17NO2 requires 351.  




Synthesis of 13-(m-tolyl)-9,10-dihydro-9,10-[3,4]epipyrroloanthracene-12,14-dione 
(121f) [R = CH3, Rʹ = H].  
Compound 120 (0.50 g, 0.81 mmol, 1 eq) was combined with m-toluidine (0.19 
g, 1.77 mmol, 1 eq) in 20 mL glacial acetic acid according to the procedure described 
above. Compound 121f was obtained as a cream solid, yield 0.40 g, 60%. Mp 199-200 
°C. 1H-NMR (400 MHz, acetone-d6)  ppm 7.47 - 7.55 (2 H, m, Ar-H), 7.29 - 7.34 (2 
H, m, Ar-H), 7.19 - 7.25 (4 H, m, Ar-H), 7.13 - 7.19 (1 H, m, Ar-H), 7.07 - 7.11 (1 H, 
m, Ar-H), 6.29 - 6.33 (1 H, m, Ar-H), 6.26 - 6.29 (1 H, m, Ar-H), 4.87 (2 H, m, CH 
dihydroanthracene), 3.42 (2 H, m, CH succinimide), 2.22 (3 H, s, CH3). 13C-NMR (150 
MHz, acetone-d6)  (ppm) 175.71 (2 C=O), 142.07 (2 Ar-C), 139.74 (2 Ar-C), 138.49 
(Ar-C), 132.55 (Ar-C), 128.90 (Ar-C), 128.42 (Ar-C), 127.42 (Ar-C), 126.72 (2 Ar-C), 
126.55 (2 Ar-C), 125.02 (2 Ar-C), 124.32 (2 Ar-C), 123.91 (Ar-C), 47.09 (2 CH 
dihydroanthracene), 45.82 (2 CH succinimide), 20.23 (CH3). IR vmax/cm-1: 3049, 3014, 
2961, 2916 (CH stretch), 1773, 1703 (C=O stretch). LC-MS (ESI) found m/z [M – H]-: 
364, C25H19NO2 requires 365.  
Synthesis of 13-(3-methoxyphenyl)-9,10-dihydro-9,10-[3,4]epipyrroloanthracene-
12,14-dione (121g) [R = MeO, Rʹ = H].  
Compound 120 (0.50 g, 1.81 mmol, 1 eq) was combined with 3-methoxyaniline 
(0.27 g, 2.19 mmol, 1.2 eq) in 20 mL glacial acetic acid according to the procedure 
described above. Compound 121g was obtained as a sand-coloured solid, yield 0.63 g, 




91%. Mp 200-201 °C. 1H-NMR (400 MHz, acetone-d6)  (ppm) 7.46 - 7.55 (2 H, m, 
Ar-H), 7.29 - 7.36 (2 H, m, Ar-H), 7.16 - 7.26 (5 H, m, Ar-H), 6.85 - 6.93 (1 H, m, Ar-
H), 6.17 - 6.23 (1 H, m, Ar-H), 5.88 - 5.94 (1 H, m, Ar-H), 4.87 (2 H, m, CH 
dihydroanthracene), 3.68 (3 H, s, CH3), 3.42 (2 H, m, CH succinimide). 13C-NMR (150 
MHz, DMSO-d6)  (ppm) 176.37 (2 C=O), 159.89 (Ar-CO), 142.12 (2 Ar-C), 139.85 
(2 Ar-C), 133.45 (Ar-C), 130.20 (Ar-C), 127.15 (2 Ar-C), 126.90 (2 Ar-C), 125.35 (2 
Ar-C), 124.90 (2 Ar-C), 119.41 (Ar-C), 114.73 (Ar-C), 112.83 (Ar-C), 55.84 (C-MeO), 
47.16 (2 CH dihydroanthracene), 45.43 (2 CH succinimide). IR vmax/cm-1: 3011, 2948, 
2905, 2832 (CH stretch), 1778, 1713 (C=O stretch), 1025 (CO stretch). LC-MS (ESI) 
found m/z [M + H]+: 382, C25H19NO3 requires 381.  
Synthesis of 13-(3-(dimethylamino)phenyl)-9,10-dihydro-9,10-
[3,4]epipyrroloanthracene-12,14-dione (121h) [R = Me2N, Rʹ = H].  
Compound 120 (0.50 g, 1.81 mmol, 1 eq) was combined with N,N-dimethy-1,3-
diamine (0.45 g, 2.15 mmol, 1.2 eq) in 20 mL glacial acetic acid according to the 
procedure described above. Compound 121h was obtained as cream crystals, yield 0.67 
g, 94%. M.p. 255-256 °C. 1H-NMR (400 MHz, DCM-d2)  (ppm) 7.41 - 7.46 (2 H, m, 
Ar-H), 7.31 - 7.36 (2 H, m, Ar-H), 7.17 - 7.24 (4 H, m, Ar-H), 7.11 (1 H, t, J = 8.1 Hz, 
Ar-H), 6.61 (1 H, dd, J = 8.4, 2.6 Hz, Ar-H), 5.85 (1 H, m, Ar-H), 5.40 (1 H, t, J = 2.1 
Hz, Ar-H), 4.83 - 4.88 (2 H, m, CH dihydroanthracene), 3.32 - 3.37 (2 H, m, CH 
succinimide), 2.82 (6 H, s, CH3). 13C-NMR (150 MHz, DCM-d2)  (ppm) 176.14 (2 
C=O), 151.19 (Ar-CN), 141.57 (2 Ar-C), 139.22 (2 Ar-C), 132.71 (Ar-C), 129.34 (Ar-




C), 126.98 (2 Ar-C), 126.73 (2 Ar-C), 125.11 (2 Ar-C), 124.33 (2 Ar-C), 114.08 (Ar-C), 
112.57 (Ar-C), 110.35 (Ar-C), 47.12 (2 CH dihydroanthracene), 45.93 (2 CH 
succinimide), 40.17 (2 CH3). IR vmax/cm-1: 3474 (NH stretch), 3031 2960 2880 2804 
(CH stretch), 1777, 1713 (C=O stretch). LC-MS (ESI) found m/z [M + H]+: 395, 
C26H22N2O2 requires 394.  
Synthesis of 3-(12,14-dioxo-9,10-dihydro-9,10-[3,4]epipyrroloanthracen-13-
yl)benzonitrile (121i) [R = CN, Rʹ = H]. 
Compound 120 (0.50 g, 1.81 mmol, 1 eq) was combined with 3-
aminobenzonitrile (0.26 g, 2.20 mmol, 1.2 eq) in 20 mL glacial acetic acid according to 
the procedure described above. Compound 121i was obtained as a white solid, yield 
0.67 g, 98%. M.p. 262-264 °C. 1H-NMR (600 MHz, DMSO-d6)  (ppm) 7.75 - 7.83 (1 
H, m, Ar-H), 7.52 - 7.59 (1 H, m, Ar-H), 7.45 - 7.51 (2 H, m, Ar-H), 7.26 - 7.32 (2 H, 
m, Ar-H), 7.14 - 7.21 (4 H, m, Ar-H), 6.81 - 6.86 (1 H, m, Ar-H), 6.72 - 6.74 (1 H, m, 
Ar-H), 4.85 (2 H, m, CH dihydroanthracene), 3.42 (2 H, m, CH succinimide). 13C-NMR 
(150 MHz, DMSO-d6)  (ppm) 176.10 (2 C=O), 141.95 (2 Ar-C), 139.80 (2 Ar-C), 
133.03 (Ar-C), 132.92 (Ar-C), 131.97 (Ar-C), 131.10 (Ar-C), 130.29 (Ar-C), 127.23 (2 
Ar-C), 126.96 (2 Ar-C), 125.36 (2 Ar-C), 124.97 (2 Ar-C), 118.13 (Ar-C), 112.42 (Ar-
C), 47.28 (2 CH dihydroanthracene), 45.41 (2 CH succinimide). IR vmax/cm-1: 3076, 
29750 (CH stretch), 1785, 1713 (C=O stretch). LC-MS (ESI) found m/z [M – H]-: 375, 
C25H16N2O2 requires 376.  





yl)benzoic acid (121j) [R = H, Rʹ = CO2H].  
Compound 120 (0.50 g, 1.81 mmol, 1 eq) was combined with 4-aminobenzoic 
acid (0.30 g, 2.17 mmol, 1.2 eq) in 15 mL glacial acetic acid according to the procedure 
described above. Precipitate formed after 25 minutes of reaction. Compound 121j was 
obtained as a white solid. Yield 0.61 g, 86%. M.p. 354-355 oC. 1H-NMR (400 MHz, 
acetone-d6)  (ppm) 7.95 (2 H, d, J = 8.8 Hz, para-Ar-H), 7.50 - 7.54 (2 H, m, Ar-H), 
7.31 - 7.35 (2 H, m, Ar-H), 7.19 - 7.23 (4 H, m, Ar-H), 6.72 (2 H, d, J = 8.6 Hz, para-
Ar-H), 4.89 (2 H, d, J = 1.6 Hz, CH dihydroanthracene), 3.47 (2 H, m, CH succinimide). 
13C-NMR (100 MHz, acetone-d6)  (ppm) 175.66 (2 C=O), 171.39 (C=O acid), 140.26 
(2 Ar-C), 139.65 (2 Ar-C), 133.07 (Ar-C), 129.97 (2 para-Ar-C), 128.64 (Ar-C), 127.27 
(Ar-C), 126.62 (2 Ar-C), 125.01 (2 Ar-C), 124.75 (Ar-C), 124.37 (2 para-Ar-C), 110.79 
(2 Ar-C), 47.21 (2 CH dihydroanthracene), 45.83 (2 CH succinimide). IR vmax/cm-1: 
3283 (OH stretch), 3020, 2972 (CH stretch), 1771, 1728, 1698 (C=O stretch), 1105 (C-
O stretch). LC-MS (ESI) found m/z [M – H]-: 394, C25H17NO4 requires 395.  
Synthesis of ethyl 4-(12,14-dioxo-9,10-dihydro-9,10-[3,4]epipyrroloanthracen-13-
yl)benzoate (121k) [R = H, Rʹ = CO2Et].  
Compound 120 (0.15 g, 0.56 mmol, 1 eq) was combined with ethyl-4-
aminobenzoate (0.11 g, 0.69 mmol, 1.2 eq) in 10 mL glacial acetic acid according to the 
procedure described above. Compound 121k was obtained as a white solid, yield 0.22 g, 




92%. M.p. 220-222 oC. 1H-NMR (400 MHz, acetone-d6)  (ppm) 7.89 - 7.98 (2 H, m, 
para-Ar-H), 7.45 - 7.56 (2 H, m, Ar-H), 7.28 - 7.38 (2 H, m, Ar-H), 7.16 - 7.24 (4 H, m, 
Ar-H), 6.67 - 6.76 (2 H, m, para-Ar-H), 4.78 - 4.99 (2 H, m, CH dihydroanthracene), 
4.32 (2 H, q, J = 7.1 Hz, CH2 aliphatic), 3.47 (2 H, m, CH succinimide), 1.33 (3 H, t, J = 
7.1 Hz, CH3). 13C-NMR (100 MHz, acetone-d6)  (ppm) 175.42 (2 C=O), 165.09 
(C=O ester), 141.95 (2 Ar-C), 139.62 (2 Ar-C), 136.42 (Ar-C), 130.27 (Ar-C), 129.65 (2 
para-Ar-C), 126.85 (2 Ar-C), 126.67 (2 para-Ar-C), 126.61 (2 Ar-C), 124.99 (2 Ar-C), 
124.37 (2 Ar-C), 60.86 (CH2 aliphatic), 47.20 (2 CH dihydroanthracene), 45.82 (2 CH 
succinimide), 13.67 (CH3). IR vmax/cm-1: 3132, 3067, 2958 (CH stretch), 1777, 1707, 
1608 (C=O stretch). LC-MS (ESI) found m/z [M + H]+: 424, C27H21NO4 requires 423.  
Synthesis of 13-(4-fluorophenyl)-9,10-dihydro-9,10-[3,4]epipyrroloanthracene-
12,14-dione (121l) [R = H, Rʹ = F].  
Compound 120 (0.13 g, 0.48 mmol, 1 eq) was combined with 4-fluoroaniline 
(0.06 g, 0.57 mmol, 1.2 eq) in 10 mL glacial acetic acid according to the procedure 
described above. Compound 121l was obtained as a pale pink solid, yield 0.17 g, 96%. 
M.p. 250-253 oC. 1H-NMR (400 MHz, DCM-d2)  (ppm) 7.40 - 7.46 (2 H, m, Ar-H), 
7.29 - 7.34 (2 H, m, Ar-H), 7.17 - 7.24 (4 H, m, Ar-H), 6.94 - 7.02 (2 H, m, Ar-H), 6.42 
- 6.49 (2 H, m, Ar-H), 4.82 - 4.88 (2 H, m, CH dihydroanthracene), 3.35 - 3.38 (2 H, m, 
CH succinimide). 13C-NMR (100 MHz, DCM-d2)  (ppm) 175.93 (2 C=O), 141.41 (2 
Ar-C), 139.05 (2 Ar-C), 128.52 (Ar-C), 128.43 (2 para-Ar-C), 127.12 (2 Ar-C), 126.80 
(2 Ar-C), 125.05 (2 Ar-C), 124.37 (2 Ar-C), 116.07 (Ar-C), 115.84 (2 para-Ar-C), 




47.10 (2 CH dihydroanthracene), 45.88 (2 CH succinimide). IR vmax/cm-1: 2975, 2891 
(CH stretch), 1777, 1708 (C=O stretch). LC-MS (ESI) found m/z [M + H]+: 370, 
C24H16FNO2 requires 369.  
Synthesis of 13-(4-chlorophenyl)-9,10-dihydro-9,10-[3,4]epipyrroloanthracene-
12,14-dione (121m) [R = H, Rʹ = Cl].  
Compound 120 (0.15 g, 0.53 mmol, 1 eq) was combined with 4-chloroaniline 
(0.09 g, 0.67 mmol, 1.3 eq) in 10 mL glacial acetic acid according to the procedure 
described above. Compound 121m was obtained as fluffy white powder, yield 0.19 g, 
94%. M.p. 275-278 oC. 1H-NMR (400 MHz, DCM-d2)  (ppm) 7.37 - 7.48 (2 H, m, 
para-Ar-H), 7.10 - 7.37 (8 H, m, Ar-H), 6.40 - 6.49 (2 H, m, para-Ar-H), 4.85 (2 H, s, 
CH dihydroanthracene), 3.31 - 3.41 (2 H, m, CH succinimide). 13C-NMR (150 MHz, 
DCM-d2)  (ppm) 175.71 (2 C=O), 141.38 (2 Ar-C), 139.00 (2 Ar-C), 134.41 (Ar-C), 
130.24 (Ar-C), 129.16 (2 para-Ar-C), 127.86 (2 para-Ar-C), 127.13 (2 Ar-C), 126.80 (2 
Ar-C), 125.04 (2 Ar-C), 124.36 (2 Ar-C), 47.10 (2 CH dihydroanthracene), 45.88 (2 CH 
succinimide). IR vmax/cm-1: 2981, 2973, 2885 (CH stretch), 1774, 1702 (C=O stretch). 
LC-MS (ESI) found m/z [M + H]+: 386, C24H16ClNO2 requires 385.  
Synthesis of 13-(4-nitrophenyl)-9,10-dihydro-9,10-[3,4]epipyrroloanthracene-12,14-
dione (121n) [R = H, Rʹ = NO2].  
Compound 120 (0.10 g, 0.37 mmol, 1 eq) was combined with 4-nitroanline (0.06 
g, 0.45 mmol, 1.2 eq) in 10 mL glacial acetic acid according to the procedure described 




above. Compound 121n was obtained as cream crystals, yield 0.12 g, 83%. M.p. 294-
295 oC. 1H-NMR (400 MHz, acetone-d6)  (ppm) 8.17 - 8.23 (2 H, m, para-Ar-H), 
7.49 - 7.55 (2 H, m, Ar-H), 7.31 - 7.37 (2 H, m, Ar-H), 7.17 - 7.25 (4 H, m, Ar-H), 6.89 
- 6.96 (2 H, m, para-Ar-H), 4.85 - 4.96 (2 H, m, CH dihydroanthracene), 3.51 (2 H, m, 
CH succinimide). 13C-NMR (151 MHz, acetone-d6)  ppm 175.28 (2 C=O), 147.17 
(Ar-CNO2), 141.83 (2 Ar-C), 139.56 (2 Ar-C), 137.85 (Ar-C), 127.45 (2 para-Ar-C), 
126.92 (2 Ar-C), 126.66 (2 Ar-C), 124.98 (2 para-Ar-C), 124.41 (2 Ar-C), 123.97 (2 
Ar-C), 47.24 (2 CH dihydroanthracene), 45.77 (2 CH succinimide).  IR vmax/cm-1: 3480, 
3121, 3082, 3017, 2973, 2860 (CH stretch), 1777, 1708 (C=O stretch), 1522 (NO2 
asymmetric), 1344 (NO2 symmetric). LC-MS (ESI) found m/z [M + H]
+: 397, 
C24H16N2O4 requires 396.  
Synthesis of 13-(p-tolyl)-9,10-dihydro-9,10-[3,4]epipyrroloanthracene-12,14-dione 
(121o) [R = H, Rʹ = CH3].  
Compound 120 (0.50 g, 1.81 mmol, 1 eq) was combined with p-toluidine (0.19 
g, 1.77 mmol, 1 eq) in 20 mL glacial acetic acid according to the procedure described 
above. Compound 121o was obtained as a white solid, yield 0.62 g, 94%. M.p. 220-222 
°C. 1H-NMR (400 MHz, DMSO-d6)  (ppm) 7.49 - 7.53 (2 H, m, Ar-H), 7.27 - 7.32 (2 
H, m, Ar-H), 7.20 (4 H, m, Ar-CH), 7.12 (2 H, m, para-Ar-H), 6.21 - 6.39 (2 H, m, 
para-Ar-H), 4.85 (2 H, s, CH dihydroanthracene), 3.38 - 3.40 (2 H, m, CH succinimide), 
2.25 (3 H, CH3). 13C-NMR (100 MHz, DMSO-d6)  (ppm) 176.59 (2 C=O), 142.21 (2 
Ar-C), 139.86 (2 Ar-C), 138.58 (Ar-C), 129.83 (2 para-Ar-C), 129.77 (Ar-C), 127.17 (2 




para-Ar-C), 126.92 (2 Ar-C), 126.84 (2 Ar-C), 125.35 (2 Ar-C), 124.93 (2 Ar-C), 47.13 
(2 CH dihydroanthracene), 45.41 (2 CH succinimide), 21.20 (CH3). IR vmax/cm-1: 3075, 
3048, 2982, 2928, 2862 (CH stretch), 1768 1704 (C=O stretch). LC-MS (ESI) found m/z 
[M – H]-: 364, C25H19NO2 requires 365.  
Synthesis of 13-(4-methoxyphenyl)-9,10-dihydro-9,10-[3,4]epipyrroloanthracene-
12,14-dione (121p) [R = H, Rʹ = MeO].  
Compound 120 (0.50 g, 1.81 mmol, 1 eq) was combined with 4-methoxyanline 
(0.27 g, 2.19 mmol, 1.2 eq) in 20 mL glacial acetic acid according to the procedure 
described above. Compound 121p was obtained as a light purple solid, yield 0.60 g, 
87%. M.p. 240-243 °C. 1H-NMR (400 MHz, DCM-d2)  (ppm) 7.38 - 7.48 (2 H, m, 
Ar-H), 7.28 - 7.35 (2 H, m, Ar-H), 7.15 - 7.26 (4 H, m, Ar-H), 6.74 - 6.84 (2 H, m, 
para-Ar-H), 6.31 - 6.40 (2 H, m, para-Ar-H), 4.81 - 4.89 (2 H, m, CH 
dihydroanthracene), 3.74 (3 H, s, MeO), 3.35 (2 H, m, CH succinimide). 13C-NMR (150 
MHz, DMSO-d6)  (ppm) 176.36 (2 C=O), 159.22 (Ar-CO), 141.88 (2 Ar-C), 139.56 
(2 Ar-C), 127.93 (2 para-Ar-CH), 126.81 (2 Ar-C), 126.57 (2 Ar-C), 125.00 (2 Ar-C), 
124.57 (3 Ar-C), 114.33 (2 para-Ar-CH), 55.58 (MeO), 46.76 (2 CH 
dihydroanthracene), 45.11 (2 CH succinimide). IR vmax/cm-1: 3393, 3012, 2949, 2905, 
2832 (CH stretch), 1779, 1710 (C=O stretch). LC-MS (ESI) found m/z [M + H]+: 380, 
C25H19NO3 requires 381.  





[3,4]epipyrroloanthracene-12,14-dione (121q) [R = H, Rʹ = Me2N].   
Compound 120 (0.50 g, 1.81 mmol, 1 eq) was combined with N,N-dimethyl-1,4-
diamine (0.30 g, 2.20 mmol, 1.2 eq) in 20 mL glacial acetic acid according to the 
procedure described above. Compound 121q was obtained as a light purple powder, 
yield 0.68 g, 95%. Mp 243-245 °C. 1H-NMR (400 MHz, DMSO-d6)  (ppm) 7.48 - 
7.53 (2 H, m, Ar-H), 7.26 - 7.31 (2 H, m, Ar-H), 7.16 - 7.23 (4 H, m, Ar-H), 6.53 - 6.63 
(2 H, m, para-Ar-H), 6.15 - 6.24 (2 H, m, para-Ar-H), 4.84 (2 H, m, CH 
dihydroanthracene), 3.35 (2 H, m, CH succinimide), 2.85 (6 H, s, 2 CH3). 13C-NMR 
(150 MHz, DMSO-d6)  (ppm) 176.89 (2 C=O), 150.63 (Ar-CN), 142.25 (2 Ar-C), 
139.86 (2 Ar-C), 127.53 (2 para-Ar-C), 127.06 (2 Ar-C), 126.84 (2 Ar-C), 125.28 (2 
Ar-C), 124.83 (2 Ar-C), 120.68 (Ar-C), 112.38 (2 para-Ar-C), 46.94 (2 CH 
dihydroanthracene), 45.43 (2 CH succinimide), 21.80 (2 CH3). IR vmax/cm-1: 3477 (NH 
stretch), 3075, 3040, 3017, 2974, 2864 (CH stretch), 1773, 1698 (C=O stretch). LC-MS 
(ESI) found m/z [M + H]+: 395, C26H22N2O2 requires 394.  
Synthesis of 13-(4-iodophenyl)-9,10-dihydro-9,10-[3,4]epipyrroloanthracene-12,14-
dione (121r) [R = H, Rʹ = I].  
Compound 120 (0.11 g, 0.38 mmol, 1 eq) was combined with 4-iodoaniline 
(0.10 g, 0.46 mmol, 1.2 eq) in 10 mL glacial acetic acid according to the procedure 
described above. Compound 121r was obtained as a white solid, yield 0.16 g, 90%. 




M.p. 303-307 oC. 1H-NMR (400 MHz, DMSO-d6)  (ppm) 7.68 - 7.75 (2 H, m, para-
Ar-H), 7.47 - 7.53 (2 H, m, Ar-H), 7.26 - 7.32 (2 H, m, Ar-H), 7.19 (4 H, m, Ar-H), 6.23 
- 6.30 (2 H, m, para-Ar-H), 4.86 (2 H, s, CH dihydroanthracene), 3.40 (2 H, s, CH 
succinimide). 13C-NMR (100 MHz, DMSO-d6)  (ppm) 176.23 (2 C=O), 142.12 (Ar-
C), 139.81 (Ar-C), 138.35 (2 para-Ar-C), 132.01 (Ar-C), 129.03 (2 para-Ar-C), 127.22 
(2 Ar-C), 126.95 (2 Ar-C), 125.31 (2 Ar-C), 124.94 (2 Ar-C), 95.17 (Ar-CI), 47.24 (2 
CH dihydroanthracene), 45.41 (2 CH succinimide). IR vmax/cm-1: 2973 (CH stretch), 
1700 (C=O stretch). LC-MS (ESI) found m/z [M + H]+: 478, C24H16INO2 requires 477.  
Synthesis of 13-(4-(tert-butyl)phenyl)-9,10-dihydro-9,10-[3,4]epipyrroloanthracene-
12,14-dione (121s) [R = H, Rʹ = t-Bu].  
Compound 120 (0.14 g, 0.51 mmol, 1 eq) was combined with t-butyl aniline 
(0.09 g, 0.61 mmol, 1.2 eq) in 10 mL glacial acetic acid according to the procedure 
described above. Compound 121s was obtained as a white solid, yield 0.19 g, 93%. 
M.p. 268-271 oC. 1H-NMR (400 MHz, DCM-d2)  (ppm) 7.43 (2 H, m, Ar-H), 7.29 - 
7.34 (4 H, m, Ar-H), 7.17 - 7.25 (4 H, m, Ar-H), 6.35 - 6.40 (2 H, m, para-Ar-H), 4.84 - 
4.86 (2 H, m, CH dihydroanthracene), 3.36 (2 H, m, CH succinimide), 1.26 (9 H, s, 
CH3). 13C-NMR (150 MHz, DCM-d2)  (ppm) 176.14 (2 C=O), 151.98 (Ar-C), 141.54 
(2 Ar-C), 139.10 (2 Ar-C), 129.06 (Ar-C), 127.06 (2 Ar-C), 126.74 (2 Ar-C), 126.08 (2 
para-Ar-C), 126.03 (2 para-Ar-C), 125.05 (2 Ar-C), 124.32 (2 Ar-C), 47.10 (2 CH 
dihydroanthracene), 45.89 (2 CH succinimide), 34.60 (quaternary C), 30.94 (3 CH3). IR 




vmax/cm-1: 2963, 2903, 2868 (CH stretch), 1773, 1707 (C=O stretch). LC-MS (ESI) 
found m/z [M + H]+: 408, C28H25NO2 requires 407.  
  




4.5.3 General methodology: biological screening 
4.5.3.1 Cell culture  
All reagents for in vitro studies were purchased from Sigma Aldrich (Poole, 
Dorset, UK) unless otherwise specified. Human pancreatic cancer cells, Panc-1 
(ATCC® CRL-1469™) and BxPC-3 (ATCC® CRL-1687™), were purchased from 
LGC Standards (LGC Limited., Middlesex, UK). Both were grown as monolayers in 
their respective culture media – Dulbecco Modified Eagle Medium (DMEM) for Panc-1 
and RPMI-1640 for BxPC-3 – supplemented with Foetal Bovine Serum (FBS, 10% v/v), 
Penicillin/Streptomycin solution (200 U), and L-glutamine (2 mM). Both cells were 
maintained in T75 cm2 flasks at 37 °C in a 5% humidified CO2 atmosphere and 
passaged at least three times a week when they had reached about 70% confluency using 
a standardised trypsinisation protocol.  
4.5.3.2 Growth of pancreatic cancer cells 
To determine the optimal assay conditions for both BxPC-3 and Panc-1 cells, the 
cells were plated in 96-well plates and their growth monitored over a period of two 
weeks to obtain “batch growth curve” characteristics. The cells were seeded at a density 
of 1000, 10,000 and 100,000 cells/well in triplicates overnight. CellTiter 96® AQueous 
Non-Radioactive Cell Proliferation Assay (MTS) reagent (Promega, UK) was added to 
the wells at 24 h and the plates incubated at 37 °C in a 5% humidified CO2 atmosphere. 
Plates were read at an absorbance at 492 nm 90 minutes after addition of the MTS 




reagent using a Multiskan Ascent 96/384 plate reader (Thermo Scientific, 
Loughborough, UK). This procedure was repeated daily over a period of two weeks.  
4.5.3.3 Preparation of compounds 
Cromolyn was purchased as the disodium salt (Sigma Aldrich, Poole, Dorset, 
UK) with ≥95% purity and the drug solutions were prepared in distilled water (10 Mm). 
Compounds to be screened (24, 24a, 24e, 24j and 121) were prepared by dissolving in 
sterile-filtered DMSO Hybri-Max™ (≥99.7%, Sigma Aldrich, Poole, Dorset, UK). The 
stock solutions of cromolyn and the compounds to be screened were filtered through 
0.22 μm sterile filters and stored at –20 °C prior to use. For the proliferation studies, 
stock solutions (1000 μM) were prepared in the appropriate cell culture medium and 
serially diluted as required.   
4.5.3.4 Proliferation studies 
Pancreatic cancer cells (1 x 104 cells/mL) in 100 μL complete cell culture 
medium were plated in clear 96-well plates (Sigma-Aldrich, Poole, UK) and incubated 
overnight at 37 °C in a 5% CO2 atmosphere. Cell viability was confirmed prior to 
seeding for the MTS assay study using the Trypan blue exclusion assay. Cromolyn 
sodium salt (Sigma Aldrich, Poole, UK), compound 24 and its analogues 24a, 24e, 24j 
and 121 were prepared from 10 mM stock solutions in serum-free medium and serially 
diluted to give concentrations of 1, 10, 100 and 1000 μM. Control samples for these 
investigations included cells incubated in the absence of drugs, cells incubated with the 
addition of the solvent DMSO at the corresponding concentration(s) used for the drug 




solutions and media-only samples. Cells were incubated with the test compounds for 24, 
48 and 72 h. At each of the three time points, CellTiter 96® AQueous Non-Radioactive 
Cell Proliferation Assay (MTS) (Promega, Southampton, UK) was added to each well 
(1:5 v/v). The plates were incubated for 90 minutes before reading the absorbance at 492 
nm using a Multiskan Ascent 96/384 plate reader (Thermo Scientific, Loughborough, 
UK). Each concentration had four replicates. The experiments were repeated twice. 
For data analysis, the background absorbance from media-only wells was 
subtracted from the absorbance from the test wells. The absorbance from control wells, 
containing DMSO at concentrations of 1, 10, 100 and 1000 μM was subtracted from the 
absorbance values obtained with wells treated with the sample compounds before an 
average of all four replicates was taken. The results are expressed as mean ±SEM of the 
three independent experiments with n = 12. Two-way ANOVA with P values of 
<0.05(*), <0.01 (**), <0.001 (***) and <0.0001 (****) relative to control were 
determined using GraphPad Prism 6.00 trial version for Windows (GraphPad Software, 
San Diego, CA, USA, www.graphpad.com) and post-test comparisons were made using 
Bonferroni test at 95% confidence interval.   
4.5.3.5 CytoTox-ONE™ Homogeneous Membrane Integrity Assay: Lactate 
Dehydrogenase (LDH) studies 
Cell membrane integrity studies were carried out in multiplex with the MTS 
assay studies. Prior to adding the MTS reagent to the wells, 50 μL of supernatant was 
removed from the wells of the clear plate and pipetted into a black 96-well plate. 




CytoTox-ONE™ Homogeneous Membrane Integrity Assay (Promega, Southampton, 
UK) was added to each well (50 μL, 1:1 v/v) and the plate incubated at room 
temperature (~ 22 °C) in the dark for 10 minutes. To stop enzyme activity, 25 μL of 
Stop Solution (Promega, Southampton, UK) was added to each well and the 
fluorescence read at an excitation wavelength of 560 nm and an emission wavelength of 
590 nm using GloMax®-Multi Detection System plate reader (Promega, Southampton, 
UK).  
For data analysis, background noise (media only wells) was subtracted from all 
wells. The absorbance of wells containing DMSO at concentrations of 1, 10, 100 and 
1000 μM was subtracted from wells containing the sample compounds before an 
average of all four replicates was taken. The results are expressed as mean ±SEM with 
of three independent experiments with n =12. P values of <0.05(*), <0.01 (**), <0.001 
(***) and <0.0001 (****) were determined relative to control using 2-Way ANOVA 
with post-test comparisons made using Bonferroni test at the 95% confidence interval. 
4.5.3.6 Chick Chorioallantoic Membrane (CAM) assay for angiogenesis studies  
Fertilised eggs (Dekalb White) were purchased from Henry Stewart & Co. 
Limited (Fakenham, Norfolk, UK) and left to settle in the laboratory overnight at room 
temperature. The eggs were incubated in a Brinsea Mini Eco Egg incubator (Brinsea 
Products Limited, Weston Super Mare, UK) at 37.5 °C, with a “no turning” setup. 
Following four days of incubation, the eggs were candled to confirm the presence of a 
developing embryo and a small volume of egg (~3 mL) removed from the blunt end of 




the egg using a sterile needle and syringe under aseptic conditions and discarded. A 
small rectangular window (~2.5 x 2.0 cm) was cut into the shell of the egg using a 
Dremel drill to expose the developing embryo before the compounds (10 μM 20 μL pre-
absorbed on sterile 1 x 1 cm2 Whatman filter paper), were loaded onto the sample. 
Compounds, 24, 24a, 24e, 24j and 121, were prepared as described in Section 4.5.3 and 
diluted in sterile PBS. The window is sealed with low-adhesive Scotch tape and eggs 
incubated at 37.5 °C. On day ten after first incubation, the eggs are removed from the 
incubator and representative images of the embryo and associated blood vessel network 
captured using GXCAM-9 digital microscope C-mount camera (GT Vision, Suffolk, 
















CHAPTER 5: General Discussion and Conclusions 
 
 




5. General Discussion 
Pancreatic cancer remains one of the most difficult cancers to diagnose and treat 
with very poor five-year survival rates [4, 50, 91]. Despite advances made in the 
treatment of many other cancers that have led to improvement in survival rates, 
pancreatic cancer still remains “the silent killer”, with little means of detecting the 
disease in its early stages.  
The main aim of this project was to identify compounds with the potential to 
disrupt the interaction between S100P and its receptor, RAGE, in the hope of finding a 
potential therapeutic candidate against pancreatic cancer. S100P is a Ca2+-binding 
protein that has been validated [125, 150, 175, 177, 181, 185] and shown to be a 
druggable therapeutic target in pancreatic cancer [195, 225, 228].  
The NMR-derived 3D experimental structure of S100P (PDB ID 1OZO) was 
used for structure-based drug design (SBDD) studies (Chapter 2) in the investigation to 
identify potential inhibitors of the S100P-RAGE interaction. The selection of the NMR 
ensemble over the X-ray crystal structure (PDB ID 1J55) was due to the former 
representing a complete experimental structure of the active (i.e. dimeric) form of the 
protein. To the best of this author’s knowledge, there is very limited data available on 
the application of the 3D-NMR ensemble of S100P for SBDD hence the rationale 
behind the present work. In addition, with the exception of the recently published papers 
of Penumutchu et al. [294, 323], there are very limited computational studies on the 




experimental S100P structures to elucidate the mechanism by which small molecules 
interact with it.  
Using in silico methods, conformer 15 of 1OZO was identified as the most 
suitable member of the NMR ensemble for use as a template for SBDD studies (Chapter 
2). This member was selected after a number of pocket-detection algorithms 
independently identified similar potential pockets at the dimeric interface of the 
conformer that were sufficiently large enough to accommodate cromolyn (4), the ligand 
reported to bind to and inhibit the protein’s interaction with its receptor RAGE 
[195].When this work was carried out there was no experimental information on the 
binding pockets of S100P, although it had been shown that interaction with target 
proteins is dependent on its dimerization [137, 284, 292, 322]. In 2014, the two reports 
by Penumutchu et al. showed the interaction of 4 with S100P as well as the protein’s 
interaction with RAGE [294, 323]. The authors identified residues on the dimeric 
interface of S100P involving helix 4 and helix 1ʹ (E5, D13, F44, Y88 and F89) that play 
a crucial role in S100P binding to RAGE, and residues F44, F89, A84, I81, I12, G9, M8, 
E5 and C85 as those involved in the binding of cromolyn to S100P [294, 323].  
These residues, with the exception of C85 which was mutated to S85 in the 
NMR ensemble, are present in the putative dimeric binding site of conformer 15 
identified by the studies presented in this thesis (Chapter 2). In retrospect, this validates 
conformer 15 of the NMR ensemble as a credible starting point for SBDD studies given 




that the putative binding site has now been shown to correlate with direct experimental 
evidence [294, 323].  
Docking studies (Chapter 2) showed three main points of interaction between 
compound 4 and S100P: two hydrogen bonding interactions involving residues T82 and 
T92 with the two oxygen atoms of one of the carboxylate groups of compound 4, and a 
hydrophobic contact between F89 and one of the chromone moieties. Two 
pharmacophore models, “stringent” and “relaxed” models, were generated from the 
predicted binding interactions. Both models have the same geometric constraints (angles 
and distances) but different pharmacophoric features (Chapter 2). Both have two 
features defined as hydrogen bond acceptors and an aromatic centre. In the “stringent” 
pharmacophore model, the two acceptor features were further classified as “anionic”. In 
the “relaxed” model, they were defined as hydrogen bond acceptors (Chapter 2).  
Both the “stringent” and “relaxed” pharmacophore models were used to virtually 
screen 653,214 lead-like compounds in the MOE database resulting in 52 and 4,619 
“hits” respectively. The huge difference in the number of “hits” obtained from the two 
virtual screens demonstrates the rigidity that the requirement for an anionic feature in 
the “stringent” pharmacophore model conveys on the results returned. Retention of the 
anionic feature could have served to reduce the variety in the hit compounds returned 
from the virtual screening experiment, which in turn would hamper drug discovery 
efforts, and as such it was important to widen the scope of the virtual screen by defining 
the “relaxed” pharmacophore. Virtual screening of the ZINC database containing 




765,278 lead-like compounds with the “relaxed” pharmacophore generated 4,789 “hits”. 
A total of 9,408 “hits” were obtained from the virtual screening of both databases using 
the “relaxed” pharmacophore (Chapter 2).  
To obtain a diverse library of compounds for biological screening, the 9,408 
“hits” from the virtual screening studies were clustered based on their maximum 
common substructure similarity [281, 282]. A total of 299 clusters were obtained with 
77 singletons. Sixty-five “hits”, 13 from the “stringent” pharmacophore search and 52 
from the “relaxed” pharmacophore query, were selected from the clusters and 
purchased. Purchased compounds were selected from different clusters to ensure 
maximum diversity. Although commercially available from specialist vendors, these 
compounds are considered “novel” as their synthesis, purification, and characterisation 
is not usually available in the public domain. Four “hit” compounds, 7, 58, 58a and 58b, 
were synthesised and characterised in-house as described in Chapter 3.  
The first round of biological screening involving 17 compounds and carried out 
in collaboration with Dr Crnogorac-Jurcevic’s laboratory at Queen Mary, University of 
London, identified five compounds, 17, 18, 20, 24, and 43, that demonstrated promising 
activity against the invasion of the S100P-expressing pancreatic cancer cell line BxPC-3 
(Chapter 3). Compound 24, in particular, showed a significant inhibition of the invasion 
of these cells at a concentration of 100 μM that was comparable to compound 4 at the 
same concentration (p<0.05). As this was one of the compounds initially purchased, and 
since repurchasing it in sufficient quantity for further explorative studies was 




prohibitively expensive, it was synthesised in-house via two synthetic routes (Chapter 
4). 
Structurally, compound 24 shares little similarity to compound 4 (Figure 5.1). 
The maximum common substructure Tanimoto similarity between the two compounds is 
0.17 meaning they share a 17% similarity. The former is a 9-NO2 anthracene-maleic 
anhydride-derived N-aryl substituted succinimide compound, whilst the latter is a 
symmetrical acid consisting of two chromone moieties joined together by an alcohol 
chain. Retrosynthetic analysis of compound 24 led to the identification of two potential 
synthetic routes a and b (Chapter 4, Section 4.2.1). 
 
 
Figure 5.1: Compound 24, which showed an inhibitory effect on the invasion of BxPC-3 cells 
comparable to compound 4, is structurally different from the latter. 
 




In route a, ethyl-3-aminobenzoate was combined with maleic anhydride in a 
two-step reaction process to give the maleimide intermediate 115. The Diels-Alder 
reaction of the dienophile 115 with 9-nitroanthracene did not however yield the desired 
target compound 24, possibly due to interaction of the N-aryl substituent of the 
dienophile with the π system of the 9-NO2 anthracene diene [362], or, the effect of the 
electron withdrawing nitro group on the π system [361]. In route b, maleic anhydride 
was combined with 9-nitroanthracene in a Diels-Alder reaction to give the cycloadduct 
intermediate 119. Reaction of 119 with 3-aminobenzoic acid led to the successful 
isolation of the target compound 24 in 80% yield from the Diels–Alders step (Chapter 4, 
Section 4.5.2.1.1). Thirty-nine analogues were also synthesised by varying substituents 
in the meta (R) or para (Rʹ) positions on the phenyl ring, and with or without the nitro 
group (X) on the dihydroanthracene ring (Figure 5.2), in excellent reproducible yields 
ranging from 61-97%. All compounds were characterised via 1H- and 13C-NMR, LC-
MS spectrometry, and IR spectroscopy to confirm that they are the desired products.  
 
Figure 5.2: Analogues of compound 24 were synthesised by varying different substituents on R, 
Rʹ and X (Chapter 4).  




Due to time limitations, five of the 40 synthesised compounds, 24, 24a, 24e, 24j 
and 121, were biologically screened against pancreatic cancer cell lines BxPC-3 and 
Panc-1 (Chapter 4). These compounds were selected to assess the effect of substituting 
the carboxylic acid group with an ester group (24a), a hydrogen (24e), and in the para 
position (24j) on biological activity relative to the main “hit” compound 24. Compound 
121, which lacks the nitro group, was included to assess the effect of this group on 
biological activity relative to 24. The compounds were assessed for cytotoxicity and for 
effect on the proliferative capability of BxPC-3 and Panc-1 cells using the LDH and 
MTS assays respectively.  
All five compounds demonstrated significant inhibitory activity against the 
proliferation of S100P-expressing BxPC-3 cells relative to control (p<0.0001) at a 
concentration of 1, 10 and 100 μM. Interestingly, a similar effect was also observed on 
Panc-1 cells, casting doubt on an S100P-specific effect from these compounds based on 
these results. The effect of compound 4 on the proliferation of both cell lines, despite 
published reports [195, 334], was not reproduced in this study, nor in numerous similar 
studies in Dr Crnogorac-Jurcevic’s laboratory (unpublished results). The inability to 
reproduce the reported effect of compound 4 on the proliferation of these cells points to 
the conclusion that S100P-RAGE may not be involved in cell proliferation, merely 
metastasis.    
Preliminary studies on the effect of the five compounds investigated on 
angiogenesis using chick chorioallantioc membrane (CAM) assay, showed initial 




promising results for compound 24. However, additional studies are required to validate 
these initial findings.  
  




6. Conclusions  
In this project, computational methods were successfully employed to identify 
putative sites on the NMR ensemble of S100P with potential to bind small molecules. 
This was the first project of its kind to do so on the NMR-derived structure of the 
protein, and has shown the feasibility of using an NMR ensemble for structure-based 
drug design studies provided due care is taken to select the most appropriate of the 
ensemble members for use as a template. Conformer 15 of the NMR ensemble was 
identified as having the most appropriate “druggable” binding site for SBDD studies, a 
hypothesis subsequently confirmed by recent experimental studies by others [294, 323], 
and was used as template to predict S100P’s interaction with compound 4 via in silico 
docking studies. The predicted binding interactions between the ligand and protein were 
used to design 3D pharmacophore models that were used to perform virtual screens on 
1,418,492 lead-like compounds, and returned molecules fulfilling the pharmacophoric 
constraints with a hit rate of 0.7%. All “hits” identified are novel in that their synthesis, 
characterisation and/or potential biological activity against pancreatic cancer cells have 
not been previously reported.  
A number of “hits” were successfully synthesised, isolated and characterised 
with excellent yields. The novelty of these compounds means that this is the first time 
their syntheses have been shown successfully, albeit by following established synthetic 
routes. Compound 24, one of the “hits” that demonstrated promising biological activity, 
was successfully synthesised and characterised having been initially purchased during 




the first round of biological screening. Thirty-nine analogues of this compound were 
also successfully synthesised to form a library for future SAR and QSAR studies. 
Biological screening to validate 17 of the “hit” compounds identified from the 
virtual screening studies show five compounds with the capability of reducing 
pancreatic cancer cell metastasis in vitro to the same extent as the marker substrate. This 
represents a 29% success rate, which can be higher considering that the 52 purchased 
“hits” and the 35 synthesised analogues of compound 24 are yet to be tested, and shows 
the significant level of enrichment in identifying potential molecules of interest that is 
afforded by the rational approach to drug design employed in this thesis when compared 
with random screening of libraries of compounds [271, 406, 407]. This is both exciting 
and encouraging as it demonstrates the relative success of the project at this stage of the 
drug discovery process, where attrition can be very high [408], and the potential and 
opportunity to develop a number of chemically distinct hit-compounds into lead 
molecules. With lead optimisation, these compounds, could provide a catalyst for 
identifying that elusive therapeutic agent for the treatment of pancreatic cancer which is 
desperately needed.   
In summary, this thesis has successfully demonstrated the close interaction 
between the fields of computational science, synthetic chemistry and biological 
technology to address a growing demand within drug discovery. In particular, this work 
has documented potential avenues of further research and confirmed possible novel 
therapeutic candidates to tackle pancreatic cancer, one of the deadliest cancers in the 
Western world.   




7. Future work 
The journey of a drug from early discovery to when it enters the market could 
take up to 10 years or more [409]. This project is in the early discovery stage and has 
identified “hits” that show promising in vitro activity against pancreatic cancer cell 
lines. These initial results provide tangible starting points for a number of follow-on 
researchers to develop a clinical candidate. Some of the steps that will be required in 
order to achieve this goal are outlined below. 
First, anti-proliferative activity of the compounds on pancreatic cancer cells 
should be investigated at nanomolar concentrations to establish the minimal effective 
concentration of these compounds. The membrane integrity assay used here to assess the 
cytotoxicity of the compounds could be optimised by investigating the effect that 
reduced foetal bovine serum will have on the assay and cells. Failing this, alternative 
assays, such as Promega’s MultiTox-Glo Multiplex Cytotoxicity Assay (Promega, 
Southampton, UK), which simultaneously measures both viability and cytotoxicity, 
could be explored.   
Once the potency of the compounds against pancreatic cancer cells is 
established, they should be tested for toxicity on normal healthy cells. This is important 
as it will allow the assessment of the structures of the compounds, identify potential 
toxophores and alteration of the molecules so that they retain their activity but reduce 
toxicity if the latter is shown to be a problem. It will also be interesting to assess the 




effect of the compounds against other cancer cell lines such as lung, breast, colon and 
prostate, in which S100P has been shown to be highly expressed.  
In addition to toxicity studies, mutagenesis studies will provide insight into the 
mechanism by which these compounds are exerting their effect. If, when the compounds 
are tested at nanomolar concentrations and they show an S100P-effect, mutating certain 
genes on the protein could offer an explanation into this mechanism. NMR spectroscopy 
or X-ray crystallography studies of the protein in complex with the compounds could be 
another avenue to provide an understanding of this mechanism in lieu of mutagenesis 
studies. The compounds can also be tested at the genetic level using microarray analysis 
to assess their effect on signalling pathways that are activated via S100 binding to 
RAGE. 
De novo synthesis could be employed to design new leads using existing 
compounds that show potency as templates or, generate novel fragments into the 
identified putative sites on S100P that have the potential to interact with key residues 
within the pocket. De novo design and synthesis are complementary to virtual screening 
studies. Both methods are excellent means of generating lead candidates although with 
de novo design, synthetic feasibility should be considered due to the novelty of the 
designed compound(s).  
Upon completion of the biological screening of the 52 purchased “hits” 
(compounds 59-110) identified from the virtual screening (Chapter 2), analogues of 
compounds showing promising activity should be synthesised to build a library for 




SAR/QSAR studies. In addition, analogues of four of the “hits” that show anti-
metastatic properties (Chapter 3) could be synthesised, similar to the synthesis of 
analogues of compound 24, to build libraries for SAR studies.  
If the chick chorioallantioc membrane (CAM) assay is going to be employed to 
further investigate the possible mechanism by which these compounds are acting, it 
would be useful to look at adapting the method of Dohle et al. [410]. This group did the 
assay ex ovo, which gave them easy access to the developing embryo and its rich blood 
network. This approach will also limit the rate of dead embryos at day 10 (as 
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Ramachandran data for conformers of the NMR ensemble 1OZO (data generated in 
MOE) 
Model Chain Residue Psi Phi 
1 A S 21 -66 131.3 
  A S 24 -20.9 179.6 
  A T 25 173 95.2 
  A K 49 -57.7 179.8 
  A D 50 44.7 -7.1 
  A D 62 -33.7 -29.3 
  A D 66 -38.8 -159.6 
  A A 67 -8.5 153.9 
  A T 92 71.5 128.7 
  A G 93 -63.3 -22.8 
  B S 19 20 -63.6 
  B S 21 -57.4 -167.5 
  B S 24 -15.3 -163.8 
  B T 25 -163.4 83.2 
  B K 49 -75 -170.5 
  B K 51 -0.2 42.6 
  B D 62 -14.7 -43.8 
  B D 66 -5.7 52.7 
  B A 67 -4.3 -177.4 
  B H 86 -80.4 -19.5 
  B F 89 -119.6 -153.5 
2 A T 25 -161.2 81.7 
  A K 49 -118.7 172.1 
  A K 51 -6.1 49.5 
  A D 62 -35.5 -28.7 
  A A 67 -50.8 144.5 
  B E 22 -116.7 30.3 
  B T 25 -102.8 118.9 
  B K 49 112.7 110.2 
  B D 66 -50.4 -178.5 
  B A 67 -1.2 163.5 
  B H 86 -52.7 -19.3 
  B F 89 -17.4 53 
3 A S 21 -69.6 115.6 
 302 
 
  A T 25 -102.9 112.6 
  A K 49 -90.5 -153 
  A A 53 -77 46 
  A K 87 24.6 37.1 
  A T 92 -38.5 -164.2 
  B S 24 -127.6 -176.7 
  B P 42 10 -38.5 
  B K 49 -7.6 -172.2 
  B D 66 -42.2 -165.2 
  B A 67 -3.5 157.2 
  B H 86 -88.8 -49.7 
  B K 87 -85.7 48 
4 A S 21 -71.2 97.4 
  A K 49 -100.3 -170 
  A A 67 -51 145 
  B S 16 -91.2 -72.5 
  B R 17 -82.2 17.3 
  B Y 18 -88.2 -40.4 
  B S 24 -16.1 126.5 
  B T 25 172.2 117.2 
  B K 49 -68.1 -171.6 
  B K 51 -14.3 139.2 
  B G 65 -67.5 -150.4 
  B A 67 -52 137.8 
  B K 91 -94.8 -77.8 
5 A S 21 -66.5 113.1 
  A D 66 -59.6 -162.1 
  A A 67 -51.4 146.2 
  A T 92 65.5 112.3 
  B S 24 -69.3 145.2 
  B T 25 52.4 179.7 
  B K 49 -108.9 173.9 
  B G 65 -72.8 -157.5 
  B D 66 -50.6 -160.2 
  B A 67 3.9 158.3 
  B H 86 11.2 -54.1 
  B T 92 95.1 -45.9 
6 A S 21 -83.1 105.9 
  A S 24 11 -24.5 
  A K 49 -18.7 -163.4 
  A D 62 -36.3 -23.1 
 303 
 
  A A 67 -50.8 143.4 
  A K 87 -74.8 42.1 
  A F 89 18 41.1 
  B E 22 17 37.8 
  B S 24 30.8 -63.8 
  B K 49 105.2 118.9 
  B K 51 -29.4 134 
  B A 67 -43 173.2 
  B E 90 -24.1 32.3 
  B T 92 60.4 144 
7 A S 21 -74.8 126.1 
  A S 24 21.5 35.8 
  A T 27 153.8 -33.7 
  A P 42 -14.3 -34.2 
  A D 50 65.3 15.1 
  A K 51 -10.9 46.2 
  A D 62 -24.9 -31.4 
  A A 67 -36.5 168.8 
  A K 87 -7.9 47.3 
  A F 89 -131 -155.7 
  B S 24 38.2 -61.2 
  B T 27 140.8 17.9 
  B K 49 92.5 111.1 
  B D 62 -22.6 -37.3 
  B A 67 6.2 167.2 
  B H 86 -13.6 -42.4 
  B F 89 -9.7 48.7 
  B K 91 142.7 166.2 
  B G 93 -22.6 47.2 
8 A S 21 -22.1 130.8 
  A S 24 -118.3 -164.3 
  A T 27 126.8 17.1 
  A K 49 -85 -177.1 
  A D 62 -35.3 -27.6 
  A D 62 -35.3 -27.6 
  A A 67 -30.9 162.5 
  B S 19 17.6 -61.5 
  B E 22 -117.4 101.8 
  B T 25 -12.1 124.9 
  B T 27 132.4 21.9 
  B Q 46 -30.6 -32.8 
 304 
 
  B K 49 138.3 74.6 
  B D 52 -106.9 -73 
  B D 62 -35.3 -27.3 
  B A 67 -44.7 142.7 
  B K 91 -85.6 17.6 
9 A S 21 -22.7 132.9 
  A T 27 129 29.9 
  A A 53 -69.2 47.6 
  A A 67 -51.9 146.2 
  A K 87 70.8 -58 
  A K 91 -114.4 -51.6 
  A S 19 30.5 -63.4 
  B S 21 -19.1 -165.1 
  B S 24 -139.9 -169.6 
  B T 27 126 33.2 
  B L 28 82.4 -61.2 
  B D 50 -36.8 134.3 
  B D 62 -34.6 -30.4 
  B A 67 -32.4 166.3 
10 A S 21 -21.7 121 
  A T 27 136.4 30.3 
  A D 50 13.4 -51.7 
  A D 66 -91.4 -157.6 
  A Y 88 0.4 141.6 
  A F 89 143.7 67.2 
  A E 90 -74.8 53.7 
  A L 94 -54.5 119.2 
  B E 22 -148.3 100.2 
  B T 25 -41.6 125.9 
  B T 27 132.2 28.9 
  B D 50 45.1 -62.3 
  B D 62 -33.8 -25.4 
  B A 67 -54.2 151 
  B K 87 -19.8 55 
  B Y 88 -2.4 -177.3 
11 A S 21 -16.8 129.9 
  A T 25 -20.7 140.5 
  A T 27 138.9 88.9 
  A D 50 20.5 -56.7 
  A G 65 -70.3 -155.9 
  A A 67 -47.7 160.5 
 305 
 
  A Y 88 -7.9 -177.8 
  A F 89 3.6 44.3 
  B T 25 -23.3 138.4 
  B T 27 126.7 66.1 
  B F 89 94.1 114.7 
  B K 91 -58.9 -16.4 
  B L 94 -28.1 140.2 
12 A S 21 -16.8 129.9 
  A T 25 -20.7 140.5 
  A T 27 138.9 88.9 
  A D 50 20.5 -56.7 
  A G 65 -70.3 -155.9 
  A A 67 -47.7 160.5 
  A Y 88 -7.9 -177.8 
  A F 89 3.6 44.3 
  B T 25 -23.5 138.4 
  B T 27 126.7 66.1 
  B F 89 94.1 114.7 
  B K 91 -58.9 -16.4 
  B L 94 -28.1 140.2 
13 A S 21 -68.7 113.7 
  A S 24 13.8 -3.1 
  A K 49 93.8 89.8 
  A K 51 -25.8 139.1 
  A D 62 -38.2 -25.9 
  A G 65 -69.6 -152.2 
  A A 67 -51.3 151.3 
  A F 89 -2.8 38.3 
  A L 94 77.8 136.7 
  B E 22 37.1 29.3 
  B S 24 42.9 -32.4 
  B T 27 142.1 15.8 
  B K 49 120.8 123.2 
  B D 62 -12.6 -44 
  B D 66 0.7 50.6 
  B A 67 -11.4 176 
  B L 94 8.8 48 
14 A S 24 5.2 -0.7 
  A T 27 139 -6.8 
  A K 49 98 146.5 
  A K51 -12.9 59.9 
 306 
 
  A D 62 -43.6 -19.1 
  A A 67 -54.3 142 
  A K 87 -5.6 -48.3 
  B E 22 -170.6 42.2 
  B S 24 1.1 44.3 
  B T 27 142.5 47.7 
  B K 49 -60.5 -169.7 
  B D 50 5.2 41.4 
  B D 62 -37.2 -29 
  B D 66 -60.8 -162.3 
  B A 67 -46.6 149.5 
  B K 87 -15.2 54.1 
16 A S 21 -55.2 125.2 
  A D 50 -76.8 53.9 
  A K 51 -26.7 172.6 
  A D62 -38 -24.3 
  A G 65 -70.7 -153.4 
  A A 67 -51.8 148.2 
  A K 87 4.9 45.4 
  A Y 88 114.3 55.5 
  B S 24 -152.9 134.2 
  B Q 26 31.4 36.3 
  B D 62 -14.1 -42.6 
  B A 67 4.3 -167.7 
  B F 89 17.7 -64.7 
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